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ABSTRACT

Cosmomycin D (CosD) is an anthracycline that possesses two trisaccharide chains
bound to its aglycone. This glycosylation pattern is substantially different from that of
anthracyclines used in the clinic such as daunomycin (Dn) and doxorubicin (Dx). A
purification method for CosD from culture supernatants of Streptomyces olindensis
ICB20 previously genetically engineered to overproduce CosD was developed. When
the bacteria cultures were propagated for several generations, in addition to CosD,
different anthracyclines appeared in the crude extracts, most likely as a result of
spontaneous mutations. Characterisation by mass spectrometry showed that these
anthracyclines were related to CosD in that they had two trisaccharide chains. The
sequences of sugars bound to the aglycones were determined by collisionally-activated
dissociation using an electrospray ionisation (ESI) quadrupole ion trap mass
spectrometer. Some of the anthracyclines had the same mass but had different HPLC
elution times using a C4 column. For example, several compounds differed from CosD
by the mass of an hydroxyl group. This project coincided with the commercial release
of an ESI quadrupole time-of-flight mass spectrometer equipped with a travelling wave
ion mobility cell (TWIMS). Some of the isobaric anthracyclines could be resolved by
TWIMS providing another example of the types of molecules that can be separated by
this ion mobility method. Furthermore, the sequence of the sugars was also determined
by fragmentation of the anthracyclines using the TWIMS cell and the results compared
to those obtained with the ion trap instrument.

Since only small amounts of CosD could be obtained, the sensitivity of mass
spectrometry (MS) was exploited in several different ways to characterise its interaction
iv

with DNA. ESI mass spectrometry was used to screen the binding of CosD to doublestranded (ds) DNA. The DNA was saturated with CosD at lower concentrations than Dn
and Dx. Fewer molecules of CosD were able to bind to DNA suggesting a larger
footprint, and all complexes formed with CosD were more stable than those obtained for
Dn and Dx. Nuclease footprinting experiments analysed by mass spectrometry showed
that CosD was able to protect the DNA to a greater extent than Dn and Dx consistent
with the binding profiles for the DNA sequences. Titration mixtures of dsDNA with
increasing amounts of CosD were also analysed by agarose gel electrophoresis (plasmid
DNA and 16 mer DNA) and CD spectroscopy (16 mer DNA) to complement the ESIMS studies. Both techniques revealed that a greater change was induced on the DNA
conformation upon binding of CosD than for Dn and Dx; this change was most likely
caused by partial unwinding of the DNA double-helix upon binding (intercalation) of
the drug molecule. In vitro RNA transcription assays showed that CosD was more
effective in inhibiting RNA production than Dn and Dx. All the experiments carried out
here support that CosD binds more tightly to DNA, exerts a larger footprint on DNA,
and has a greater ability to perturb the DNA conformation than Dn and Dx.

Since CosD was a purified natural product available only in milligram quantities,
synthesis of its aglycone, β-rhodomycinone, was attempted using Dn as starting
material owing to the similarity of the aglycone of CosD and Dn. Sugar removal and
functional group modification led to the unexpected synthesis of a novel compound,
necessitating the devising of an alternative synthetic route. Although the synthesis of the
aglycone was not completed owing to time restraints, the DNA-binding studies of the
synthesised intermediate compounds were carried out and confirmed the importance of
the sugars in DNA-binding.
v

This is the first comprehensive DNA-binding study of CosD. Early studies of
CosD showed that it induced differentiation in mouse leukemia cells. This effect was
not observed for Dn and Dx. The different effects of CosD on cells related to its
structure are yet to be fully investigated. The difference from Dn and Dx may lead to a
new chemotherapeutic agent, or alternatively, if the effects on cell differentiation are
shown to be reproducible, CosD may serve as a tool to be used to study the process of
differentiation in cell culture.
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CHAPTER 1
General Introduction

Among the wide range of natural compounds characterized to date only a fraction
possess biological activity and are used as pharmaceuticals; these include anti-bacterial,
anti-microbial and anti-tumour agents. In order to overcome their side effects and drug
resistance, scientists are always searching for new, better and less toxic drugs. Playing a
crucial role in the life cycle, DNA has been a target for drug treatment. Natural
bioactive compounds such as anthracyclines, produced by Streptomyces bacteria, are
known to exert their action through intercalative binding to DNA.

1.1.

Anthracyclines

Many organisms, such as plants and microbes, protect themselves by producing and
secreting secondary metabolites toxic to potential predators. Over 100 000 of these low
molecular weight secondary metabolites have been characterized and half of these
compounds are from microorganisms.1 Among these, a large number of compounds
possess useful biological activities; they have applications as insecticides,
immunosuppressant agents, antiparasitics, antibiotics and anti-tumour agents.1,2 About
three-quarters of these biologically active compounds are produced by Streptomyces,
which are Gram positive bacteria of the Actinomycetes order.2,3 Aromatic polyketide
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antibiotics such as anthracyclines belong to this class of compounds and have
widespread application in cancer chemotherapy. Anthracyclines are used in the
treatment of a variety of solid tumours and other types of cancers and include the two
most commonly used antineoplastic drugs, daunomycin and doxorubicin.4

1.1.1. Chemical Structures
The first anthracycline compounds were investigated in the 1950s by Brockmann et
al.5,6 and were later identified as tetracyclic aromatic polyketides possessing a common
7,8,9,10-tetrahydrotetracene-5,12-quinone structure.7 The main aglycone structure is
identical from one drug to the other, however additional substituents on the aglycone
define them as belonging to a particular sub-family (see Figure 1.1).8 For example, all
molecules possessing an aglycone resembling cosmomycin D belong to the
β-rhodomycin group of antibiotics. Each compound from these families, in addition to
having a common aglycone structure, possesses one or more saccharide chains. These
chains vary in length (1 to 5 sugars),9 the nature of the sugar unit constituting the chains
(e.g.

L-rhodosamine,

2-L-deoxyfucose and rhodinose for cosmomycin D and

daunomycin)10 and the positions of attachments to the aglycone moiety via an
α-glycosidic bond (linked to C7 for daunomycin and doxorubicin11,12 or C1 and C2 for
nogalamycin13).11,14-16 Most of the anthracycline compounds possess only one
saccharide chain that varies in the number of residues. Figure 1.1 shows different
examples of anthracycline compounds as well as the aglycone numbering system.
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Figure 1.1. Structures of some anthracycline compounds. The numbering system and
the names of the rings (A, B, C and D) for the aglycone are shown at the bottom with R
being any functional group.
All these anthracyclines show the two structural units: the aglycone which is substituted
differently for each compound and the sugar moieties that also vary from one compound
to the other. All the sugar units are 6-membered ring units, as is mostly the case for
anthracycline compounds. Cosmomycin D and aclarubicin possess trisaccharide chains.
Cosmomycin D possesses chains on carbons C7 and C10 whereas aclarubicin only has
one chain attached at C7, with the two inner sugars (L-rhodosamine, and 2-Ldeoxyfucose) being identical for the two compounds. In contrast, daunomycin and
nogalamycin possess only monosaccharide sugar chain, attached in both cases to carbon
C7 with a second monosaccharide chain on carbon C1 and C2 for nogalamycin. In the
examples shown in the figure, when the sugar chains contain more than one sugar, the
sugar units are linked in a 1Æ4 axial linkage. These differences (substitution, sugar
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length and position of attachment to the aglycone) are the origin of the biological
activity for each compound (see section 1.2.2).17,18

1.1.2. Anthracyclines Used in the Clinic
Anthracycline antibiotics are widely used to treat a range of different cancers;4 however,
only a handful of the two thousand compounds characterised are actually used in the
clinic. Daunomycin (daunorubicin, Dn) and doxorubicin (Adriamycin®, Dx) were
isolated in the 1960s from Streptomyces peucetius and were the first compounds to be
used in chemotherapy treatment.11,12,19,20 They continue to be the most used compounds
today.21 These two compounds have similar structures only differing by one functional
group; Dx possessing an additional hydroxyl group on the extremity of the C9 chain
compared to Dn. This small structural difference has a significant effect on the antitumour activities of these two compounds. Daunomycin is used for the treatment of
acute lymphoblastic or myeloblastic leukemia, whereas doxorubicin is used to treat
solid tumours such as breast, lung and ovarian cancer, childhood solid tumours,
Hodgkin’s disease, sarcomas, soft tissue carcinomas and aggressive lymphomas.19,22

Since the discovery and use of daunomycin and doxorubicin, other natural and synthetic
compounds have been isolated and used in the clinic to treat tumours. These compounds
include: aclacinomycin A (aclarubicin, see Figure 1.1) which is used against acute
leukemia, lymphomas and different solid tumors,23-25 valrubicin which is used for the
treatment of carcinomas in the bladder,20 pirarubicin (4-tetrahydropyranol analogue of
Dx) which shows a modest improvement against development of drug resistance
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compared to Dn and Dx and is used for the treatment of carcinomas, lymphomas and
sarcomas.23 Epirubicin is the epimer of Dx at position C4′ where the hydroxyl of the
daunosamine sugar is equatorial rather than axial, and idarubicin is an analogue of Dn
where the methoxy group at position C4 has been removed. The latter two compounds
are used as alternatives to Dn and Dx as they possess a broader spectrum of activity.19
Owing to its increased lipophilicity, higher cumulative doses of idarucibin are possible
without a corresponding increase in cardiotoxicity, a known side-effect of anthracycline
chemotherapy.19 More recently, rebeccamycin analogues, XL119 and NSC #655649,
have shown some promising anti-cancer properties and are currently undergoing phase I
and II clinical trials, respectively,26,27 as well as sabarubicin (MEN-10755, third
generation doxorubicin analogue) which is in Phase II clinical trials for the treatment of
doxorubicin-resistant ovarian tumours.28

1.1.3. Production, Isolation, Purification and Characterisation of
Anthracyclines
Anthracyclines are produced by Streptomyces organisms. In a general sense they all
require similar production, isolation and purification strategies. Streptomyces colonies
secrete coloured pigments providing evidence for the synthesis of secondary
metabolites (Figure 1.2). These metabolites are chemically diverse bioactive compounds
that often have medicinal applications.29 Variable amounts of compound are obtained
from bacterial cultures; the compounds are isolated from the mycelia cake by extraction
followed by chromatography, generally using silica, and eluted using different solvents
depending on the nature of the compound.8,30-35
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Figure 1.2. Streptomyces colonies producing coloured secondary metabolites. (A)
Several examples of Streptomyces colonies secreting coloured secondary metabolites.
(B) Colonies of Streptomyces coelicolor which produces several metabolites, including
the antibiotic actinorhodin, contained in the blue aqueous droplets on the surface of the
colonies. Figure taken from reference 29.

Daunomycin and doxorubicin have been used in the clinic for the treatment of various
cancers for over 30 years and possess a well documented mode of production, isolation
and purification.36 For newer compounds, production, isolation and purification requires
experimentation and development of new methods in order to obtain the compound in
its pure form.

All new anthracyclines are characterized using conventional characterisation techniques
for organic compounds such as appearance, melting point, UV absorption, IR, optical
rotation and molecular composition.10-12 For most compounds the biological activity is
tested as part of its characterisation allowing insight to its potential for clinical
applications;37,38 however, owing to the large number of reported new compounds,
around 500 a year,1 additional studies are rarely performed even if they show biological
activity. For example, cosmomycin D39-41 was characterised for the first time in 198510
and promoted cell differentiation in Friend leukemia cells F5-5 that was not observed
for Dn and Dx,37,38 but has not been studied in greater detail.
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1.2.

Mechanism of Action

While anthracycline compounds have been used as an important part of
chemotherapeutic regimens for more than 30 years, their mode(s) of action remain
unclear and subject to controversy.19,42 The structures of the anthracyclines allow for
many interactions with cellular components and macromolecules. The anti-cancer
properties of these compounds are thought to be predominantly the result of their ability
to bind DNA. Mechanisms for their anti-cancer activity include: (i) changes in the DNA
conformation due to intercalation and causing interference to the action of enzymes, (ii)
generation of free radicals that may damage DNA, lipids and proteins, (iii) alkylation of
DNA, (iv) DNA cross-linking, (v) direct inhibition of enzymes that unwind DNA such
as helicases, (vi) direct membrane effects, (vii) direct or indirect DNA damage caused
by inhibition of topoisomerase II, and (viii) induction of apoptosis in response to
topoisomerase II inhibition.19,42-44 The mechanisms outlined above are not exclusive of
each other, and there are numerous overlapping cellular processes that can be affected.
Although the binding of anthracyclines to several cellular targets has an influence on
cytotoxicity, it is the binding to DNA that is the crucial element in their biological
activity.45

1.2.1. Anthracycline Binding to DNA
DNA is an important target for drug activity. At the centre of most cell functions, it
possesses the genetic information that codes for proteins directing all cellular metabolic
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functions, growth and division.46-48 Targeting DNA through DNA-drug interactions
leads to the disruption of cell function.49,50 These interactions have been exploited for
many years in order to treat diseases involving, bacteria, helminths, viruses (e.g.
Herpes, hepatitis and HIV), malaria and tumours.51 There are a number of different
ways in which molecules are known to interact with DNA. Broadly classified, these
interactions can be either covalent or non-covalent. Anthracyclines belong to the noncovalent class of compounds.

The binding of anthracyclines to DNA (in vitro) has been extensively investigated using
a range of biochemical and biophysical techniques, including equilibrium dialysis,52
fluorescence spectroscopy,53 flow cytometry,54 observation of changes in melting
temperature (Tm) of DNA55 and Dnase I footprinting analysis.14,56 Analysis of X-ray
crystal structures of DNA-anthracycline complexes allow a better understanding of the
mode of binding of anthracycline compounds to DNA by revealing information on the
interaction of each functional group with DNA.16,45,57 From these studies, anthracycline
compounds have been described as possessing three different interaction domains: the
aglycone which is composed of the planar tetracyclic system, the functional groups on
ring A of the aglycone and the sugar chain(s) attached to the aglycone57,58 (see Figure
1.1). Each of these components has its own role in the binding interaction to DNA.

1.2.1.1.

Intercalation

Anthracycline antibiotics are molecules belonging to the non-covalent DNA binding
drugs and are the best characterised group of agents that interact with DNA by
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intercalation.16,49 Their ability to bind to DNA interferes with normal DNA functions
such as replication or transcription.51 Based on X-ray crystal structures of daunomycin
and doxorubicin complexed with the DNA hexamer d(CGATCG)2 (see Figure 1.3),45,57
the process of intercalation into DNA can be summarised as follows. The aglycone
planar ring systems slides in between DNA base pairs of double stranded DNA with
ring D out of the major groove (see Figure 1.3 (C), left).45 During the intercalation
process, the DNA locally unwinds in order to allow insertion of the aglycone in between
the DNA base pairs.16,57

The presence of different functional groups on the aglycone can create a wide range of
interactions with DNA.51 For example, modification of the functional group on the
fused rings B, C and D of the aglycone can change the orientation of the aglycone in the
complex, and modification of the substituents on ring A can alter its conformation
leading to a different orientation of the amino sugar in the minor groove.45 There have
been some studies that suggest that the binding site of the drug to DNA is not random.
The anthracyclines seem to favor the binding to alternating pyrimidine-purine tracts
with a preference for cytosine-guanine d(CpG) sites in close proximity to AT or TA
sequences.45,57 The presence of the intercalated drug in between the DNA base pairs
causes a reduction of base stacking effects along the z axis, causing a partial unwinding
of the double helix.57 This unwinding causes a modification in the conformation of
DNA and has subsequent effects on its interaction with other macromolecules, thus
disrupting their functions.59,60 Although these compounds seem to have some DNAbinding sequence specificity, they remain non-specific in the sense that all living cells
possess such DNA sequences. This overall non-specificity of the anthracycline
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compounds is at the origin of their effects on all fast dividing cells in vivo indifferent to
their nature, cancerous or healthy, and responsible for the majority of the undesired side
effects.

Figure 1.3. Crystal structures of DNA-anthracycline intercalating complex. (A) Doublestranded DNA (dsDNA) alone (stick structure on the left and space filling model
on the right). (B) dsDNA-anthracycline complex with two anthracyclines intercalated,
doxorubicin molecules (in blue) on the left (stick structure) and daunomycin (in red) on
the right (space-filling) viewed perpendicular to the 2-fold axis. (C) dsDNAdaunomycin complex, represented in space filling model view down the 2-fold axis
from the major groove (on the left) and down the minor groove (on the right).
(D) Projection onto the plane of the doxorubicin aglycone chromophore. The G-C base
pairs represented in black and grey bonding are above and below parallel planes
compared to the doxorubicin plane (shaded). Hydrogen atoms of doxorubicin are
highlighted in yellow and its H-bonds to DNA are in green. In all cases the doublestranded DNA is the hexamer d(CGTACG)2. Figure adapted from references 57 and 58.
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1.2.1.2.

Minor Groove Binding

The intercalation of the aglycone moiety in between DNA base pairs is an important
part of their binding process; however, additional effects need to be considered. The
various substituents carried by the aglycone as well as the substituents present on the
sugar(s) can each interact with the DNA. Crystal structures of doxorubicin with a DNA
hexamer reveal that ring A is located in the minor groove and that the functional groups
carried on this ring interact with the DNA bases directly above and below the
intercalation site by hydrogen bonding.45,57 For example, for doxorubicin, the hydroxyl
group of the ring A at position C9 (9-OH) makes two hydrogen bonds to the guanine
residue G2 at positions N2 and N3 (see Figure 1.3 (D)) and the carboxyl oxygen on
position C9 forms an indirect hydrogen bond to the O2 of C1 via one bridging water
molecule.14,16,45 Multiple hydrogen bonding is also observed between the daunosamine
sugar lying in the minor groove and the DNA backbone and DNA minor groove.45,57
These additional interactions all contribute to the stabilisation of the complex in the
minor groove57,58 and are also responsible for orienting the aglycone within the
complex.45

Considering all the interactions occurring during the binding process, changing the side
chains present on the anthracyclines can lead to modification of the binding strength of
the compound to the DNA.51 An increase in the sugar chain length may lead to an
increase in binding affinity allowing more interaction between the DNA and the drug
molecule and possibly an increase in the drug sequence specificity;16,51 however, no
direct correlations have been established between binding affinity and anti-tumour
activity.61
11

1.2.2. Importance of the Sugars
By comparing the biological activity and toxicity of anthracyclines containing
uncommon sugars, Zhu et al. demonstrated that the sugar moieties play a crucial role in
determining the cytotoxicity and biological activity of these compounds.18,62,63 To
obtain any biological activity, the linkage between the sugars must be axial (an
α-glycosidic linkage).16,18 Removal of the sugars results in a great loss of activity, with
the aglycone alone being 70- to 100-fold less active.18 Different substituents present on
the aglycone ring system as well as on the sugars modify the drug binding affinity for
double-stranded DNA with anthracyclines typically possessing binding constants in the
106-107 M range.51,64 Increasing the length of the saccharide chains could potentially
lead to an increase in binding affinity of the anthracyclines and increase in their efficacy
against tumour cells.16,19,62 In the last few years there has been increasing interest in
different glycosylated forms of anthracyclines, especially those containing longer chains
such as di- and trisaccharides (see section 3.1 for more details) as they show, for
example, an increase in protection of DNA from cleavage by nucleases during digestion
owing to a larger “footprinting” on DNA.14

The binding constant/affinity of the drug for the DNA is partially dependent upon the
DNA base pair sequence and on the presence and number of charged amino groups in
the sugars.49,65 The presence of an amino group at the 3′ position of the first sugar
creates additional interactions with DNA, stabilising the intercalating complex and also
positioning the first sugar in the minor groove.16 The presence and position of the amino
sugar in the sugar chain is important as there is evidence that it influences the
intercalation sequence specificity.14,57 Directly linked to the aglycone, amino sugars
12

seem to favour intercalation of the anthracycline in a DNA region containing GC base
pairs in close proximity to AT rich regions. The presence of an amine is, however, an
important, but not compulsory structural factor required for DNA binding and
biological activity; if replaced by an OH group, the compound still shows some
activity.16

The crystal structure of sabarubicin with a double-stranded DNA hexamer shows that
the second sugar ring present in the disaccharide chain can produce different modes of
binding.16 As demonstrated by Temperini et al., the presence of a second sugar on the
molecule does not modify the binding mode of the aglycone or of the first sugar, and the
double-stranded DNA conformation is not significantly modified when compared to the
intercalation mode of an anthracycline bearing a monosaccharide bound to doublestranded DNA.16 Anthracyclines containing an amino group on the first sugar are less
flexible and the presence or absence of this group can affect the position of the second
sugar.16 In the case where the second sugar resides out of the minor groove, the tilted
position of this sugar moiety can promote interaction with external agents such as
macromolecules, and could interact at their active site as they approach DNA thus
inhibiting their function.59,60 Enzymes or proteins participate in a wide range of cellular
processes such as replication or transcription. For example: helicases are involved in
unwinding DNA for replication,66 RNA polymerases are required for the initiation of
DNA replication67 and topoisomerase enzymes control DNA conformation during
replication.68-70
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There are two major classes of topoisomerases enzymes: types I and II. Type I enzymes
induce single-stranded cuts in DNA, while type II enzymes cut and cross through
double-stranded DNA.68,69 Topoisomerase II, which is a type II enzyme, has been
implicated in the mechanism of action of anthracyclines.

1.2.3. Interaction with Topoisomerase II
Topoisomerase II (TPII) is one of the enzymes that govern DNA conformation. Its
function is in changing the topology of DNA to preserve genetic information during
processes such as mitotic chromosome condensation,71 transcription, recombination and
chromosome partitioning at cell division.68-70 An initial step is the introduction of a
double-stranded break into the DNA. Following the induction of a break in the DNA,
single- or double-stranded DNA strands are moved through the breaks, and the cut
strands are resealed by the enzyme in a controlled manner whereby the genetic
information is conserved.21,68-70 The movements that occur through the DNA break
allow adjustments in DNA superhelical tension, to open and close circular DNA
molecules or to tie or untie DNA knots.72,73 TPII is a crucial element for cell survival.73

Several classes of drug are capable of inhibiting topoisomerase activity such as
coumarins, quinolones, acridines, alkaloids and anthracyclines.72 Figure 1.4 shows some
examples of drugs capable of inhibiting TPII. TPII possesses several functions in the
cell, and inhibition of this particular enzyme is thought to be the main mechanism of
action of the anthracyclines.59,74 Drugs that target TPII are classified into two groups: (i)
TPII poisons, which work by stabilising the DNA-TPII complex and induce permanent
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DNA strand breaks,75 and (ii) TPII catalytic inhibitors, that interact with the DNA-TPII
complex during the catalytic cycle of the enzyme without causing DNA strand breaks.76
Recently the mechanism of action of this second group of compounds has been
challenged, proposing that the effect on the TPII catalytic cycle was to cause DNA
damage such as chromosomal aberrations and DNA strand breaks when compounds
such as bis-dioxopiperazine ICRF-193 were used.77-79

Figure 1.4. Examples of drugs capable of inhibiting TPII function. Image adapted from
reference 73.
Anthracyclines poison topoisomerase activity by intercalating into DNA which causes a
stabilisation of the intermediate DNA-TPII complex (in which the DNA is cleaved and
covalently bound to the enzyme through its tyrosine residues),16,19 thus stopping the
religation process.60 Intercalation of the anthracyclines into DNA is necessary but is not
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sufficient to confer anti-cancer properties to the anthracycline drug. The binding
sequence preference of anthracyclines is in agreement with the sequence specificity of
TPII16 and the positioning of the second sugar may be an important factor in stabilising
the ternary complex. Intercalation alone does not inhibit TPII80 and when no sugar
moiety is present, the biological activity of the anthracyclines is also greatly reduced.18
Compounds such as aclarubicin43 or annamycin81 have been successfully used to inhibit
TPII function. Aclarubicin exerts its action not only by intercalating into DNA which
modifies the conformation of the double-stranded helix preventing TPII from binding to
DNA,23 but by also a “poisoning” / inhibiting effect on TPI.43

The stabilisation of the DNA-TPII complex causes an increase in the number of strand
breaks. The high level of DNA cleavage can trigger cell death16,18,49,68,73,82 or cause
chromosomal aberrations during the religation step.73 Studies also show that the nature
of the drug used to poison TPII, such as the nature of substituents at C-4 or C-3′ or the
position of the side chains on the molecule, has an effect on the site at which the
enzyme introduces strand breaks.21,60 The effect on TPII is only one of the mechanism
by which the anthracyclines can exert their anti-tumour properties. Other mechanisms
such as free radical formation are also able to induce cell death.

1.2.4. Other Anti-Tumour Mechanisms of Anthracyclines
Despite extensive clinical use of anthracyclines, their modes of action remain unclear
although the mechanism in which TPII inhibition is at the centre of anthracycline
anti-tumour activity is the most widely accepted. Other studies suggest that
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TPII-independent mechanisms could contribute to the anti-tumour properties of these
compounds through DNA damage and induced cell death.83

1.2.4.1.

Formation of Free Radicals

Production of reactive oxygen species (ROS) and free radicals is a multi-step process.
These species are produced through the mitochondrial respiratory chain and through
non-enzymatic pathways involving iron.84-86 Quinone moieties present on ring C of
anthracyclines can form semiquinones by a one-electron addition reaction.84-86 These
semiquinones are able to rapidly react to return to their quinone state in two different
ways. They can react with oxygen, reducing it to ROS such as superoxide anion (O2•−)
and hydrogen peroxide (H2O2) or they can react with the oxygen linking the sugar to the
aglycone of an anthracycline, leading to the reductive deglycosylation of the
compound.84-88 The deglycosylated aglycones have an increased lipophilicity which
increases their potential for insertion into biological membranes.89 This lipophilicity
increase and the reversibility of the quinone/semiquinone redox cycle results in the
production of ROS closer to the cell membranes.19 Superoxide anion (O2•−) and
hydrogen peroxide (H2O2) are relatively mild oxidising agents, however, reaction of
these species with iron through the Fenton reaction creates hydroxyl radicals (OH•)
which is a much more potent oxidant leading to DNA damage, lipid peroxidation of
membranes and other effects that cause membrane lesions.84-86,88,89 The oxidative
damage caused by such species has been considered as playing an important role in the
mechanism of action of anthracyclines in tumour cells.42
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1.2.4.2.
DNA

DNA Crosslinking

cross-linking

occurs

when

drugs

such

as

doxorubicin,

daunomycin,

epidoxorubicin and idarubicin are used since they are able to alkylate DNA.19,87,90 The
term virtual cross-linking was first introduced by Taatjes et al.22 and involves a covalent
bond between an anthracycline to a DNA strand by a methylene chain coming from a
formaldehyde unit. The crosslink occurs at 5'-GC-3' sequences and covalently links the
amino group of the anthracycline to the 2-amino group of a guanine base on the
DNA.22,87 The covalent binding to DNA is accompanied by hydrogen bonding of the
9-OH of the anthracycline to the guanine base of the other strand and hydrophilic
interaction of the anthracycline aglycone.22 The cross-linking transforms the initial
non-covalent intercalating complex to a drug covalently bound to the DNA. Figure 1.5
shows a schematic of the virtual cross-linking of two doxorubicin molecules to doublestranded DNA.

The origin of the formaldehyde in vivo has not yet been confirmed but some studies
suggest that it could be the result of Fenton oxidation reaction of a polyamine such as
spermine, biologically available and in close proximity to the DNA.22,87 The virtual
cross-linking results in a significant increase in the stability of the duplex DNA, which
activates cell death by some mechanism that is not clearly understood.83,87

1.2.4.3.

Other Mechanisms

Several mechanisms, other than the two examples described above have been suggested
for the anti-tumour activity of anthracyclines. For example, the protein p53 has been
18

Figure 1.5. Doxorubicin virtual cross-linking to DNA. Schematic structure of the
double-stranded DNA d(GCGCGCGC)2 with two doxorubicin-formaldehyde virtual
cross-links. Hydrogen bonds are highlighted in green and the covalent bond of the drug
via a methylene chain (red) to the DNA bases (blue) is shown. Image adapted from
reference 87.
implicated in playing an important role in anthracycline anti-tumour activity by
inducing apoptosis in tumour cells. p53 is the transcription factor that regulates the cell
cycle; its role is to conserve stability by preventing genome mutations.87,91,92 Adam et
al.93, among others, report the role of the proteasome in modulating anthracycline
activity. The proteasome is involved in the processing and degradation of regulatory
proteins that control metabolism and cell growth.93,94 Moreover, recent studies proposed
new possible mechanisms of action such as nuclear import of anthracyclines,19,95 and
telomeric DNA as a potential new target for anthracyclines.19
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It is important to note that most of the studies carried out to determine the mechanisms
of action of anthracyclines have been carried out using anthracycline concentration
ranges well above the clinically relevant concentrations.19 Therefore some of the
proposed mechanisms have had to be considered with caution and in some cases
re-evaluated.19,42 This includes the role of free radicals in DNA damage and the
involvement in oxidative damage in cancerous cells as there are conflicting reports.87
Under clinically relevant drug concentrations, mechanisms involving TPII remain the
most persuasive for explaining the anti-tumour properties of anthracyclines.19

1.2.5. Side Effects of Anthracyclines Used as Drugs
Medicinal chemists, biochemists and clinicians have attempted over the years to
overcome the side effects of anthracyclines by developing and testing new compounds
using different approaches such as screening of natural products produced by different
species of Streptomyces,10 total or partial synthesis of new anthracyclines18 and genetic
manipulation of Streptomyces sp.96,97 In total, over 300 new compounds have been
identified and more than 2000 analogues have been obtained by total synthesis or by
modification of natural products.19,20 Given the complexity of the effects of
anthracyclines in the cell, no clear relationships between structure and biological
activity or clinical effects have been established.65,98 As a consequence, it is not possible
to predict the side effects these anthracyclines will have when administered to
patients.19

20

1.2.5.1.

Cardiotoxicity

The use of anthracyclines in the treatment of tumours can result in acute and chronic
cardiac problems. While the acute side effects are usually manageable, chronic effects
that develop after a few weeks of treatment are of a greater concern. They can lead to
serious cardiotoxicity evidenced by hypotension, tachycardia, cardiac dilation and
ventricular failure, potentially causing congestive heart failure in patients irrespective of
their cardiac history.67,85,99 Several mechanisms of action have been proposed and the
most well accepted involves the quinone/semiquinone redox cycle (see section 1.2.4.1)
in the production of reactive oxygen species and free radicals.42,89 Cumulative
cardiotoxicity is still an enduring problem today and it limits the total drug dose that can
be administered to a patient.20

Though the exact mechanism of action at the molecular level remains the subject of
debate,99 Monneret et al. have proposed an explanation for the cumulative
cardiotoxicity. The low levels of catalase present in heart tissues and the destruction of
glutathione peroxidase by anthracyclines prevents the decomposition of free radicals
resulting in increased radical damage to the heart tissues.20 In vitro use of compounds
such as vitamin E, superoxide dismutase (SOD), catalase, ICR-187 and in vivo use of
dexrazoxane (iron chelator) have been used to protect heart tissues against radicals by
decreasing the amount produced or by quenching the free radicals without affecting the
anti-tumour activity of the anthracyclines.42,100 Compounds such as epirubicin,
pirarubicin, idarubicin and aclarubicin show reduced cardiotoxicity when compared to
the parent compounds daunomycin and doxorubicin.101
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1.2.5.2.

Development of Drug Resistance

Another problem associated with the use of anthracyclines as chemotherapeutic agents
is that tumours tend to develop resistance to these agents.18,20 In order to produce
anthracyclines that are able to overcome drug resistance, a range of strategies in drug
design has been employed to alter the structures of aglycones and/or the sugar
residues.51,81 A few compounds (e.g. epirubicin, pirarubicin, idarubicin, MEN10755 and
aclarubicin) show modest improvements against development of drug resistance
compared to daunomycin and doxorubicin.16,51,101 Despite these efforts, very few new
compounds are currently used as anti-cancer drugs and the original compounds
daunomycin and doxorubicin, used now for over 30 years, remain the most effective
intercalating anti-tumour agents.16 New effective and less toxic anti-tumour
anthracyclines are still being actively pursued.

1.3.

DNA-Anthracycline Complex Characterisation
Techniques

Several techniques enabling the study of fragile non-covalent complexes formed
between DNA and small organic molecules, such as DNA-anthracycline complexes,
have been described in the literature. Gel mobility shift assays and footprinting
experiments are the two main biochemical techniques used to characterise such
complexes. Other methods such as X-ray, NMR, circular dichroism and fluorescence
spectroscopies have also been used.45,57,102 More recently, mass spectrometry has
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become routine in the characterisation of these complexes. The principles of some of the
techniques relevant to this project are briefly described below.

1.3.1. Mass Spectrometry

1.3.1.1.

Electrospray Ionisation

Mass spectrometry (MS) has been used for many years to analyse a wide range of
systems; however, the analysis of biomolecules such as DNA and proteins has only
been achievable in the last twenty years because the previous ionisation techniques
caused fragmentation during the ionisation process.103 Electrospray ionisation (ESI) is a
gentle ionisation technique that enables the study of large molecules and different types
of non-covalently bound complexes without disrupting them.104-106 This fast and
sensitive tool is excellent for analysing complexes involving biological macromolecules
and allowing direct observation of stoichiometries from relatively small amounts of
sample.102,104 Numerous articles have been published demonstrating the use of ESI-MS
in determining relative binding affinities and the stoichiometries of non-covalent DNAdrug complexes involving anthracycline antibiotics, minor groove binders and other
small molecules.7,102,103,105-110

Figure 1.6 shows how molecules are transferred from solution to the gas phase during
the electrospray ionisation process. A solution containing the analyte is injected into the
electrospray source via a capillary, the potential applied at the end of the capillary and
helped by the presence of a nebuliser gas (usually nitrogen) cause the solution to
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Figure 1.6. Electrospray ionisation principle. A solution is injected into the electrospray
source via a capillary. The potential applied at the end of the capillary and the presence
of a nebuliser gas causes the solution to vaporise into a mist of highly charged droplets
(yellow). The droplets reduce in size through evaporation until they reached the charge
density limit and explode into smaller sized charged droplets; this process continues
until the ions are fully desolvated (represented by M).

vaporise into a mist of highly charged droplets.111,112 The droplets reduce in size
through evaporation until they reach the charge density limit and explode into smaller
sized charged droplets. This process continues until the ions are fully desolvated.111,112
The ions thus produced then enter the mass spectrometer where they are focused and
subjected to mass analysis. Under defined experimental conditions the spectrum
obtained has been shown to be a reflection of the interactions present in the liquid
phase.104
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1.3.1.2.

Collision-Induced Dissociation (CID) and Multi-Stage
Fragmentation (MSn)

Tandem mass spectrometry (MS2) involves selecting an ion of interest, fragmentation
and analysis of the product ions to yield structural information. There are several
methods of ion activation/fragmentation: metastable ion decomposition, collisioninduced dissociation, electron capture dissociation, infrared multiphoton dissociation or
blackbody infrared radiative dissociation.113 Collision-induced dissociation (CID) which
is also called collision-activated dissociation (CAD) is the most common ion activation
method.114,115

Figure 1.7. Schematic of the CAD mechanism occurring in the collision cell of a mass
spectrometer. Figure taken from reference 116.
The fragmentation process during CAD occurs in two steps: (i) activation and (ii)
dissociation (fragmentation). Figure 1.7 shows a schematic diagram of the CAD
mechanism during the activation and fragmentation processes in a collision cell. Ions
formed in the mass spectrometer source (precursor ions) are subjected to a potential
which accelerates the ions, giving them some translational or kinetic energy.117 The
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precursor ion selected for the fragmentation (specific m/z) reaches and enters the
collision cell that contains a chemically inert gas, often N2, Ar or He at a high pressure
compared to the rest of the mass spectrometer. Once in the collision cell the ion collides
with successive gas particles. Each successive collision increases the internal energy of
the precursor ion until the dissociation energy is reached leading to fragmentation of the
precursor ion to smaller fragments called product ions.116

The fragmentation occurring varies as a function of the nature of the precursor ion and
the energy involved.116 For low energies, molecules lose mainly neutrals such as H2O,
CO or CH3OH. This does not provide much structural detail but enables information on
the functional groups present on precursor ions to be gained. At higher energy,
structurally relevant fragmentations are observed due to bond cleavage at characteristic
positions.116 Comparison of the resulting tandem mass spectra to a library of product ion
spectra for identification of the precursor ion is called fingerprinting.118 When such
comparisons are not possible, the masses of each of the fragment ions produced allows
information on parts of the molecules to be combined to reconstitute the identity of the
precursor ion.

CAD has been used principally to obtain partial or complete structural determination of
compounds, analyte identification through fragment fingerprinting or for peptide
sequencing. It has been applied to a wide range of samples, from small to large organic
molecules

such

as

acetone,119

propane

or

methane,120

functionalised

buckminsterfullerene (also known as C60),121 to biological systems such as glycosylated
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compounds,122-124 peptides,125,126 proteins,126,127 different DNA structures128-130 and
DNA complexes with metal ions109,131 or drugs.132,133

1.3.1.3.

Ion Mobility

Ion mobility mass spectrometry (IMMS) is a relatively new technique for analysis of
biological molecules. Since the development of IMMS, a large number of systems has
been analysed, ranging from small organic molecules and polymers to small and large
biomolecules such as DNA and proteins.134-138 There are different types of IMMS139
such as drift-time ion mobility spectrometry (DTIMS), field-asymmetric waveform ion
mobility spectrometry (FAIMS) as well as the new technology (TWIMS) employed in
the Synapt™ HDMS™ (described in more detail in section 3.1). These techniques allow
the separation of structural isomers,135 peptides and proteins,136,137 complex biological
samples140 and chiral compounds and polymeric conformers.139

The general principle behind the separation of the molecules by IMMS is the same for
all these techniques. In IMMS, the cross-section (or collisional cross-section) of each
ion is related to its size, shape and charge state. Ions of large cross-section travelling
through a cell subjected to an electric field and under low pressure of unreactive gas are
retarded in their path and take a longer time to travel to the detector. Therefore
molecules that have the same mass/charge (m/z) ratio but different shapes or masses can
be detected separately.139
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Figure 1.8. (A) Mobility plot of a protein showing different sizes, conformations and
m/z. (B) Mass spectrum from driftscope, vertical slice through (A). (C) Profile of the
drift time distribution of ions at m/z aligned with horizontal blue arrow from (A).
Instead of a two dimensional mass spectrum which is a plot of ion abundance against
m/z, the IMMS can present information as a three dimensional plot which plots m/z
against ′′drift time′′ with the ion relative intensities represented by different colours as
shown in Figure 1.8 (A). The software can extract information from this plot by taking
vertical and horizontal slices through the data,141 thus obtaining conventional mass
spectra (Figure 1.8 (B)) or chromatograms representing the spatial distribution of the
species with a same m/z (Figure 1.8 (C)), respectively. This enables separation of the
different components of a complex mixture without liquid chromatography.

1.3.2. Gel Electrophoresis
Since it was first developed in 1809,142 electrophoresis has been applied to a wide range
of systems. Gel electrophoresis is the most commonly used technique for the analysis,
identification and purification of proteins, DNA and RNA.143 Different techniques
(e.g. one144 and two145 dimensional gels electrophoresis, constant146 or pulse field147
gel

electrophoresis

and

capillary

gel

electrophoresis)148,149

and

gels

types
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(e.g. polyacrylamide,144,150 agarose,145,150 cellulose acetate,150 agar,147 pectin151 and
starch152) have been used for the analysis of systems such as polymers,148 DNA147 and
RNA,153 proteins150-152 and chiral compounds.149

Whatever the technique chosen or the sample studied, the electrophoresis separation
principle can be described as follows. A mixture of charged molecules placed in a
matrix or gel under a uniform electric field migrates toward either the cathode or anode
as a function of the charge.143 The size (mass and conformation) of the molecules also
play an important role in the migration and separation, smaller molecules will migrate
faster/further than larger molecules as they will encounter a smaller resistance when
they travel through the matrix. As a result, the different molecules in the mixture will
separate into discrete bands which are then visualised by an array of different
techniques (e.g. UV fluorescence after staining DNA with ethidium bromide)7. The
migration of these bands as well as their resolution can be influenced by different
experimental factors such as the gel type (concentration, type of material) or the buffer
concentration.143

The most two common gel matrices used are agarose and polyacrylamide gels. Agarose
is a low resolution gel and is used for the separation and analysis of DNA from 200 to
50 000 base pairs.143 One percent gels are the most commonly used, however, gels
varying from 0.7% (good separation or resolution of large DNA fragments, 5 to 10 kb)
to 2% (good resolution for smaller fragments, 0.2 to 1 kb),154 and in some cases 3%
(analysis of short sequence) are used.155 On the other hand, polyacrylamide gels are
better suited for the analysis and separation of proteins; they possess a much higher
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resolving power than agarose gels and are able to separate molecules over a smaller
mass range. These gels can also be employed for the analysis of DNA sequences of 500
base pairs of less.143 In both cases, samples can be analysed or purified without
denaturation of the sample allowing recovery of the purified or separated compound if
desired. Several studies have reported the effects of binding molecules on the migration
of different types of DNA in agarose gels; this is described in more detail in section 5.1.

1.3.3. Enzymatic Digestion
Enzymatic digestion has been used to characterise proteins and oligonucleotides.143,156
The digestion of these macromolecules can occur in gels (in situ)157 or in solution prior
to analysis followed by gel electrophoretic158,159 or mass spectrometric160,161 detection.
A large number of studies have been reported on Dnase I footprinting experiments of
oligonucleotides. In these studies DNA-protein or DNA-drug complexes are subjected
to enzymatic digestion and compared with digestion products in the absence of the
protein or drug, giving their “footprint”. These experiments have been used to determine
the binding sequence specificity of daunomycin and derivatives,162-164 ditrisarubicin
(two trisaccharide chains)165 and nogalamycin,166 to determine the chemical footprint of
the anthracyclines14 and to study the positions of DNA crosslinks.167

1.3.4. Circular Dichroism
Circular dichroism (CD) is a useful technique to study the conformation of molecules168
and the interactions between molecules in solution.169 Circular dichroism is defined as

30

the difference in absorption of left and right circularly polarized light by asymmetric
molecules as represented in the schematic in Figure 1.9.

Figure 1.9. Schematic of the CD principle. Schematic from reference 170.
During the recording of a CD spectrum, left- and right-circularly polarized light is
passed through a solution containing the molecules to study. The detector records the
difference in absorbance of the left- and right-circularly polarized light. Once all data
points are recorded, the software allows a visualisation of these results by plotting the
corresponding CD spectrum of the molecule over the selected wavelength range. In
most cases, although the instrument records differences in absorbance, the CD spectrum
is not plotted as the difference in absorbance between the left (Al) and right (Ar)
polarized lights but is expressed in units of ellipticity (θ, millidegrees) versus
wavelength (λ, in nm). The relation linking the two parameters is: 170
CD = Al - Ar = θ / 32,982
Although this technique is simple to apply, care should be taken when planning an
experiment. The analyte needs to be soluble and the solution homogeneous to record a
representative spectrum. Unlike most UV spectrophotometers, the CD instrument is a
single beam instrument, meaning that prior to collecting CD spectra independent
absorption spectra for the sample and the buffer should be conducted over the same
wavelength range as desired for the CD experiments. In order to obtain a reliable CD

31

spectrum the absorbance of the analyte and buffer should not exceed two absorbance
units and be in between 0.2 and 1.5 absorbance units with an absorbance of 1.1 being
theoretically optimal. In the case when the absorbance is higher than two units, a
smaller path length cell, a lower analyte concentration or a different buffer should be
used.170

1.4.

Scope of this Project

The overall aim of this project is to compare the DNA-binding affinity of
cosmomycin D (CosD) to that of daunomycin and doxorubicin, the two main drugs used
for chemotherapy treatments in the clinic. CosD is of interest as it possesses two
trisaccharide chains, an uncommon structure for a compound belonging to the
anthracycline family. Moreover, in early work, CosD was shown to induce
differentiation in Friend (mouse) leukemia cells under conditions where Dn and Dx had
no activity,37 suggesting that CosD was involved in a different set of intermolecular
interactions and might be a compound that would have different activity in the clinic.
All the reagents used and the methods employed in this thesis are described in
Chapter 2.

Chapter 3 describes the development of the purification method developed to obtain
pure cosmomycin D from the crude extract (kind gift from U. Sao Paulo, Brazil)
obtained from Streptomyces olindensis ICB20. After optimisation of the purification
conditions, it was observed that additional compounds to cosmomycin D were produced
by the bacteria which had been cultured for several generations. In addition to CosD,
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these new unknown compounds were separated from crude extracts and were
characterised using an array of different techniques. Degradation tests were carried out
on CosD to determine the best storage conditions. In addition to CosD, each of the
compounds collected from the crude extracts were characterised using several mass
spectrometric techniques. High resolution mass spectrometry was use to obtain the
exact mass of these new compounds as well as their elemental composition. CAD
allowed the identification of the sugar sequences present on these compounds and ion
mobility mass spectrometry was used to confirm the sequences observed and to gain
insight into the conformation of isobaric compounds when possible.

Although cosmomycin D has been isolated previously,10 there have been no studies to
date reporting its DNA-binding properties other that the recent report published by our
group7 and limited investigations were carried out on its potential chemotherapeutic
properties.10,37,41 The DNA-binding properties of cosmomycin D were assessed in
Chapter 4 by mass spectrometry. The DNA-binding stoichiometries of CosD were
determined and compared to that of daunomycin and doxorubicin for different types of
DNA structures (double-stranded, quadruplex and forked structures). The relative
binding strengths of these compounds to DNA were assessed by dissociation of the
DNA-drug complexes formed in solution by tandem mass spectrometry experiments.
Enzymatic digestions of the DNA-drug complexes were also carried out and the
products analysed by mass spectrometry to evaluate the footprint/protection of each
drug on a specific double-stranded DNA sequence.
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In Chapter 5, techniques additional to mass spectrometry were used to characterise
further the DNA-CosD interactions and compare them to the results obtained under the
same experimental conditions for Dn and Dx. Circular dichroism was used to determine
the effects of the different drugs on DNA conformation (lengthening or uncoiling of the
helix) upon binding. Similar effects were studied by agarose gel electrophoresis using
plasmid DNA and a short sequence of double-stranded DNA. The ability of each drug
to inhibit RNA transcription in an in vitro assay was also assessed.

Finally, in Chapter 6, owing to the small quantities of natural compounds obtained
through culture and purification of the Streptomyces olindensis ICB20 crude extract,
synthesis of the cosmomycin D aglycone, β-rhodomycinone, was attempted as a starting
point for synthesis of different glycosylated forms of cosmomycin D. Obtaining such
compounds will allow a detailed study of the influence of the sugars on the DNAbinding affinity of these compounds.
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CHAPTER 2
Materials and Methods

2.1.

Materials

All chemical reagents and solvents used were of the highest grade commercially
available. MilliQ™ water from Millipore (Molsheim, France) was used in all
experiments.

2.1.1. Reagents Used for the Mass Spectrometry, HPLC and
DNA-Binding Assays
Daunomycin (Dn, Daunorubicin), doxorubicin (Dx, Adriamycin®), leucine enkephalin
(Leu-Enk), sucrose, boric acid, deionised formamide, MOPS (3-(4-morpholino)propane
sulfonic acid), formaldehyde (37% solution), ethylenediaminetetraacetic acid (EDTA),
sodium phosphate monobasic and dibasic, HindIII (enzyme from Haemophilus
influenzae, as a buffered aqueous glycerol solution), deoxyribonuclease I (Dnase, from
bovine pancreas) and phosphodiesterase I (PdI, from Crotalus adamanteus venom) were
purchased from Sigma-Aldrich (St Louis, USA). Ammonium acetate (NH4OAc),
sodium acetate (NaOAc), acetonitrile (ACN, HPLC grade), methanol (MeOH, HPLC
grade), ethyl acetate (EtOAc, HPLC grade), dimethylformamide (DMF), glacial acetic
acid and ammonia were obtained from Ajax Finechem (Seven Hills, Australia).
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Tris base (Ultrol grade), bromophenol blue and glycerol were purchased from ICN
Biomedicals (now MP Biomedicals, Aurora, USA). Ethidium bromide (EtBr, 10 mg/mL
solution) and molecular biology grade agarose were purchased from Bio-Rad (Hercules,
Australia). RNA transcription assay kits (RiboMax™ large scale RNA production
system T7) and the DNA template used for the transcription assays (pGEM® express
positive control template) were obtained from Promega (Madison, USA). Cartridge
columns (Alltech C18, 100 mg, 1.0 mL, phase of 1 cm) used in the pre-purification of
the S. olindensis ICB20 crude extracts were purchased from Alltech (Deerfield, USA).
The plasmid DNA (pUC9, MW 1800000 Da) was expressed, grown and purified using
a QIAGEN plasmid Maxi Kit (purchased from QIAGEN, Doncaster, Australia).

2.1.2. Reagents Used for Synthesis
Daunomycin for use as a starting point for the synthesis of the CosD aglycone was
purchased from 3B Medical Systems Inc. Anhydrous dimethylformamide (DMF),
methanol

and

anhydrous

methanol

(MeOH),

benzenesulfonylhydrazone

(NH2NHSO2Ph), sodium cyanoborohydrate (NaCNBH3), triphosgene, pyridinium
toluene-4-sulfonate (pyridinium-p-toluene sulfonate, PPTS) and p-toluenesulfonic acid
(PTSA) were purchased from the Sigma-Aldrich Chemical Company. Dichloromethane
(CH2Cl2), acetonitrile, ethyl acetate (EtOAc), anhydrous magnesium sulfate (MgSO4),
sodium chloride (NaCl), petroleum spirit (Pet. Spirit) and acetone were purchased from
Crown Scientific. Anhydrous tetrahydrofuran (THF) was freshly distilled from sodium
benzophenone ketyl. Petroleum spirit was within the boiling range 40-60 °C. All
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deuterated NMR solvents (acetone-d6, DMSO-d6, methanol-d4, chloroform-d with
TMS) were purchased from Novachem Pty. Ltd.

2.2.

Methods

2.2.1. CosD Purification
Cosmomycin D (CosD) and related anthracyclines used in this study were kindly
provided by Dr. Gabriel Padilla (University of Sao Paulo, Brazil) as crude extracts
obtained from fermentation cultures of Streptomyces olindensis ICB20. Details of
growth conditions and preparation of the crude extracts are reported elsewhere.7,171
A method for purification of CosD, from crude S. olindensis ICB20 extracts was
determined as part of this research project. The complete details of the development of
these procedures are the subject of Chapter 3. Briefly, the final purification procedure
involved two main steps. Firstly, a pre-purification step where water-soluble material
from methanol extracts of mutant cultures of S. olindensis ICB20 was cleaned by
extraction of less soluble anthracyclines into ethyl acetate. The material obtained in this
way was purified further by HPLC on a C4 column using a Waters HPLC system.

2.2.1.1.

HPLC Columns and Methods

Three different columns were used during the method development for the purification
of CosD. The column types and suppliers are described in Table 2.1. Several HPLC
methods were tested during development of the CosD purification procedures and these
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are summarised below in Table 2.2. The compositions of the mobile phase solutions,
buffer A and B were the same in all methods. Buffer A was 100 mM ammonium acetate
in water and buffer B was 100 mM ammonium acetate in water/acetonitrile 35/65 v/v.

Table 2.1. HPLC columns used during development of the CosD purification
procedure.

a

Column type

CC18a

CC4Aa

Type name

Symmetry

Supplier

Waters

Phase

®

®

Jupiter

CC4SPa

®

Jupiter
®

®
®

Phenomenex

Phenomenex

C18

C4

C4

Diameter

4.6 mm

4.6 mm

10 mm

Length

50 mm

50 mm

250 mm

Particle size

5 μm

5 μm

5 μm

Pore size

300 Å

300 Å

300 Å

Particle shape

spherical

spherical

spherical

Abbreviated column name (see text)

Table 2.2. HPLC methods used during the CosD purification.
Method name

MethCC18

MethCC4A

MethCC4SP

Column used

CC18

CC4A

CC4SP

1.0 mL/min

1.0 mL/min

3.0 mL/min

Flow rate

Gradient (linear)

UV detection
CosD elution time

0-100% buffer B
from 0 to 30 min

0-100% buffer B
from 0 to 30 min

0-30% buffer B
from 0 to 5 min
30-70% buffer B
from 5 to 45 min
70-100% buffer B
from 45 to 50 min

254 nm

254 nm

254 nm

No CosD eluted

t ~ 23.4 min

t ~ 35.2 min

Using method MethCC4A pure CosD was obtained on an analytical scale. To purify
greater quantities of CosD, the method was adapted to a semi-preparative scale
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(MethCC4SP) (see Chapter 3 for method development). The pre-purification step was
unchanged. Pure CosD was kept in the – 20 ºC freezer as a 0.5 mM stock solution in
100 mM ammonium acetate, pH 7.5.

2.2.2. Oligonucleotide Preparation

2.2.2.1.

Oligonucleotide Sequences

Oligonucleotides were all purchased from Geneworks (South Australia) with the trityl
group removed. Their sequences and abbreviated names are summarised in Table 2.3.

The HPLC purification method used was the same for all the oligonucleotides. Each
single-stranded oligonucleotide was dissolved in 1 mL of 10 mM ammonium acetate
before being purified on a Waters HPLC system. All purifications were carried out
using a C18 octadecylsilyl column (8 x 100 mm Waters Delta Pack™ Radial Pak™
Cartridge, 15 μm, 300 Å) equilibrated with 10 mM ammonium acetate at a flow rate of
1 mL/min. A linear gradient of 0-60% aqueous acetonitrile in 10 mM NH4OAc was
used to elute the DNA from the column, and detection was carried out by UV
absorbance with the wavelength set at 260 nm. The peaks corresponding to the singlestranded DNA (ssDNA) were collected and freeze-dried using a Savant Speedy Vac
(Selby-Biolab, Australia), then redissolved in 100 mM NH4OAc, pH 7.5, and stored
at -20 °C. In the case of the single-stranded sequences used to obtained quadruplex
DNA, the purification was carried out in the same way as described above using
150 mM ammonium acetate, pH 7.5, to redissolve the single-stranded DNA. The purity
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of the single-stranded DNA was assessed by mass spectrometry using the Meth.dsDNA
method (see Table 2.4).

Table 2.3. Sequences, abbreviated names and molecular masses of oligonucleotides
used in the experiments.
Name

Molecularb
mass (Da)

Detailed sequence

Single-stranded sequencesa
ss01

d(TGCTCGGACG)

3044.0

ss02

d(CGTCCGAGCA)

3013.0

ss10A1

d(TGCTCGGACGAAAAAAAAAA)

6175.1

ss10A2

d(AAAAAAAAAACGTCCGAGCA)

6145.1

ss10T1

d(TGCTCGGACGTTTTTTTTTT)

6086.0

ss20A1

d(TGCTCGGACGAAAAAAAAAAAAAAAAAAAA)

9308.2

ss20A2

d(AAAAAAAAAAAAAAAAAAAACGTCCGAGCA)

9277.2

ss20T1

d(TGCTCGGACGTTTTTTTTTTTTTTTTTTTT)

9128.0

Double-stranded sequences

a

Rt1

d(CTCGTCCGATTCGATC) • d(GATCGAATCGGACGAG)

9763.5

F0AT

d(ss01) • d(ss02)

6057.0

F10T1A2

d(ss10T1) • d(ss10A2)

12262.1

F20T1A2

d(ss20T1) • d(ss20A2)

Partially double-stranded structures

18436.2
a

F10A1

d(ss02) • d(ss10A1)

9220.1

F10A2

d(ss10A2) • d(ss01)

9158.1

F10T1

d(ss02) • d(ss10T1)

9130.0

F20A1

d(ss02) • d(ss20A1)

12352.2

F20A2

d(ss20A2) • d(ss01)

12290.2

F20T1

d(ss02) • d(ss20T1)

12172.0

F10A1A2

d(ss10A2) • d(ss10A1)

12318.2

F20A1A2

d(ss20A2) • d(ss20A1)

18585.4

Quadruplex sequence
G5
a
b

d(TTGGGGGT)4

9986.4

Drawings of some of these structures appear in the relevant chapters.
Average molecular mass
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Table 2.4. Titration conditions used for the analysis of the various DNA-drug
complexes.
Method namea

Meth.dsDNA

Meth.pdsDNA

Meth.qDNA

Meth.OrgRt1

Type of DNA run
under these
conditions

ss- and
dsDNAb

pdsDNAc

qDNAd

Rt1

Compounds used
for the titration

Dn, Dx, CosD

Dn, Dx, CosD

CosD

2, 3, 5, 12,
13, 14e
Dn, EtBrf

Ion mode

Negative ESI

Negative ESI

Negative ESI

Negative ESI

Capillary (kV)

2.5

2.5

2.5

2.5

Cone (V)

100

100

150

100

Rf lens 1 energy (V)

70

70

70

60

Source
temperature (°C)

80

80

60

80

Desolvation
temperature (°C)

100

100

200

100

Desolvation
flow (L/hr)

300

300

150

300

4

4

4

5

500-4000

500-4000

500-3500

500-4000

25

20

20

30

Ion optic region
pressure (mbar)

3x10-3

3x10-3

3x10-3

3x10-3

MCP (V)

2100

2100

2100

1700

Collision energy (V)
Acquisition mass
range (m/z)
Number of
acquisition (scans)g

a

All the methods described here were used on the Waters Q-Tof Ultima™.
Single- and double-stranded DNA (e.g. Rt1, ss01, ss02, ss10T1, see Table 2.3).
c
Partially double stranded DNA (e.g. F10A1A2, F20T1, see Table 2.3).
d
Quadruplex DNA (G5, see Table 2.3).
e
Compounds obtained by organic synthesis (see section 6.6 for their full chemical
names and structures).
f
Ethidium bromide (EtBr) and Dn were used as comparison compounds.
g
Number of acquisitions summed in order to get a representative spectrum
b
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2.2.2.2.

Calculation of Oligonucleotide Concentration

The concentrations of oligonucleotides were calculated by measuring their UV
absorbance at 260 nm (UV-vis spectrophotometer, Shimadzu) using the Beer-Lambert
law. The molar extinction coefficients for each DNA strand were calculated from the
extinction coefficient at 260 nm (ε260) of the individual bases obtained from the
Oligonucleotide Properties Calculator website.172 The extinction coefficients used for
adenine, guanine, cytosine and thymine were 15200, 12010, 7050 and 8400 M-1.cm-1,
respectively.

2.2.2.3.

Preparation of Secondary and Higher Order DNA
Structures

Double-stranded (dsDNA, e.g. Rt1, F0AT), or partially double-stranded (pdsDNA,
e.g. F20A1A2) DNA structures were obtained by annealing the appropriate relative
amounts of the complementary or partially complementary single strands in 100 mM
ammonium acetate, pH 7.5, in order to give a 1 mM solution. These solutions were
heated in a water bath to 90 °C for 15 min then cooled slowly to room temperature
before being stored in the freezer at -20 °C. In the case of quadruplex DNA (qDNA,
e.g. G5) the annealing process was carried out using 150 mM ammonium acetate,
pH 7.5. To determine that the DNA had been annealed, ESI mass spectra of the ds- or
pdsDNA solutions (5 μM DNA in 100 mM NH4OAc, pH 7.5) were acquired using the
Meth.dsDNA and Meth.pdsDNA methods, respectively (see Table 2.4). In the case of
quadruplex DNA, dilute solutions of DNA (5 μM qDNA in 150 mM NH4OAc, pH 7.5)
were analysed using the Meth.qDNA method (see Table 2.4).
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2.2.3. Preparation of the DNA-Drug Complexes
The solutions used for titration experiments were prepared as follows. Equimolar (1:1)
anthracycline-DNA mixtures were made by adding to 78 μL of 100 mM ammonium
acetate, pH 7.5, 1 μL of the appropriate DNA solution (1 mM, dsDNA or pdsDNA) and
1 μL of stock anthracycline (1 mM). In the case of CosD (stock solution, 0.5 mM in
100 mM ammonium acetate, pH 7.5), the solution was made by adding 1 μL of dsDNA
and 2 μL of CosD to 77 μL of the ammonium acetate solution. Other anthracyclineDNA mixtures (1:2, 1:3, 1:4, 1:5, 1:7, 1:9, 1:11, 1:13) were prepared in a similar way by
altering the relative amounts of anthracycline and ammonium acetate, but maintaining
the DNA concentration and a total volume of 80 μL. After an equilibration time of 10
minutes, the solutions were diluted just prior to ESI-MS analysis by adding 120 μL of
100 mM ammonium acetate, pH 7.5, to give a final DNA (dsDNA or pdsDNA)
concentration of 5 μM. In the case of quadruplex DNA-drug complexes, the preparation
of the different mixtures was carried out in the same way using 150 mM ammonium
acetate solution, pH 7.5.

2.2.4. Mass Spectrometry Conditions
Different mass spectrometers and instrument conditions were used depending on the
type of experiments being carried out. The instruments and range of conditions used
during the different sets of experiments (e.g. DNA-drug titration, enzymatic digestion)
are detailed below. The experimental conditions reported for each set of experiments
were obtained after the optimization of the different parameters in order to obtain the
best spectrum possible (peak intensity, peak shape and signal-to-noise). All instruments
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were externally calibrated with a solution of 1 mg/mL cesium iodide (CsI) over the m/z
acquisition range. All experiments were repeated at least twice and the results were
reproducible.

The data were processed using either MassLynx V4.0 (data collected from the Waters
Synapt™ HDMS™, Q-Tof Ultima™ or Quattro Micro™) or Xcalibur Qual Browser
(data collected using the ThermoFisher LTQ). For experiments using MassLynx,
typically 10 to 50 acquisitions were combined to obtain a representative spectrum. Each
spectrum was then background subtracted using a polynomial order of 11 with 40%
below curve, then smoothed using the MassLynx software, where 20 channels were
smoothed twice. Using Xcalibur, typically 50 to 100 scans were combined to obtain a
representative spectrum.

2.2.4.1.

MS Analysis of the Fractions Collected After HPLC
Purification of the Crude Anthracycline Extracts from
S. olindensis ICB20. Method Name: Meth.Quattro

All the fractions collected from HPLC purification of the different crude extracts were
analysed using electrospray ionisation mass spectrometry (ESI-MS) (Meth.Quattro
method, described below). The analysis was carried out using a Waters Quattro Micro™
ESI mass spectrometer equipped with a Z-spray ionisation source and a quadrupole
mass analyser with a m/z range of 4000. Samples were injected to the mass spectrometer
using the instrument syringe pump at a flow rate of 20 μL/min. All spectra were
acquired using an Rf lens energy of 1.6 V and the cone and capillary voltages were 20 V
and 3.0 kV, respectively. The source and desolvation temperatures were 80 °C and the
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desolvation gas flow rate was 250 L/hr. Spectra were acquired in positive ion mode over
the range m/z 300-2000 and typically 30 acquisitions were summed to obtain a
representative spectrum.

2.2.4.2.

Accurate Mass Determination of the Anthracyclines
Collected from the Crude Sample. Method Name:
Meth.Lockspray

The exact masses of anthracyclines collected in the HPLC fractions from purification of
the crude extracts were determined using a Waters Synapt™ HDMS™ ESI mass
spectrometer equipped with a Z-spray ionisation source, a quadrupole mass analyser
with a m/z range of 4000 and a lockspray attachment using CsI as the standard. Samples
(~10 μM) were prepared by dissolving the compound in 100 mM ammonium acetate,
pH 7.5, with 10% methanol (to assist desolvation), then injected to the mass
spectrometer using a Harvard Model 22 syringe pump (Natick, MA, USA) at a flow rate
of 10 μL/min. All spectra were acquired using the Meth.Lockspray method as follows.
The acquisition was carried out using a MCP potential of 1800 V, capillary voltage of
2.5 kV and the sampling and extraction cone voltages were 80 V and 4 V, respectively.
The source temperature was 80 °C and the desolvation gas flow rate was 400 L/hr at a
temperature of 200 °C. Spectra were acquired in positive ion mode over the range m/z
400-2000 and typically 40 acquisitions were summed. The corrected mass was obtained
by adjusting the values to the CsI reference ion at m/z 1172.1450 Da. The elemental
composition of the anthracyclines were determined using the MassLynx elemental
composition calculator and the same software parameters were used in all cases to select
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the possible molecular formulae and were as follows: + 5 mDa range of the
monoisotopic mass and each fit was calculated using 3 isotope peaks.

2.2.4.3.

Tandem Mass Spectrometry (MSn) of the Anthracyclines.
Method Name: Meth.MSn

Fragmentation of anthracyclines collected from the HPLC purification of the crude
extracts was performed using a ThermoFisher LTQ linear quadrupole ion trap mass
spectrometer equipped with a ESI source. Anthracyclines (20 μM in methanol) were
injected into the instrument at a flow rate of 5 μL/min. Positive ion ESI mass spectra
were acquired using a source voltage, capillary voltage and temperature of 3.71 kV,
60 V and 49 °C, respectively. For all MSn (n=1-5) experiments, the isolation width was
2-3 Th, CAD fragmentations were induced using a collision energy of 20-40 V, and the
typical activation time was 30 ms. Spectra were acquired over the range m/z 350 - 1300
and 100 scans were summed to obtain a representative spectrum.

2.2.4.4.

Ion Mobility Mass Spectrometry of Anthracyclines. Method
Name: Meth.IMSanthr

The ion mobilities of anthracyclines from HPLC were analysed using the Waters
Synapt™ HDMS™ ESI mass spectrometer. All samples were prepared in 100 mM
ammonium acetate, pH 7.5, at a concentration of ~5 μM, and injected to the mass
spectrometer using the instrument syringe pump at a flow rate of 5 μL/min. All spectra
were acquired using a MCP potential of 1800 V, capillary voltage of 2.0 kV and the
sampling and extraction cone voltages were 20 V and 4 V, respectively. The source
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temperature was 80 °C and the desolvation gas flow rate was 400 L/hr at a temperature
of 200 °C. The Triwave™ settings used were as follows: the trap and transfer collision
energies were 6.0 V and 4.0 V, respectively, the IMS gas flow was 25 mL/min, the trap
DC entrance, bias and exit voltages were 5.0 V, 27.0 V and 5.0 V, respectively; IMS
DC entrance and exit voltages were 5.0 V and 2.0 V, the transfer DC entrance and exit
voltages were both 2.0 V, and the IMS wave velocity and height were 350 m/s and
14 V, respectively. Spectra were acquired in positive ion mode over the range
m/z 1000 - 1300 and 35 acquisitions were summed to obtain a representative spectrum;
all drift time results were expressed in ms. The instrument was calibrated using a CsI
solution (1 mg/mL) over the range m/z 500-2000.

2.2.4.5.

Hydrolysis of Anthracycline Sugars and MS Analysis.
Method Name: Meth.Digest

Reaction mixtures for the analysis of the stabilities of anthracycline fractions were
prepared as follows: 120 mM ammonium acetate stock solution at a different pH values
(3.5, 5.5, 7.5, 9.5 and 10.5) were prepared by addition of either acetic acid or ammonia.
The digestion mixtures were obtained by adding 10 μL of 30 μM CosD solution in
water to 50 μL of the corresponding 120 mM ammonium acetate buffer to give 60 μL of
5 μM CosD in 100 mM ammonium acetate. Each solution was then subjected to
different conditions: 3 temperatures at 4 °C (fridge), 25 °C (room temperature) and
40 °C (water bath); 3 digestion times of 1 h, 4 h and 18 h. The mixtures were then
analysed using the LTQ ESI mass spectrometer using the method Meth.Digest as
follows. MS analyses of the digested solutions were performed using a ThermoFisher
LTQ linear quadrupole ion trap mass spectrometer equipped with an ESI source.
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Solutions that had been treated at different pH values and temperatures were injected
into the instrument at a flow rate of 5 μL/min. Positive ion ESI mass spectra were
acquired using a source voltage, capillary voltage and temperature of 3.71 kV, 60 V and
49 °C, respectively. Spectra were acquired over the range m/z 500-1300 and 160 scans
were summed in average to obtain a representative spectrum.

2.2.4.6.

Investigations of the DNA-Binding Properties of Several
Anthracyclines

The mixtures containing the various DNA-drug complexes (for mixture preparation, see
section 2.2.3) were analysed using a Waters Q-Tof Ultima™ ESI mass spectrometer
equipped with a Z-spray ionisation source and a quadrupole mass analyser with a m/z
range of 32,000. Note that this high mass range quadrupole is not essential for these
experiments; 4000 would suffice. All samples were injected to the mass spectrometer at
a flow rate of 20 μL/min using a Harvard Model 22 syringe pump (Natick, MA, USA)
and the instrument was externally calibrated using CsI (1mg/mL) over the m/z
acquisition range. The different DNA structures used required different sets of
conditions for the analysis of the corresponding DNA-drug complexes by mass
spectrometry; these are summarised in Table 2.4.

2.2.4.7.

Tandem Mass Spectrometry
Anthracycline Complexes

(MS/MS)

of

dsDNA-

DNA-anthracycline complexes (dsDNA:Dn 1:1, 1:3 and 1:5 ratios; dsDNA:Dx 1:3, 1:5
and 1:9 ratios; and dsDNA:CosD 1:2, 1:3 and 1:4 ratios) were prepared as described
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above (see section 2.2.3.3). The DNA-anthracycline mixtures were analysed using a
Waters Q-Tof Ultima™ ESI mass spectrometer equipped with a Z-spray ionisation
source and a quadrupole mass analyser with a m/z range of 32,000. All solutions were
injected to the mass spectrometer using a Harvard model 22 syringe pump. All tandem
mass spectrometry spectra (MS/MS) were acquired using a MCP potential of 2100 V,
Rf lens energy of 70 V, and cone and capillary voltages were 100 V and 2.5 kV,
respectively. The source temperature was 80 °C and the desolvation gas flow was
300 L/hr at a temperature of 100 °C. Argon was used as the collision gas and set to a
pressure of 15 psi. The collision energy was varied from 0 to 26 V to establish a
relationship between the amount of energy applied, the dissociation patterns and the
product ions observed. Spectra were acquired in negative ion mode over the range
m/z 500 - 4000 and typically 10 acquisitions were summed to obtain a representative
spectrum. The instrument was calibrated using a CsI solution (1 mg/mL) over the same
m/z range.

2.2.4.8.

Enzymatic Digestion

All DNA-anthracycline complexes (1:6, 1:6 and 1:2.5 for dsDNA:Dn, dsDNA:Dx and
dsDNA:CosD, respectively) were prepared as described in section 2.2.3.3.
Phosphodiesterase I and Dnase were diluted into water and stored on ice. Their UV
absorbances at 280 nm (A280) were measured using a 0.1 cm pathlength quartz cuvette
and were 0.158 and 0.870, respectively. Nuclease digestion was commenced by addition
of 10 μL of PdI or 20 μL of Dnase to 50 μL of DNA-anthracycline complex (25 °C). At
each time point (1 min, 10 min, 20 min and 30 min), 10 μL of the reaction mixtures
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were added to 90 μL of 5 mM ammonium acetate, 50% in acetonitrile to stop the
reaction and the solutions were immediately analysed by ESI-MS. All samples were
analysed using a Waters Q-Tof Ultima™ ESI mass spectrometer equipped with a
Z-spray ionisation source and a quadrupole mass analyser with a m/z range of 32,000
and were injected to the mass spectrometer using a Harvard Model 22 syringe pump.
All nuclease digestion experiments were acquired using a MCP potential of 2100 V,
Rf lens at 70 V, and the cone and capillary voltages were 250 V and 2.5 kV,
respectively. The source temperature was 60 °C and the desolvation gas flow was
300 L/hr at a temperature of 200 °C. Spectra were acquired in negative ion mode over
the range m/z 500-4000 and typically 40 scans were summed to obtained a
representative spectrum. The instrument was calibrated using a CsI solution (1 mg/mL)
over the same m/z range and the products of nuclease digestion were analysed by
reference to Mongo Oligo Mass Calculator website.173

2.2.5. Other Characterisation Techniques

2.2.5.1.

Electrophoresis: Gel Mobility Shift Assays

Two types of gel mobility shift assays were performed, each one used a different type of
DNA. For the first set of experiments plasmid DNA (pUC9) was prepared and purified
using a QIAGEN plasmid Maxi Kit and its concentration was calculated from its UV
absorption at 260 nm. The DNA (pUC9, 50 μg/mL) and drug (1 to 20 μM for Dn and
CosD and 1 to 50 μM for Dx) stock solutions were prepared in 50 mM ammonium
acetate, pH 7.5. The electrophoresis buffer was made by dilution (1:10) of the stock
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TBE buffer solution (10 mM EDTA, 445 mM boric acid, 446 mM Tris base Ultrol
grade, in 1 L of water). For a typical sample, 5 μL of stock anthracycline solution
(different concentrations, see results section 5.3.3.1) were added to 5 μL of plasmid
DNA (50 μg/mL). The 5 μL of anthracycline solution was replaced by 5 μL of
1:10 TBE buffer in the control samples and by 5 μL of the restriction enzyme HindIII
for opening of the supercoiled DNA. The solutions were equilibrated at room
temperature for 15 min before adding 2.5 μL of loading dye (0.25% bromophenol blue
in sucrose 40% w/v), and 10 μL of these mixtures were loaded onto a 1% agarose gel.
The 1% agarose electrophoresis gel was prepared by mixing 0.5 g of agarose in 50 mL
of the 1:10 diluted buffer, and heating the solution to boiling until all agarose was
dissolved. The gel was poured (tank: 90 x 100 mm, 16 wells) and left to set for 45 min.
The gels were electrophoresed using a PowerPac Basic generator (Bio-Rad, Hercules,
Australia) for 5 h at 30 V, stained in ethidium bromide solution (15 μL of 10 mg/mL of
ethidium bromide in 500 mL of water) for 35 min and then rinsed in water for 20 min.
Gels were then photographed using a Bio-Rad Molecular Imager Gel Doc XR System.

Double-stranded DNA used in the second set of experiments was purified and annealed
as described above (see sections 2.2.2.2 and 2.2.2.3). The dsDNA (Rt1, 20 μM) and
drug (20 to 260 μM for Dn and Dx and 20 to 250 μM for CosD) stock solutions were
prepared in 50 mM ammonium acetate, pH 7.5. The electrophoresis buffer was made by
dilution (1:10) of the stock TBE buffer solution (as above). For a typical sample, 5 μL
of stock anthracycline solution (different concentrations, see results section 5.3.3.2)
were added to 5 μL of dsDNA (Rt1, 20 μM). Three control samples were obtained, Rt1
(dsDNA), Rt1A and Rt1B (ssDNA), by replacing the 5 μL of anthracycline solution by
51

5 μL of 1:10 buffer. The solutions were equilibrated at room temperature for 15 min
before adding 2.5 μL of loading dye (0.25% bromophenol blue in sucrose 40% w/v),
and 10 μL of these mixtures were loaded onto a 4% agarose gel. The 4% agarose
electrophoresis gel was prepared by mixing 2.4 g of agarose in 60 mL of 1:10 TBE
diluted buffer, heating to boiling until all agarose was dissolved, then poured into the
tank and left to set for 45 min. The gels were electrophoresed for 3 h at 50 V using the
same electrophoresis equipment as described above, stained (35 μL of 10 mg/mL of
ethidium bromide in 250 mL of water) for 35 min then photographed.

2.2.5.2.

RNA Transcription Assays

The solutions used in these assays were, for the most part, included in the RNA
transcription kit (RiboMAXTM Large scale) purchased form Promega. The T7 DNA
template (pGEM) was purchased separately from Promega. All other buffer solutions
used in these experiments were made from the relevant chemicals as follows; MOPS
buffer: 0.2 M MOPS, pH 7.0, 50 mM sodium acetate and 5 mM EDTA pH 8.0; RNA
sample buffer: 10 mL of deionised formamide, 3.5 mL of formaldehyde (37 % solution)
and 2.0 mL of MOPS buffer; RNA loading buffer: 50% glycerol (very high grade,
RNase free), 1 mM EDTA and 0.4 % bromophenol blue and TAE running buffer stock
solution: 242 g of Tris Base, 57.1 mL of glacial acetic acid, 100 mL of 0.5 M EDTA
pH 8.0. All drug stock solutions were prepared in 50 mM NH4OAc, pH 7.5 (range for
Dn 25 – 250 μM, for Dx 200 μM to 2 mM and for CosD 10 to 100 μM). The
compositions of the reaction mixtures used in these experiments are shown in Table 2.5.
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Table 2.5. Compositions of the reaction mixtures (drug solutions and control samples)
for the transcription assays.
Sample name

Control C1
(no drug)

Control C2
(no enzyme)

Control C3
(NH4OAc
buffer)

Solutions
containing
drug

2

2

2

2

ATP

0.75

0.75

0.75

0.75

GTP

0.75

0.75

0.75

0.75

CTP

0.75

0.75

0.75

0.75

UTP

0.75

0.75

0.75

0.75

T7 DNA template (μL)b

0.5

0.5

0.5

0.5

H2O nuclease free (μL)a

3.5

4.5

2.5

2.5

Drug volume (μL)

-

-

-

1

Drug concentration (μM)

-

-

-

μMc

Enzyme (μL)a

1

0

1

1

50 mM NH4OAc buffer (μL)

0

0

1

0

Total volume (μL)

10

10

10

10

Component
T7 buffer (μL)a

NTPs (μL)a

a

Solution contained in the RNA transcription kit purchased.
pGEM DNA template purchased from Promega
c
For the various concentrations used see results section 5.3.4
b

Each reaction mixture (10 μL) was mixed thoroughly and incubated for 1 h at 37 ºC.
After incubation a 5 μL aliquot of each solution was placed in separate Eppendorf tubes
followed by the addition of 150 μL of RNA sample buffer and 30 μL of RNA loading
buffer. The resulting solutions were mixed, heated to 67 ºC for 7 minutes in a water
bath, cooled down to room temperature and 10 μL of this final mix was loaded onto a
1% agarose gel. The electrophoresis buffer was made by dilution (1:50) of the TAE
running stock buffer solution. The 1% agarose gel was obtained by mixing 0.5 g of
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agarose in 50 mL of the 1:50 diluted TAE buffer, heated until dissolved, then poured
into the tank and left to set for 45 min.

All gels were electrophoresed at 30 V for 2 h using a Cleaver Scientific Multisub midi
horizontal electrophoresis system, stained with ethidium bromide (15 μL EtBr at
10 mg/mL in 500 mL) for 35 min and photographed using a Bio-Rad Molecular Imager
Gel Doc XR System. Inhibition effects were quantified by using the Bio-Rad Molecular
Imager Gel DocTM XR software Quantity One by measuring the band intensities for
different concentrations of anthracyclines. All results were analysed/graphed using
Microsoft Excel software.

2.2.5.3.

UV Absorption

A Shimadzu UV-1700 UV-vis spectrophotometer was used to measure the absorbances
of anthracycline solutions in order to determine their extinction coefficients (ελ) at
different wavelengths (λ). All anthracycline solutions were prepared by dilution of a
stock solution (Dn or its aglycone (Agly), 10 mM in DMF). For a typical dilution, 1 μL
of the stock solution was diluted to a final volume of 400 μL in DMF. All solutions
(25 μM to 100 μM, Dn and Agly) were obtained by altering the amount of stock
solution while maintaining a total volume of 400 μL of DMF. Absorption spectra were
recorded using a 0.1 cm path length (l) quartz cuvette. The determination of the
extinction coefficient at each selected wavelength was obtained by plotting
Abs/l = f(concentration) using Microsoft Excel software. A similar procedure was
followed to obtain the CosD extinction coefficients (ελ) at different wavelengths;
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however, the concentration range and solvent used were 1.6 μM to 25 μM in water and
the solutions were prepared from a CosD stock solution of 0.5 mM.

2.2.5.4.

Circular Dichroism

Circular dichroism measurements were made using a Jasco J-810 spectropolarimeter.
All spectra were recorded using a 0.1 cm quartz cell and the following parameters:
λ = 190-360 nm; step: 0.2 nm; recording speed: 100 nm/min; response: 4 s; spectral
band width: 1 nm; number of accumulated scans: 6. Ammonium acetate (100 mM,
pH 7.5) was used as reference and as solvent for all solutions. All CD spectra shown in
the results section were obtained after subtraction of the solvent spectra. In all
measurements, the temperature was kept constant at 25 ºC using a Ratek
thermoregulator water bath.

The double-stranded DNA Rt1 was used in all experiments and was purified and
annealed as described in sections 2.2.2.1 to 2.2.2.3 to obtain a 1 mM stock solution in
100 mM ammonium acetate, pH 7.5. The titration experiments for each drug were
carried out as follows. A solution of Rt1 alone (20 μM) was prepared by appropriate
dilution of the DNA stock solution and its spectrum recorded under the conditions
described above. Successive aliquots of a stock solution containing both the 20 μM of
Rt1 and an anthracycline were added to the initial Rt1 solution to obtain different
reaction mixtures containing several different Rt1:drug ratios. The concentration of Rt1
in the Rt1-anthracycline stock solution was 20 μM to maintain the DNA concentration
constant after addition of the different aliquots. The concentration of the anthracycline
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in the stock solution varied as a function of the drug used and was 0.5 mM for Dn and
Dx and 0.4 mM for CosD. The different DNA:drug ratios obtained were 1:1, 1:3, 1:5,
1:7, 1:9, 1:11 and 1:13 for Dn and Dx and were 1:1, 1:2, 1:3, 1:4, 1:5 and 1:6 for CosD.
In between the addition of each aliquot, the solution was mixed thoroughly and allowed
to equilibrate for 10 minutes before recording the CD spectrum. The CD spectra of the
drug alone, at the same concentrations as used for the different DNA:drug solutions,
were also recorded to evaluate the CD activity of the drugs.

The CD spectra presented were obtained after subtraction of the buffer component, and
the effects of the drug were evaluated by plotting the changes in the CD bands for each
ratio as function of the wavelength.

2.2.6. Characterisation of the Synthesised Compounds
Melting points were obtained using a Eurotherm BTC-9090 hot-stage apparatus and are
uncorrected. IR spectra were recorded of neat solids using an Avatar 360 FT-IR
spectrometer with wavenumbers reported in cm-1. Optical rotations [α]25D were
recorded using a Jasco DIP-370 digital polarimeter. 1H and

13

C NMR spectra were

recorded using a VARIAN NMR System (500 MHz) fitted with a high-field triple
resonance gradient probe. Chemical shifts were recorded in ppm (δ) relative to TMS as
an internal standard. J values are given in Hertz. 1H and

13

C peak assignments of all

compounds were confirmed using 2D-NMR experiments (DQF-COSY, HSQC, HMBC
and NOESY). Silica-gel 60 (ASTM 0.04 - 0.06 mm; 230-400 mesh) was used for
column chromatography and Silica-gel 60 F254 (Merck) was used for thin-layer
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chromatography (TLC). High resolution (EI) mass spectra (for M+) were recorded using
a VG Autospec mass spectrometer operating at 70 eV and a source temperature of
250 oC. High resolution (HR) ESI mass spectra were recorded on a Waters Q-Tof
Ultima Mass Spectrometer (Wythenshawe, UK).

The detailed synthetic procedures are described in section 6.6 in Chapter 6: Attempted
synthesis of β-rhodomycinone, the aglycone of cosmomycin D.
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CHAPTER 3
Purification and Characterisation of
Cosmomycin D

3.1.

Introduction

Anthracycline antibiotics are one of the best characterised groups of anticancer drugs. In
the last few years there has been increasing interest in different glycosylated forms of
anthracyclines. The presence of sugar chains on anthracyclines, their length and
composition are essential elements which determine their cytotoxicity and their
biological activity.18 Numerous anthracyclines with a wide variety of sugars have been
studied.11-13,18,20 Cosmomycin D contains two trisaccharide chains on carbons C7 and
C10, each consisting of a rhodinose (Rho) residue linked directly to the aglycone,
2-deoxy-L-fucose (deFuc) as the middle sugar and rhodosamine (RhN) at the terminus
of each chain (Figure 3.1). CosD was first isolated from Streptomyces cosmosus over
twenty years ago10 and more recently from Streptomyces olindensis ICB20.7

The structure of CosD is not common among anthracyclines, only a few other
anthracyclines with one or two trisaccharide chains have been characterised. For
example, ditrisarubicin (Dtr, Figure 3.1) contains two trisaccharide chains with its two
end sugars fused on each chain; aclacinomycin A (aclarubicin, Acla; Figure 3.1) has one
trisaccharide chain on C7 and is currently used in the clinic;19 cosmomycins A and B
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possess one trisaccharide chain on position C10, and cosmomycin C resembles CosD in
that it has the same sugar sequences with the exception of an hydroxyl group missing
from the 2-deoxy-L-fucose of the sugar chain attached to the aglycone at position C10
(Figure 3.1).10 The more extensive glycosylation could give rise to new potent
compounds against an array of resistant forms of cancers. Therefore discovery of new
sources of anthracyclines must involve complete structural characterisation.
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Figure 3.1. Structure of several anthracycline antibiotic compounds possessing
trisaccharide chains. Cosmomycin C (CosC); cosmomycin D (CosD); aclarubicin
(Acla); ditrisarubicin (Dtr). The aglycone common to all anthracyclines is represented at
the top with its atom numbering system with R being any functional group.
Numerous techniques have been used to characterise these compounds, including
melting point, UV-vis absorption, NMR or infrared spectroscopies.7,10,37 While NMR
spectroscopy can yield complete structural details, substantial amounts of sample are
required. Mass spectrometry requires only small amounts of sample and has
applications for determining the length, composition and position of attachment of sugar
chains by tandem mass spectrometry (ESI-MS/MS, see below). Ionisation methods such
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as electron ionisation,174 chemical ionisation,175 field desorption176 and fast atom
bombardment177 have been used to determine the structures of anthracyclines such as
daunomycin and doxorubicin derivatives, aclacinomycins, carminomycin rubidozone
and detorubicin. Recently, the first positive ion electrospray ESI-MS/MS experiments
have been carried out on doxorubicin, daunomycin and the structurally similar
epirubicin and idarubicin using a triple quadrupole mass spectrometer.178 Furthermore,
dissociation mechanisms have been proposed for CosD based on negative ion
desorption chemical ionisation39 and positive field desorption ionisation mass
spectrometry.41

Tandem mass spectrometry was briefly described in section 1.3.1.2. Successive CAD
fragmentation is known as multistage mass spectrometry or MSn (with ′n′ indicating the
number of stages of mass spectrometry). A suitable instrument for this task is the
ThermoFisher LTQ linear quadrupole ion trap mass spectrometer used in the current
work.

Figure 3.2 shows the multistage tandem mass spectrometry principle and an
hypothetical example of multiple stage tandem mass spectrometry where three
successive isolation/fragmentation cycles were carried out, in this case MS3. In the
original mass spectrum, the peak corresponding to [M + H]+ is the base peak ion and is
isolated from the other peaks and selected for fragmentation. A MS2 spectrum is
obtained from the fragmentation of the [M + H]+ precursor ion (Figure 3.2 (B) shown in
red) and on this spectrum fragment ions can also be observed. In these examples, MS3
spectra are obtained by selecting and applying energy to two different product ions from
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the MS2 spectrum. The resulting MS3 spectra show further fragmentation. The
successive fragmentation process can be repeated “n” times, as long as the ion has
sufficient abundance and is able to fragment further.

Figure 3.2. Diagram of the multistage tandem mass spectrometry principle (A) with an
example, in this case MS3 (B). Figure adapted from reference 116. The precursor ion is
[M + X]+.
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Recently (mid-2006), an instrument has been released commercially that combines a
Q-Tof instrument with ion mobility mass spectrometry (Synapt™ HDMS™). Ion
mobility mass spectrometry (IMMS, described in section 1.3.1.3) is an analytical
method that allows the separation of ions as a function of their cross-section (charge,
mass and shape) enabling analysis of complex mixtures without separation prior to
analysis. The new technology (TWIMS) employed in the Synapt™ HDMS™ uses a
voltage pulse along rings of stacked electrodes (Triwave™ technology)141 to produce a
traveling voltage wave which is at the origin of the ion separation in the drift
cell.137,139,179

Figure 3.3. Schematic of the Synapt™ HDMS™ mass spectrometer. Figure adapted
from the Waters website (http://www.waters.com/waters/nav.htm?locale=en_US&cid=
514457).
The combination of IMMS with the Q-Tof capabilities in the Synapt provides new
dimensions for analysis of molecules or complexes via CAD experiments. Figure 3.3
shows a schematic diagram of the Synapt™ HDMS™. Figure 3.4 shows different
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possibilities for fragmentation:141 TRAP T-wave fragmentation where the dissociation
occurs prior to mobility separation with the product ions separated both by m/z, shape
and size (Figure 3.4 (A)), TRANSFER T-wave fragmentation where fragmentation
occurs after mobility separation facilitating the analysis of mixtures of isomers and
conformers (Figure 3.4 (B)) and,

time-aligned parallel (TAP) fragmentation, with

fragmentation occurring both prior and post mobility separation. (Figure 3.4 (C)).

Figure 3.4. Fragmentation modes of the Synapt™ HDMS™: (A) TRAP T-wave
fragmentation, (B) TRANSFER T-wave fragmentation and (C) Time aligned parallel
(TAP) fragmentation. Figure adapted from reference 141.
In the TAP fragmentation process, a specific ion is selected in the quadrupole and
collision energy is applied in the trap region in order to induce fragmentation. The ions
produced are called first generation product ions. These ions are then released to the
mobility cell where they are separated as a function of their drift time (related to their
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masses, charges and sizes). The bigger their cross section, the longer the time it takes to
travel through the mobility cell. After ion mobility separation the ions enter the transfer
region at different times; each packet of ions is then subjected to collision energy,
inducing more fragmentation and producing second generation product ions. All ions
then enter the oa-Tof detector where they are separated based on of their mass/charge.
This fragmentation technique has a great advantage as it allows identification of the
parent ion that produced each fragment because all fragments are time-aligned.

3.2.

Scope of this Chapter

In this chapter the development of a purification method to obtain CosD from crude
extracts of Streptomyces olindensis ICB20 is described. Several mass spectrometric
techniques were applied to characterise CosD and some unknown anthracycline
compounds collected during the purification of the crude extract. The sensitivity of the
mass spectrometry techniques allowed characterisation from small amounts of material.
Firstly, the purity of each fraction was assessed using an ESI triple quadrupole mass
spectrometer and the concentrations of the fractions were estimated by UV-visible
spectrophotometry. The exact masses and the elemental compositions of these
compounds were determined using a Waters Synapt™ HDMS™ ESI mass
spectrometer. Further characterisation was achieved using complementary mass
spectrometric techniques. Multi-stage collisionally-activated dissociation (CAD) and
time-aligned parallel fragmentation were used to determine and confirm the sugar
sequences present on each compound and isobaric compounds were separated in the
travelling wave ion mobility cell of the Synapt™ HDMS™ mass spectrometer.
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3.3.

Results and Discussion

3.3.1. Development of the Purification Method
Crude anthracycline extracts containing cosmomycin D were obtained by methanol
extraction of culture supernatants from Streptomyces olindensis ICB20 obtained from
the laboratory of Dr. Padilla (U. Sao Paulo, Brazil). These extracts were obtained from
three bacterial cultures, two of which had been genetically modified with the aim to
stimulate overproduction of CosD.171

S020 was the first of the three crude samples to be analysed. In order to determine the
relative amount of pure cosmomycin D in the sample, a small amount of the crude
powder was dissolved in water and a positive ion ESI mass spectrum was obtained. This
solution and all subsequent fractions collected were analysed using the Quattro ESI
mass spectrometer using the Meth.Quattro method (see 2.2.4.1.) to evaluate purity and
the molecular masses of the major components in the solutions. The mass spectrum
(Figure 3.5) showed the presence of some CosD, at m/z 595.7 and 1189.8 corresponding
respectively to [CosD + 2H]2+ and [CosD + H]+, among many other unknown ions.

Figure 3.5. Positive ion ESI mass spectrum of the crude S020 sample in water before
any purification.
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Knowing that the S020 crude material contained some of the desired product, a
purification of the crude extract was carried out by HPLC, dissolving around 2 mg in
600 μL of 100 mM NH4OAc, pH 7.5. The solution was mixed by vortex, centrifuged,
filtered and separated using a C18 HPLC column. Only three peaks were observed in
the chromatogram as judged by measurement of the absorbance at 254 nm (t1 – t3, see
Figure 3.6). These three fractions were collected, but analysis of the solutions by mass
spectrometry (Meth.Quattro), showed that no CosD was present in the fractions.

Figure 3.6. Chromatogram of the S020 crude (supernatant after centrifugation of the
suspension and filtering using a 0.45 μm nylon syringe filter) obtained after HPLC on a
C18 column equilibrated with 100 mM ammonium acetate and eluted using acetonitrile
using method: MethCC18.
Therefore, the gradient and/or solvent used were not appropriate for elution of CosD
from the column. To address these issues, a pre-purification step was introduced in
order to remove some of the most apolar compounds prior to HPLC.

3.3.1.1.

Pre-Purification on C18 Cartridge Columns

The crude sample was passed through a small cartridge column and eluted using
phosphate buffer and acetonitrile to separate CosD from some of the impurities
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contained in solution. The buffers used were 10 mM sodium phosphate buffer, pH 6.0
or 8.0 (PBS) with acetonitrile in the ratios 80/20, 50/50 and 20/80. The pre-purification
was carried out at two different pHs in order to determine whether this had an influence
on the separation of some of the impurities and the amount of CosD recovered after
purification by HPLC.

The pre-purification steps were identical for the two pH conditions and were as follows:
The cartridge was wet with the 10 mM PBS/ACN 50/50 (2 mL), then equilibrated three
times with 1 mL of 10 mM PBS. Crude S020 extract (20 mg) was dissolved in 1 mL of
10 mM PBS and loaded onto the column. The column was washed six times: three
times with 1 mL of 10 mM PBS, then three times with 1 mL of 10 mM PBS/ACN
80/20. Fractions were eluted from the column using 3 ° 1 mL of 10 mM PBS/ACN
20/80, then three more times using 1 mL of acetonitrile. Six fractions of 1 mL were
collected, combined, and dried down.

The dried fractions were dissolved in 1 mL of 100 mM ammonium acetate
(corresponding pH), injected onto the HPLC and purified as described above (method
MethCC18). For HPLC the elution buffers were adjusted to pH 6.0 (or pH 8.0) for the
separation of the crude fractions obtained after the pre-purification steps. In each case
multiple fractions were collected throughout the run (see Figure 3.7).

Fractions were collected and taken to dryness. Since cosmomycin D is red-purple in
colour,10 only the coloured fractions were redissolved in 50% aqueous methanol and
analysed by ESI-MS (Meth.Quattro method section 2.2.4.1). Among all the coloured
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fractions only one fraction collected from each run contained cosmomycin D,
t8=29.6-30.6 min and t6=24.4-25.7 min from the chromatograms shown in
Figures 3.7 (A) and (B), respectively.

Figure 3.7. Elution profiles obtained after the HPLC purification at: (A) pH 6.0, (B) pH
8.0. The fractions collected are indicated by ti with i = 1 – 12 for (A) and i = 1 – 11 for
(B).
In the spectra shown in Figure 3.8 (A) and (B), ions corresponding to [CosD + 2H]2+
and [CosD + H]+ at m/z 595.4 and 1189.8, respectively, were detected, indicating the
presence of cosmomycin D. None of these fractions contained the compound in its pure
form; other ions from impurities eluting at the same time were observed in the mass
spectra (e.g. at m/z 701.6, 475.4 and 365.2). The purification was repeated a few times
but was not highly reproducible.
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Figure 3.8. Positive ion ESI mass spectra obtained for each fraction containing CosD
from the purification at the two different pH values. (A) Fraction collected at
t8=29.6-30.6 min (from the chromatogram obtained at pH 6.0 (Figure 3.7 (A)), (B)
fraction collected at t6=24.4-25.7 min (from the chromatogram obtained at pH 8.0
(Figure 3.7 (B)).
Owing to the inconsistencies in the results obtained by HPLC, this method was
abandoned and a new pre-purification step was developed to try to improve
reproducibility and recovery of CosD during the purification by HPLC.

3.3.1.2.

Exploitation of the Greater Solubility of CosD in Water

Daunomycin and doxorubicin are rather water soluble as a result of their amino sugar.
Cosmomycin D has a similar ring system, bearing similar functional groups, but
possesses more sugars. The presence of these additional sugars, forming two
trisaccharide chains attached to the C7 and C10 carbon of ring A (see Figure 3.1) makes
cosmomycin D more water soluble than daunomycin and doxorubicin. The new
pre-purification method described below took advantage of the differences in solubility
(in methanol vs. water) of CosD and the impurities present in the crude extract.
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The S020 crude powder containing CosD was dissolved in water and sonicated for 15 to
20 min until the crude material was homogeneously dispersed in the solution.
A suspension was obtained since all the compounds contained in the crude extract were
soluble in methanol but not in water. This suspension was centrifuged (17000 g, 15 min,
4 ºC) and the non-soluble material was separated from the supernatant. The non-water
soluble material was dissolved in methanol and analysed by mass spectrometry; no
CosD was detected in the sample. Therefore only some of the impurities present in the
crude sample were not soluble in water and cosmomycin D was entirely dissolved in the
supernatant.

The supernatant was stored at -20 ºC then thawed to room temperature. After freezing
and thawing, some material came out of solution. The resulting suspension was
centrifuged, and as before and the non-soluble fraction was separated from the
supernatant. To investigate the composition of the non-soluble residue obtained after the
freeze/thaw cycle, it was dissolved in methanol and analysed by mass spectrometry
(Figure 3.9, method Meth.Quattro).

Figure 3.9. Positive ion ESI mass spectrum of the insoluble residue in methanol
collected after a freeze/thaw cycle.
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No cosmomycin D was contained in the non-soluble residue. In order to determine
whether the freezing time had an effect on the amount of impurities coming out of
solution, three identical samples were frozen for different periods of time: 4 h, 20 h and
60 h. After freezing, the samples were thawed to room temperature, centrifuged, the
supernatant was separated from the non-soluble fraction and analysed by mass
spectrometry using the same conditions as described before (method Meth.Quattro). In
this case the supernatant was analysed since the previous experiments showed that the
non-soluble fraction did not contain any cosmomycin D.

Figure 3.10. Positive ion ESI mass spectra of the supernatant obtained after different
freezing times. Freezing time: (A) 4 h, (B) 20 h and (C) 60 h.
ESI mass spectra of the supernatants, treated at -20 ºC for 4 h, 20 h and 60 h are shown
in Figure 3.10. Only a small difference was observed in the relative abundances of
impurities appearing in the different spectra. CosD was the major component in each
case ([CosD + 2H]2+ and [CosD + H]+ at calculated m/z 595.6 and 1189.5, respectively).
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[CosD + 2H]2+ was the most abundant ion in each spectrum under the conditions used
(method Meth.Quattro). The amount of impurities collected from each sample after
centrifugation varied as a function of the time the sample had spent at -20 ºC. As the
time spent at -20 ºC increased, the amount of impurities collected after centrifugation
also increased, reaching a maximum for 20 h in the freezer. From these tests, the
optimum freezing time was determined to be around 20 h.

3.3.1.3.

Extraction of Impurities Using Ethyl Acetate

In order to improve further the pre-purification of the sample, an extraction step was
attempted. Ethyl acetate is a non-water miscible polar organic solvent (dielectric
constant 6.02 ε0 at 25 °C, density 0.897 g/cm-3) and was selected as solvent of choice to
extract impurities from the aqueous solution containing CosD. The extraction was
carried out on the supernatant of the crude sample after initial elimination, by
centrifugation, of the non-water soluble compounds. To a volume of crude sample,
about one-half of the equivalent volume of ethyl acetate was added. The resulting
solution was sonicated for 15 min and then centrifuged (15000 g, 15 min, 4 ºC) to assist
with the phase separation. The ethyl acetate phase was removed and the process was
repeated with an identical volume of ethyl acetate. The resulting organic phases were
pooled. The aqueous crude solution before extraction was an orange-red colour, and
became lighter after the extraction process. The ethyl acetate phase after the extraction
step was orange. These changes in colour from both the solutions meant that some
compounds were transferred from the aqueous to the organic phase. In order to
determine whether any of the CosD was transferred from the aqueous to the organic
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phase, the pooled ethyl acetate phases were dried down using a Savant Speed Vac. The
resulting dried ethyl acetate residue was then dissolved in methanol and analysed by
mass spectrometry (method Meth.Quattro). No CosD was detected in these fractions
(data not shown). Therefore, no CosD was transferred to the organic phase during the
extraction procedure.

Figure 3.11. Positive ion ESI mass spectra obtained before (A), and after (B) extraction
of the crude sample (no freezing) with ethyl acetate.
The spectra shown in Figure 3.11 were obtained by analyzing the aqueous phase before
(A), and after (B), extraction with ethyl acetate. There were fewer impurities in the
crude solution after extraction with ethyl acetate.

The two pre-purification steps developed (removal of impurities by freeze/thaw and
ethyl acetate extraction, as described above) both gave good individual results toward
the removal of impurities from the crude sample. These two methods allowed the
removal of impurities by using the solubility properties of the compounds present in the
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crude samples. To maximize the elimination of the impurities from the crude sample,
they were combined before subjecting the sample to further separation by HPLC. The
different steps of the pre-purification process are summarised in Figure 3.12.

Figure 3.12. (A) Summary of the different steps involved in the pre-purification process
used to treat the crude extracts. (B) Mass spectrum of the pre-purified extract.
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The purity of CosD was clearly improved following this pre-purification process
(Figure 3.12 (B)), however CosD was not sufficiently pure to be used directly in
DNA-binding experiments. Further purification by HPLC was necessary.

3.3.1.4.

Further Purification by HPLC

Different sets of conditions were tested on the HPLC. Table 2.1 shows the HPLC
columns trialled and Table 2.2 summarises the elution methods. The sample was dried
under reduced pressure (Savant Speed Vac) and redissolved in 100 mM ammonium
acetate, pH 7.5. Firstly the sample was loaded onto a C18 column, and eluted using a
0 - 100 % acetonitrile gradient (MethCC18, Table 2.2). None of the eluted fractions
contained CosD. To remedy to this problem, a more polar C4 HPLC column was used
(method MethCC4A, Table 2.2).

Figure 3.13. HPLC elution profile of the pre-purified crude extract using a C4 HPLC
column, method MethCC4A. The fractions eluting between 15 and 35 min are shown in
detail (inset) and all fractions collected during the run are marked by ti, with i = 1-13.
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The chromatogram obtained is shown in Figure 3.13. A group of peaks was eluted
between 15 and 35 min and 11 fractions, t3 – t13, were collected. The fractions were
analysed by mass spectrometry. Most of these fractions were coloured ranging from
brown-yellow to red-purple. Fraction t9 (23.3 min) was found to contain cosmomycin D.
All other fractions were analysed under the same conditions. All these compounds were
coloured and had masses that were relatively close to that of CosD suggesting that these
compounds were likely to be anthracyclines related to CosD. The characterization of
these compounds is discussed further in section 3.3.2. The HPLC purification of the
pre-purified crude extract was repeated several times. The method was reproducible and
pure CosD was collected at an identical retention time for each HPLC run.

Figure 3.14. Mass spectra tracing the evolution of the purity of the S020 sample
through the purification procedure. (A) MS of the S020 crude sample before any
purification, (B) MS of the S020 crude sample obtained after applying the
pre-purification method developed and (C) MS of the pure CosD collected at an elution
time of 24.3 min after purification by HPLC using the MethCC4A method.
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Figure 3.14 shows the evolution of the purity of the sample collected after each stage of
the purification procedure. Figure 3.14 (A) shows the ESI mass spectrum of the crude
sample obtained after dissolution in water and separation of the initial suspension; (B) is
the spectrum of the sample obtained after the pre-purification outlined in Figure 3.12,
and (C) is the spectrum of the fraction containing CosD collected after the HPLC using
the C4 column. This method gave reliable results and a pure compound on an analytical
scale; however the amount of pure CosD recovered was small (under 0.5 mg of pure
compound). To purify greater quantities of CosD, the method was adapted to a
semi-preparative scale using a C4 HPLC column with greater capacity (MethCC4SP,
see Table 2.2). Pure CosD was kept in the freezer as a 0.5 mM stock solution in
100 mM ammonium acetate, pH 7.5.

3.3.1.5.

Evolution of the Composition of the Crude Sample

Over the period of this project successive S020 crude extracts were obtained from
cultures of cosmomycin D-producing Streptomyces olindensis ICB20; however, the
composition of the crude material received from our collaborator changed over time. A
possible explanation for this observation is that propagation of the Streptomyces for
many generations caused spontaneous mutations that resulted in production of a range
of structurally related anthracyclines by the bacteria. Spontaneous mutations by
Streptomyces are well documented in the literature.180 Cultures that had originally
produced CosD as the major anthracycline were now producing a number of different
compounds. The preparative HPLC gradient used during the development of the
purification process (MethodCC4SP, see Table 2.2 section 2.2.1) had to be slightly
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modified in order to separate the new impurities present in the crude material from
CosD. This new gradient, MethodCC4SP-2, was as follows: 0-25% of buffer B from
0 to 8 minutes; 25-60% of buffer B from 8 to 43 minutes; 60-100% from 43 to
44 minutes and 100% of B from 44 to 54 minutes.

Figure 3.15. Evolution of the HPLC elution profile of the pre-purified crude sample
with time. Crude received and purified: (A) May 2006, (B) July, 2007 and (C) August
2007. The fractions eluting between 30 and 48 min are shown in detail (inset), the CosD
fraction is marked with an arrow (v), and the impurities with a circle (y).
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Figure 3.15 shows the HPLC elution profiles obtained for three different crude samples
obtained from successive propagation of the same cosmomycin D-producing organism.
The major difference was observed for the impurities possessing an elution time under
15 minutes; multiple fractions were collected in this region and neither CosD nor any
coloured fractions were observed. As seen in the above chromatograms, the mutation of
the bacteria also caused an increase in the number of compounds with an elution time
ranging from 30 and 48 minutes (shown in the insets in Figure 3.15) as well as a
decrease in the relative and absolute quantity of CosD produced by the bacteria.171,180

The spontaneous mutation(s) that had occurred during the successive propagations led
to the production of compounds that ranged in colour from yellow-brown through to
red-purple. Considering the close elution time of CosD and the impurities and the range
of colours observed for these different compounds it was postulated that these
compounds were related to CosD. These compounds could be anthracyclines that
possessed a structure relatively close to the one of CosD. To try to evaluate the effect of
these mutations on the type of compound produced, several of the compounds that had a
retention time close to that of CosD were collected for further characterisation.

Figure 3.16 shows the elution profile shown in Figure 3.15, but with the collected
fractions containing the CosD-related compounds shown in the inset labelled from A to
K. Each of these fractions was dried down (Speed Vac) and kept in the freezer. The
characterisation of these compounds using an array of different techniques such as mass
spectrometry is reported in section 3.3.2.
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Figure 3.16. HPLC elution profile of the pre-purified S020 crude (MethodCC4SP-2).
The fractions eluting between 28 and 46 min are shown in detail (inset) and all fractions
collected for identification during the run are marked from A to K. CosD is fraction A.
In order to determine the best storage conditions for the pure compounds (CosD and
compounds A to K, Figure 3.16) collected from the Streptomyces crude extract, stability
experiments were carried out on CosD.

3.3.1.6.

Effect of pH and Temperature on Stability of CosD

CosD was subjected to different sets of conditions (temperature, solution pH and
reaction time) to evaluate its stability in solution. In total, forty-five solutions were
prepared in order to test the effects of the variables on the stability of the compound in
solution (Table 3.1).

Each of the 45 solutions were analysed by ESI-MS under the same conditions using
method Meth.Digest (section 2.2.4.5) and compared against a CosD control in 100 mM
ammonium acetate. The following figures show some of the results obtained for the
stability experiments. The results displayed in these figures were chosen because they
were the most representative of the degradation taking place in the sample for the
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Table 3.1. Summary of the 45 combinations of parameters applied to CosD to test its stability.

Solution
name

pH

Time
(h)

T
(°C)

Solution
name

pH

Time
(h)

T
(°C)

Solution
name

pH

Time
(h)

T
(°C)

S1
S2
S3
S4
S5
S6
S7
S8
S9
S10
S11
S12
S13
S14
S15

3.5
5.5
7.5
9.5
10.5
3.5
5.5
7.5
9.5
10.5
3.5
5.5
7.5
9.5
10.5

1
1
1
1
1
4
4
4
4
4
18
18
18
18
18

4
4
4
4
4
4
4
4
4
4
4
4
4
4
4

S16
S17
S18
S19
S20
S21
S22
S23
S24
S25
S26
S27
S28
S29
S30

3.5
5.5
7.5
9.5
10.5
3.5
5.5
7.5
9.5
10.5
3.5
5.5
7.5
9.5
10.5

1
1
1
1
1
4
4
4
4
4
18
18
18
18
18

25
25
25
25
25
25
25
25
25
25
25
25
25
25
25

S31
S32
S33
S34
S35
S36
S37
S38
S39
S40
S41
S42
S43
S44
S45

3.5
5.5
7.5
9.5
10.5
3.5
5.5
7.5
9.5
10.5
3.5
5.5
7.5
9.5
10.5

1
1
1
1
1
4
4
4
4
4
18
18
18
18
18

40
40
40
40
40
40
40
40
40
40
40
40
40
40
40

parameter being studied; however, all 39 possible combinations (see Appendix 1) were
considered.

Figure 3.17 shows the effect of time on the stability of the CosD solution. All the
spectra in the figure were obtained from solutions that were subjected to the same
temperature (40 °C) at a pH of 3.5 and were analysed by ESI-MS after 1 h, 4 h and 18 h.
New ions that were not present in the control sample (CosD spectrum at the front in
Figure 3.17) were observed at m/z 1075.4, 961.4, 831.4 and 538.2, with an increase in
their intensities with time.

Figure 3.17. Effect of time on the stability of CosD in solution. Constant parameters:
pH 3.5 and temperature of 40 °C.
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Table 3.2 shows the relative intensities of the ions appearing as a result of degradation
of the sample. All possible combinations (see Appendix 1) were considered. No
degradation with time was observed under the following conditions: 40 °C, pH 7.5, 9.5
and 10.5; 25 °C at pH 5.5, 7.5, 9.5 and 10.5 and for any of the pHs at 4 °C. At 40 °C, for
solutions at pH 5.5, some degradation was observed but to a lesser extent than the
solutions at pH 3.5. At 25 °C, degradation was only observed for pH 3.5. Generally, an
increase in the time of exposure caused a greater degradation of the sample as judged by
the increasing intensities of the ion as shown in Figure 3.17 and Table 3.2.

Table 3.2. Relative intensities of the ions appearing with time as a function of pH and
temperature.
Intensitiesa (% of peak at m/z 1189.5)
of the ions appearing with
temperature, time and pH
Ions observed
(Th)
Conditions
25 °C
pH 3.5
40 °C
pH 3.5
40 °C
pH 5.5

1h
4h
18 h
1h
4h
18 h
1h
4h
18 h

538.4

831.4

961.4

1075.4

2.6
3.6
6.3
4.0
20.2
11.9
6.5
10.3
7.0

0.6
0.7
1.6
1.6
2.9
11.0
0.6
2.6
3.5

0.9
1.1
1.6
1.6
7.1
39.0
0.6
7.7
7.0

2.4
4.3
9.4
9.9
33.2
43.2
2.6
37.2
11.4

a

The intensities are expressed as a percentage of the intensity of the [CosD+H]+ ion at
m/z 1189.5 for each spectrum. The table only summarises the intensities obtained under
the conditions where some degradation was observed. The values in bold represent the
intensities of the peaks in Figure 3.17.
Figure 3.18 shows the effect of temperature on the stability of the CosD solution. All
the spectra in the figure were obtained when solutions were subjected to pH 3.5 for 18 h
at different temperatures, 4 °C, 25 °C and 40 °C. As observed in the time test, the same
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new ions were observed at m/z 1075.4, 961.4, 831.4 and 538.2 increasing in intensity as
the temperature of the solution was increased.

Figure 3.18. Effect of temperature on the stability of CosD in solution. Constant
parameters: pH 3.5 and time of 18 h.
Table 3.3 summarises the intensities of the ions appearing as a result of degradation in
the sample; also see Appendix 1. There was no observable effect of the temperature
under following conditions: 1 h at pH 5.5, 7.5, 9.5 and 10.5 and for 4 h and 18 h at pH
7.5, 9.5 and 10.5. An increase in degradation was observed for pH 3.5 and 5.5 after 4 h
and 18 h of exposure as well as for pH 3.5 after 1 h of exposure when the temperature
was increased to 40 °C. Generally, an increase in temperature caused a greater
degradation of the sample as judged by the increasing intensities of the ions as shown in
Figure 3.18 and Table 3.3.
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Table 3.3. Relative intensities of the ions appearing with time as a function of pH and
temperature.
Intensitiesa (% of peak at m/z 1189.5)
of the ions appearing with
temperature, time and pH
Ions observed
(Th)
Conditions
1h
pH 3.5
4h
pH 3.5
4h
pH 5.5
18 h
pH 3.5
18 h
pH 5.5

4 °C
25 °C
40 °C
4 °C
25 °C
40 °C
4 °C
25 °C
40 °C
4 °C
25 °C
40 °C
4 °C
25 °C
40 °C

538.4

831.4

961.4

1075.4

2.4
2.6
4.0
3.4
3.6
20.2
0
0
10.3
0
6.3
11.9
0
2.3
7.0

0.6
0.6
1.6
0.6
0.7
2.9
0
0
2.6
0.8
1.6
11.0
0
0
3.5

1.8
0.9
1.6
1.1
1.1
7.1
0
0.5
7.7
0.4
1.6
39.0
0.2
1.2
7.0

2.2
2.4
9.9
1.7
4.3
33.2
0
0.8
37.2
2.5
9.4
43.2
0.4
4.7
11.4

a

The intensities are expressed as a percentage of the intensity of the [CosD + H]+ ion at
m/z 1189.5 for each spectrum. The table only summarises the intensities obtained under
the conditions where some degradation was observed. The values in bold represent the
intensities of the peaks in Figure 3.18.

Figure 3.19 shows the effect of pH on the stability of the CosD solution. All the spectra
in the figure were obtained after analysis of solutions that were subjected to 18 h of
exposure at 40 °C at different pH values (3.5, 5.5, 7.5, 9.5 and 10.5). As observed in the
previous tests (time and temperature) the same new ions were observed at m/z 1075.4,
961.4, 831.4 and 538.2 increasing in intensities when the pH of the solution was
decreased.
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Figure 3.19. Effect of pH on the stability of CosD in solution. Constant parameters:
temperature of 40 °C and time of 18 h.
Table 3.4 shows the intensities of the ions appearing as a result of the pH effect on the
degradation in the sample; also see Appendix 1. No degradation with time was observed
under the following conditions: solutions at 4 °C for 1 h, 4 h and 18 h and at 25 °C for
1 h. Almost no degradation was observed for 4 h at 25 °C and 18 h at 4 °C, only the ion
at m/z 1075.4 was observed in the pH 3.5 mixture with relative intensities of 2.1% and
3.4%, respectively. Greater degradation was observed in the samples subjected to 40 °C
for 1 h, 4h and 18 h and a similar trend was observed for the 18 h mixture at 40 °C.
Generally, a decrease in the solution pH caused a greater degradation of the sample as
judged by the increasing intensities of the ion as shown in Figure 3.19 and Table 3.4.
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Table 3.4. Relative intensities of the ions appearing with time as a function of pH and
temperature.
Intensitiesa (% of peak at m/z 1189.5)
of the ions appearing with
temperature, time and pH
Ions observed
(Th)
Conditions
1h
40 °C

4h
40 °C

18 h
25 °C

18 h
40 °C

pH 3.5
pH 5.5
pH 7.5
pH 9.5
pH 10.5
pH 3.5
pH 5.5
pH 7.5
pH 9.5
pH 10.5
pH 3.5
pH 5.5
pH 7.5
pH 9.5
pH 10.5
pH 3.5
pH 5.5
pH 7.5
pH 9.5
pH 10.5

538.4

831.4

961.4

1075.4

4.0
6.5
0
0
0
6.3
2.3
0
0
0
20.2
10.2
0
0
0
11.9
7.0
5.0
0
0

1.6
0.6
0
0
0
1.6
0
0
0
0
2.9
2.6
1.5
0
0
11.0
3.5
1.7
0
0

1.6
0.6
0
0
0
1.6
1.2
1.0
0.5
0
7.1
7.7
3.3
1.2
0.7
39.0
7.0
3.4
5.3
4.2

9.9
2.6
0
0
0
9.4
4.7
2.6
2.1
1.6
33.2
37.2
8.3
2.9
3.1
43.2
11.4
5.1
5.3
4.3

a

The intensities are expressed as a percentage of the intensity of the [CosD + H]+ ion at
m/z 1189.5 for each spectrum. The table only summarises the intensities obtained under
the conditions where some degradation was observed. The values in bold represent the
intensities of the peaks in Figure 3.19.
It is important to notice that no degradation was observed for any of the solutions at
4 °C, pH 7.5 providing an indication that the following storage conditions: 100 mM
ammonium acetate pH 7.5 at - 20 °C, were suitable. The stability under such conditions
was confirmed when the compounds were analysed over time before being used in any
experiments (data not shown).
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For each of the parameters tested, common trends were observed. In all the spectra, ions
at m/z 1189.5 ([CosD + H]+) or 595.3 ([CosD + 2H]2+) were the base peak, indicating
that CosD was the major compound in solution even after some degradation had
occurred. For each of the variables studied, the same ions were obtained from the
degradation of CosD. These ions were observed at m/z 1075.4, 961.4, 831.4 and 538.4.
From previous characterisation of CosD it is known that the compound possesses two
trisaccharide chains each composed of a rhodosamine (RhN, sugar 1 and 1′), a 2-deoxyL-fucose

(deFuc, sugar 2 and 2′) and a rhodinose (Rho, sugar 3 and 3′) sugar residue

(Figure 3.1) and that fragmentation in MS/MS occurs at the glycosidic bond.10,39,41 The
theoretical masses of the possible products arising from hydrolysis as well as the
corresponding m/z of the singly and doubly charged ions that would be observed in ESI
mass spectra are reported in Table 3.5.

Table 3.5. Theoretical masses and expected positive ions from CosD and its hydrolysis
products.
Molecule
cosmomycin D
cosmomycin - sugar 1a
cosmomycin - sugar 1 and 2
cosmomycin - sugar 1, 2 and 3
cosmomycin - sugar 1 - sugar 1′
cosmomycin - sugar 1 - sugar 1′ and 2′
cosmomycin - sugar 1 - sugar 1′, 2′ and 3′
cosmomycin - sugar 1 and 2 - sugar 1′
cosmomycin - sugar 1 and 2- sugar 1′ and 2′
cosmomycin - sugar 1 and 2 - sugar 1′, 2′ and 3′
cosmomycin - sugar 1, 2 and 3 - sugar 1′, 2′ and 3′
cosmomycin - sugar 1, 2 and 3 - sugar 1′, 2′ and 3′
cosmomycin - sugar 1, 2 and 3 - sugar 1′, 2′ and 3′

Molecular
mass (Da)
1188.6
1074.5
944.5
787.3
960.4
830.4
673.3
830.3
700.3
543.2
673.3
543.2
386.1

[M+xH]x+
x=1
x=2
1189.6
595.3
1075.5
538.3
945.5
473.2
788.3
394.7
481.2
961.4
416.2
831.4
674.3
337.6
831.3
416.2
701.3
351.2
544.2
272.6
674.3
337.6
544.2
272.6
387.1
194.1

a

Since the two sugar chains on CosD are the same, the masses obtained for symmetric
products (replacing sugar 1, 2 and 3 by 1′, 2′ and 3′) would be the same. The ions
observed in the degradation experiments are shown in bold.
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From the theoretical ions reported in Table 3.5, the ions observed during the
degradation tests can be identified. The ion observed in the spectra at m/z 538.4
corresponds to [CosD – s1 + 2H]2+ (or s1′) which is the doubly charged form of the ion
observed at m/z 1075.4 ([CosD – s1 + H]+ (or s1′)). The ion at m/z 961.4 corresponds to
the CosD molecule that had lost the outermost sugars, s1 and s1′ from each trisaccharide
chain and the ion observed at m/z 831.4 corresponds to CosD that had lost sugar 1, 1′
and 2 (or 2′).

The hydrolysis tests conducted here did not allow a full determination of the sugar
sequence of CosD. In each case, an increase in the hydrolysis of the sugar residues of
CosD was observed when the temperature and the time of exposure to the different
conditions were increased and the process was catalysed under acid conditions.
Degradation was greatest when the different factors were combined (high temperature,
long time and low pH). To access the full sequence of CosD by hydrolysis the
experiments would need to be conducted over a longer time period, use higher
temperature, lower pH or a combination of these in order to speed up the hydrolysis
process and obtain all the intermediate hydrolysed forms of CosD.

In order to investigate the longer term effects of degradation, CosD (5 µM) in 100 mM
ammonium acetate, pH 7.5, was left at 25 °C for 15 days then analysed by ESI-MS.
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Figure 3.20. UV-vis absorption spectra and mass spectra of CosD before and after the
degradation for 15 days at 25 °C. (A) UV-vis absorption spectra of CosD before (dark
blue, (1)) and after (light blue, (2)) degradation, (B) photo of the solutions in sample
tubes before (1) and after (2) degradation, (C) mass spectra of CosD before (1) and after
(2) degradation.
Figure 3.20 shows the changes that occurred during the extended treatment at room
temperature and near neutral pH for the CosD solution. CosD solution lost its pink-red
colour (Figure 3.20 (B), (1)) and was almost colourless (Figure 3.20 (B), (2)). The
absorption maximum at 497 nm in the visible region was not present. This change was
also accompanied by the almost complete disappearance of the UV absorption maxima
at 235, 254 and 293 nm and an increase of the absorption toward 200 nm.
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Some differences were also observed between the mass spectra of CosD acquired at the
different times. In both solutions (before and after exposure) the [CosD + H]+ ion at
m/z 1189.4 was the most abundant. The differences observed were principally an
increase or a decrease in the intensity of some of the ions in the spectra. The spectra
were normalised to the base peak at m/z 1189.4 in the spectrum of the control sample
with all the intensities expressed as a percentage of the intensity of this base peak ion.
After treatment at 25 °C for 15 days, a decrease was observed for the peaks
corresponding to [CosD + H]+ and [CosD + 2H]2+ at m/z 1189.4 and 595.3, respectively,
indicating that some degradation occurred during the time of exposure of the solution.
The intensities of the ions at m/z 701.4, 945.3, 1059.4, 1173.4 and 1221.4 (7, 13, 4, 11
and 9% of the base peak ion for the control solution, respectively) decreased to 3, 6, 1, 4
and 7%, respectively, after treatment. Some unknown peaks, for example at m/z 525.4
and 1049.4, increased in intensity from 1 and 2% in the control sample to 12 and 9%
after 15 days.

In summary, the CosD solution underwent some changes. The decrease in colour
suggests loss of the chromophore. The mass spectra, however, show that some CosD
remains since [CosD + H]+ at m/z 1189.4 was observed in the ESI mass spectrum. An
explanation of these observations is that the remaining CosD was not sufficiently
abundant to exhibit an intense absorption. Since only positive ion ESI mass spectra over
the range m/z 500-1300 were acquired, it is possible that higher molecular mass
products and/or products that do not efficiently ionize under the conditions were
formed.
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3.3.2. Characterisation of CosD and Related Anthracyclines
In this section several techniques, principally mass spectrometry, were used to
investigate the chemical structures of the unknown compounds (fractions A to K,
Figure 3.16).

3.3.2.1.

Concentration and Extinction Coefficient Determination by
UV-Visible Spectroscopy

All the unknown anthracycline compounds collected as well as CosD were obtained in
small quantities (under 0.5 mg). It was not possible to accurately weigh the small
amounts of material which were needed for the mass spectrometry experiments (to give
10 to 20 µM). Therefore UV-vis absorption was used to determine the concentrations of
the anthracyclines in solution.

To determine whether the presence of the sugars on the aglycone had an influence on
the absorption spectra of the anthracycline or on the ελ values of the absorption maxima,
solutions of different concentrations of Dn and its aglycone (Agly) were prepared.
These two compounds were selected for several reasons. Firstly, the study could not be
carried out using CosD owing to the extremely small amount of compound available,
and the non-availability of the corresponding aglycone. Secondly, daunomycin is a
commercially available compound and simple hydrolysis of its sugars allowed access to
its aglycone in large quantities. Lastly, the aglycone of Dn and the sugar residue present
on the molecule was considered sufficiently similar to that of CosD and unknown
compounds that were structurally closely related to CosD.
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A solvent was chosen that would dissolve both Dn and the aglycone. Daunomycin is
soluble in water and methanol; however, the elimination of the sugar to obtain the
aglycone caused a great reduction in solubility in methanol and insolubility in water.
Therefore water could not be used as solvent for these experiments. The decrease in
solubility in methanol was a problem, not only because now the range of concentrations
could not be wide enough to obtain reliable data but also owing to the rapid evaporation
of the methanol, the drug concentration was not stable over the course of the
experiment. As a result, dimethylformamide (DMF) was selected as an appropriate
solvent because it allowed dissolution of both compounds in high concentrations and
did not evaporate to an appreciable degree over the course of the experiments,
maintaining stable concentrations.

Figure 3.21 shows the absorption spectra obtained for Dn (Figure 3.21 (A)) and for
Agly (Figure 3.21 (B)) over the 260 to 590 nm range. All the experiments were
conducted under the same conditions. Thirty different solutions were prepared (0 to
0.95 mM) and their absorbances recorded. Only 6 of these are represented in Figure
3.21 for greater clarity (0, 0.2, 0.4, 0.6, 0.8 and 0.95 mM). Four local maxima were
observed, 290, 481, 497 and 532 nm, and were the same for Dn and Agly. This
observation allowed the conclusion that the presence of the sugar on the aglycone did
not affect the wavelength at which the maximum absorption was observed. The
absorption wavelength of a compound is directly linked to the conjugation system and
the functional groups present in the chromophore.181
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Figure 3.21. UV absorption spectra of Dn (A) and Dn aglycone (B) in DMF. The
concentration range tested was from 0 to 0.95 mM in the 260 to 590 nm region. All
spectra were recorded using 0.1 cm quartz cuvettes.
For dilute solutions containing a pure compound, the absorbance of the solution is
proportional to the concentration of the analyte in the solution, as described by the BeerLambert law: A = ελ.c.l (with A being the absorbance of the solution at a specific
wavelength, ελ being the extinction coefficient (ε) of the compound considered at a
specific wavelength (λ) expressed in L.mol-1.cm-1, c being the concentration of the
analyte in the solution and l being the solution pathway length in cm). The extinction
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coefficient at a specific wavelength can be calculated by plotting A/l versus solution
concentration. For each of the four absorption maxima, data were collected and reported
in a table as A/l values for all solution concentrations prepared, with l = 0.1 cm. These
values can be found for Dn and Agly in Appendices 2 and 3, respectively.

Figure 3.22. Calibration curves and their equations obtained from the data collected
from the absorption spectra (Figure 3.21) of Dn (A) and of Agly (B) (for the values see
Appendices 2 and 3).
The

graphs

shown

in

Figure

3.22

were

obtained

by

plotting

Abs/l = f(drug concentration). The extinction coefficients (ελ) obtained for Dn (A) and
Agly (B) are summarised in Table 3.6.
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Table 3.6. Extinction coefficients (ελ) obtained for Dn and Agly in DMF for the four
maxima observed in the absorption spectra (see Figure 3.22) and expression of their
differences as a percentage of the Dn ελ.

ελ

Wavelength
(nm)

Dn

Agly

Difference
in %

261

14912.0

16242.0

8.9

290

6402.3

6951.8

8.6

481

9135.4

9660.6

5.7

497

8892.7

9543.5

7.3

532

4621.1

5124.0

10.9

Although the presence or absence of the sugar on the aglycone did not change the
absorbance maxima, removing the sugar from Dn had an effect on the value of the
extinction coefficients. The removal of the sugar increased the values of the extinction
coefficients from ~5 to 11% for each of the maxima. This implies that determining the
concentration of the aglycone using the extinction coefficient of daunomycin would
lead to a small over-estimation of the actual concentration in solution. These
approximations were sufficient for the experiments described in this work.

Supposing that the same was true for CosD and its aglycone, CosD extinction
coefficients were used to estimate the concentrations of the unknown anthracycline
solutions knowing that they were structurally related to CosD. All the unknown
anthracycline compounds (compounds B to K see below) were related to CosD
(possessing two trisaccharide chains) making it likely that all the compounds would be
water soluble. Therefore water was the solvent used in all the following experiments.
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The extinction coefficient of CosD was determined using the same method as for
daunomycin and its aglycone. A 0.5 mM CosD stock solution was prepared in 100 mM
NH4OAc and several dilutions were made to obtain solutions covering the 0 to 24 µM
concentration range. Since CosD was a precious natural product, the concentration
range chosen was relatively small and only 7 concentration points were prepared within
that range. As for Dn and Agly, the solution absorbances were measured, and the
absorption maxima were used to determine CosD extinction coefficients by plotting the
corresponding A/l versus concentration calibration curves.

Figure 3.23. CosD UV-vis absorption spectra (A) and calibration curves (B) for the
three maxima 254, 293 and 497 nm.
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Three maxima were observed for CosD at 254, 293 and 497 nm (Figure 3.23 (A)). The
slope of each calibration curve gave the extinction coefficients at each wavelength
(Figure 3.23 (B)), with ε254nm = 37132 L.mol-1.cm-1, ε293nm = 14606 L.mol-1.cm-1 and
ε497nm = 18414 L.mol-1.cm-1.

Figure 3.24. Absorption spectra of the fractions A to K. (A) Range 200 - 600 nm, (B)
expanded absorption spectra 350 - 600 nm. (C) Compounds collected during the
purification of the crude extracts; fraction names are indicated on the figure. All
solutions were made in 100 mM NH4OAc, pH 7.5, at a concentration ~10 μM.
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The absorption spectra of the unknown anthracycline compounds (B to K, Figure 3.24)
were recorded under the same conditions as for CosD, and their concentrations were
evaluated using the extinction coefficients calculated for CosD. As observed in Figure
3.24 (A) all the solutions possessed UV maxima at 232, 254 and 290 nm. In the visible
region, different absorption maxima of the compounds made the determination of the
concentration of each compound not possible using ε497nm. The extinction coefficient at
254 nm was used to determine the concentrations in the samples B to K, and each
solution was diluted further if necessary to obtain a concentration of about 10 μM in
order to carry out the various mass spectrometry experiments.

Figure 3.24 (C) is a photograph of all the fractions collected from the purification of the
crude extracts; the compounds collected were of several different colours. The
difference in colour did not come from their concentration as all solutions (A to K) were
~10 μM in 100 mM NH4OAc. The different colours observed were related to their
absorbance maxima as seen on Figure 3.24 (B). The compounds can be separated into
three different groups based on their visible absorbance maxima. The first group
containing fractions A, E, F and K, have an absorbance maximum around 497 nm
making the sample appear red; the second group, fractions B, D, G and J, have a
maximum around 430 nm, making the solutions appear yellow; and the remaining
fractions C, H and I, were orange and have an absorbance maximum around 460 nm.

The different colours observed for the fractions indicate that not all of the unknown
anthracyclines possessed the same chromophore. Compounds E, H and K are expected
to have a chromophore similar to that of CosD (compound A) considering the solution
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colours. All the other compounds are orange to yellow in colour, suggesting that the
chromophores are different. It is possible that a functional group on the aglycone is
substituted, different or is removed leading to a different conjugation system in the
chromophore.

3.3.2.2.

Purity and m/z Estimation of Compounds in the Fractions
by Mass Spectrometry

All fractions (A-K, Figure 3.16) were dissolved in 100 mM NH4OAc, pH 7.5, at a
concentration of ~20 μM (estimated by UV-vis absorption) and were analysed by
ESI-MS (Meth.Quattro, see section 2.2.4.1) to evaluate their purity and the molecular
mass of the major component of the solution (Figure 3.25).

Figure 3.25 shows that most of the peaks from the chromatogram were sufficiently
separated (e.g. fraction E or K, see Figure 3.16) to obtain relatively pure compound;
however, in some cases the separation was poorer (e.g. I and J, see Figure 3.16) which
led to the observation of the several compounds in the ESI mass spectra as a result of
contamination by compounds from preceding or subsequent fractions.

The ESI mass spectrum obtained for fraction A (CosD, Figure 3.25) showed two main
ions. An ion of high abundance at m/z 595.3 ([CosD + 2H]2+) and another of lower
abundance corresponding to the molecular ion, [CosD + H]1+, at m/z 1189.5. In all the
other fractions an ion of high abundance corresponding to [Compound + 2H]2+ was
observed at m/z values of 570 to 590 with a lower abundance ion corresponding to the
molecular ion of the particular compound, [Compound + H]+, at m/z 1140 to 1170. Each
100

Figure 3.25. Positive ion ESI mass spectra obtained for each collected fraction (from A
to K, see Figure 3.16), with Fraction A corresponding to CosD. Method used:
Meth.Quattro (section 2.2.4.1).
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of the compounds had similar ionisation properties to CosD and they all possessed
masses consistent with CosD minus one to three hydroxyl groups (-16 for each). Some
of the anthracyclines that were separated by HPLC had the same mass. Three categories
of compound were identified with positive molecular ions in the ESI mass spectra at
m/z 1173.6 for the fractions B, C, E, F, H, at 1157.6 for fractions D, G, I, K and 1141.3
for fraction J. In order to confirm this observation and obtain the elemental composition
of these compounds an exact mass determination was carried out for each of the
compounds A to K.

3.3.2.3.

Accurate Mass Determination

The accurate mass determinations of each of the compound, compounds A to K were
carried out by ESI-MS using the Meth.Lockspray method (see section 2.2.4.2). The
exact mass of the anthracycline in each of the fractions was determined experimentally
and compared to the calculated masses based on the proposed molecular formulae of the
anthracyclines.

Table 3.7 shows the proposed molecular formula for each fraction, its calculated mass,
the experimental exact mass and the difference in ppm. In all cases the differences
between the calculated and measured masses was within 3 ppm. Exact mass
determination of these compounds confirmed that several compounds had identical
masses. A group of compounds, fractions B, C, E, F and H had molecular masses of
1172.6 Da, a second group, fractions D, G, I and K had molecular masses of 1156.6 Da
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and fraction A (CosD) and fraction J had molecular masses of 1188.6 Da and 1141.6
Da, respectively.

Table 3.7. Exact mass determination of the anthracyclines contained in the different
fractions separated by HPLC.

Fraction
name

Predicted
formula

Calculated Experimental
mass (Da)
mass (Da)

Error
(mDa)

Error
(ppm)

A

C60H89N2O22+

1189.5907

1189.5922

1.5

1.3

B

C60H89N2O21+

1173.5958

1173.5933

-2.5

-2.1

C

C60H89N2O21+

1173.5958

1173.5940

-1.8

-1.5

D

C60H89N2O20+

1157.6009

1157.5990

-1.9

-1.6

E

C60H89N2O21+

1173.5958

1173.9620

0.4

0.3

F

C60H89N2O21+

1173.5958

1173.5966

0.8

0.7

G

C60H89N2O20+

1157.6009

1157.5978

-3.1

-2.7

H

C60H89N2O21+

1173.5958

1173.5979

2.1

1.8

I

C60H89N2O20+

1157.6009

1157.6002

-0.7

-0.6

J

C60H89N2O19+

1141.6060

1141.6079

1.9

1.7

K

C60H89N2O20+

1157.6009

1157.5984

-2.5

-2.2

It was postulated that all of the compounds possessed two trisaccharide chains on their
aglycones and that they differed from CosD by one to three fewer oxygen atoms (loss of
hydroxyl groups; e.g. 1188.6 – 16 = 1172.6, 1172.6 – 16 = 1156.6). To determine the
position of the loss of the hydroxyl group as well as the sugar sequences carried by the
different compounds collisionally-activated dissociation was carried out. CAD is a
process that promotes the fragmentation of ions in the gas phase. The fragments thus
obtained are characteristic of the precursor ion (e.g. functional groups) and can lead to
determination of the structure of the precursor ion.121,122,1243
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3.3.2.4.

Mass Spectrometry (MSn) of CosD and Related Compounds

A linear quadrupole ion trap ESI mass spectrometer was used to characterise further the
anthracycline fractions A to K separated by HPLC (Figure 3.16). In order to determine
whether it was the aglycone and/or the sugars which were altered from the structure of
CosD, each fraction was subjected to multiple stages of collisionally-activated
dissociation (CAD).
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Figure 3.26. CosD molecule with the possible missing OH groups, represented in green
when on the aglycone, and in red when on the sugar chains. With Rho: L-rhodosamine
(sugar 1 and 1′), deFuc: 2-deoxy-L-fucose (sugar 2 and 2′) and RhN: L-rhodinose (sugar
3 and 3′).
Previous results (section 3.3.2.3) showed that these compounds, A to K, were related to
CosD, but that one to three hydroxyl groups were “missing”. The position from which
the hydroxyl group had been lost could either come from one of the sugar residues on
one of the side chains or from the aglycone (Figure 3.26). In order to determine the
sugar sequences of each compound as well as the position from which the oxygen
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(hydroxyl group) had been lost relative to CosD, successive tandem mass spectrometry
was conducted on the major compound contained in each fraction. The tandem mass
spectra were obtained by collisionally-activated dissociation (up to MS5) and were
acquired using the Meth.MSn method (see section 2.2.4.4). Figure 3.27 shows ESIMS/MS of CosD (A), fraction B (B) and fraction C (C).

The precursor ions ([M + H]+) for CosD (fraction A), fractions B and C were 1189.4,
1173.2 and 1173.3, respectively. The product ions from CosD were: 1075.2 (low
intensity, -114, consistent with the loss of one of the outermost sugars, 1 or 1′ from
Figure 3.26, Rho); 945.3 (high intensity, -130, consistent with the loss of a middle
sugar, 2 or 2′, deFuc); 831.3 (low intensity, -114, consistent with the loss of the
outermost sugar on the second trisaccharide chain, 1′ or 1, Rho); 701.3 (high intensity, 130, consistent with the loss of the middle sugar from the second chain, 2′ or 2, deFuc),
and 544.3 (low to moderate intensity, -157, consistent with loss of one of the innermost
amino sugars, 3 or 3′, RhN). The relative intensities of the product ions suggest that the
glycosidic bond between sugars 2 and 3 (or 2′ and 3′) is more labile under the
conditions than the bond between sugars 1 and 2 (or 1′ and 2′).

When comparing the product ions obtained here for CosD to the products observed
during the hydrolysis experiments (section 3.3.1.6), a difference was observed. Unlike
the fragmentation in the gas phase where the loss of one outermost sugar s1 (or s1′, m/z
1075.2) and the simultaneous loss of the two outermost sugars 1 and 2 (or 1′ and 2′, m/z
945.3) were the main products observed, the hydrolysis of CosD in solution gave
products from successive loss of one outermost sugar (1 or 1′, m/z 1075.4), then the
105

Figure 3.27. ESI-MS/MS (MS2) of anthracycline fractions from HPLC. (A) CosD; (B)
Fraction B; (C) Fraction C. The activation energies applied to give the spectra in A, B
and C were 35, 36 and 38 V, respectively. The dotted lines were drawn to extend the
intensities of the observed peaks so that the arrows indicating loss of fragments could be
drawn. The numbers (1, 2 and 3) on top of the arrows refer to the sugars (Figure 3.26)
that are lost from the structures. Note that it is not possible to distinguish among sugar 1
and 1′, or 2, and 2′ or 3 and 3′.
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second outermost sugar (1′ or 1, m/z 961.4) before losing any of the centre sugars (2 or
2′, m/z 831.4). These differences are expected given the different mechanisms for sugar
loss occurring in the gas and solution phases. In the gas phase, the energy transmitted to
the precursor during the collision is distributed throughout the molecule resulting in the
fragmentation of the most fragile bond, which from the experimental data obtained here
appears to be the glycosidic linkage between sugars 2 and 3 (or 2′ and 3′).

Collisional activation (MS3, 22 V) of the ion at m/z 544.3 corresponding to the CosD
aglycone with 1 RhN sugar remaining, gave product ions at m/z 369.0, 351.0 and 323.2.
The ion at m/z 369.0 is consistent with an aglycone moiety that has lost the OH, most
likely from C7, concomitant with dissociation of the last amino sugar from the
aglycone. This could result in formation of a double bond between C7 and C8 of ring A,
or may be the result of loss of the amino sugar followed by a rapid spontaneous loss of
water (Figure 3.28). The ions at m/z 351.0 and 323.2 are consistent with loss of a second
water molecule from the side chain of ring A followed by ethylene. Similar neutral
losses (e.g. H2O, CO) from the side chain of ring A of doxorubicin, daunomycin,
epirubicin and idarubicin have previously been observed using a triple quadrupole ESI
mass spectrometer,178 as well as in the current work when daunomycin and doxorubicin
were subjected to CAD for comparison with CosD.

Figure 3.28 shows possible fragmentation pathways for loss of the anthracycline sugars
proposed by Guglielmetti et al.39 in addition to the proposed fragment ions from Dn and
Dx based on the experimental results observed in the current work as well as that
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Figure 3.28. Fragmentation pathways of glycosidic bonds (A) (adapted from
reference 40 and (B) proposed fragmentation scheme for daunomycin (Dn) and
doxorubicin (Dx) (proposed fragments ions for Dn and Dx from experimental results in
this work and Dx mechanism adapted from reference 178). No attempt has been made
here to determine the precise localization of charges on these molecules.
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proposed by Sleno et al.178 for Dx. The oxygen of the glycosidic bond is the first site of
protonation

for

anthracycline

antibiotics.182

Following

this

protonation

the

fragmentation of the glycosidic bond can follow two possible mechanisms as shown in
Figure 3.28 (A).178 The first mechanism (mechanism A) involves cleavage of the
glycosidic bond with hydrogen transfer to the sugar leaving the hydroxyl group on the
fragment ion possessing the aglycone. The second mechanism (mechanism B) involves
a proton transfer to the fragment ion possessing the aglycone while the sugar residue is
lost as a lactone.178 Only mechanism A was observed in the current work and by
Guglielmetti et al. during the fragmentation of Dn or Dx for the loss of the sugar
moiety. The presence of an hydroxyl group on Dx compared to Dn, led to dissociations
observed only for the Dx aglycone as seen in Figure 3.28 (B) (chemical structures
marked with ∗). Water loss and side chain fragmentation were observed from the
aglycone as observed in previous experiments where the formulae of the proposed
fragment ions were confirmed using accurate mass measurements.178

Table 3.8 summarises the ions observed here during the MSn experiments on Dn and Dx
(and also observed by Sleno et al.)178 carried out for comparison with CosD. Figure 3.29
shows the proposed formulae for the different product ions obtained from CosD using
fragmentation pathways similar to those proposed for Dn and Dx (Figure 3.28).39,41,178
As was the case for Dn and Dx, only products consistent with mechanism A were
observed during the fragmentation of CosD.
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Table 3.8. Fragment ions (in Th) observed for Dn and Dx after multiple stage
fragmentation (MSn with n ≤ 5).
Fragment typesa
Compounds
Dn

[M + H]+ [M+H]+-H2O

528

510
484

Agly

[M + H]+Side chain

[M + H]+CH3 radical

399
381
363

321
306
(291)

306

361
346
Dx
(306)
544
(333)
321
a
The fragments in bold were observed during our fragmentation experiments as well as
in previous studies178 and the ions in brackets were only observed in previous studies.
526
508

415
397
379

Figures 3.27 (B) and (C) show the MS2 spectra of the anthracyclines from fractions B
and C which possess an identical molecular mass ([M + H]+ of 1173.2 and 1173.3,
respectively). The patterns of dissociation of these compounds were markedly different
confirming that they differ in structure. The differences could arise from a difference in
either the sequence of the sugars in the trisaccharide chains or the number and positions
of the oxygen group on the molecule (sugar or aglycone). Since these anthracyclines
have similar retention times when separated by HPLC (Figure 3.16), it is likely that they
possess a general structure resembling CosD. Further, given that the main fragmentation
pathway for CosD involves the cleavage of the glycosidic bonds where the 2-3 and 2′-3′
bonds are the most labile, and that charge is retained on the aglycone, the sequence of
sugars in compounds B and C can be proposed.

Collisionally-activated dissociation of the precursor ion for compound B at 1173.2 gave
1059.1 (-114) Æ 929.3 (-130) Æ 815.4 (-114) Æ 685.3 (-130) Æ 528.3 (-157) Æ 334.9
(MS3; -157 and -H2O). These dissociation products are consistent with compound B
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2

2

Figure 3.29. Proposed fragmentation pathways and formulae for the different product
ions of CosD (m/z 1189.6) obtained during the collisionally-activated dissociation
experiments. With s1: L-Rhodosamine (Rho, sugar 1), s2: 2-deoxy-L-fucose (deFuc,
sugar 2), s3: L-rhodinose (RhN, sugar 3), s1′: L-rhodosamine (Rho, sugar 1′), s2′: 2deoxy-L-fucose (deFuc, sugar 2′) and s3′: L-rhodinose (RhN, sugar 3′).
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bearing the same sugar residues as CosD, but having a different aglycone. The aglycone
of compound B gave a product on MS3 at m/z 334.9 compared with 351.0 for CosD.
This is consistent with the aglycone of compound B containing one fewer hydroxyl
groups than CosD. Compound C dissociated via a similar fragmentation pathway
suggesting loss of sugar residues, but in this case, the products are consistent with one
of the middle sugars (2 or 2′, see Figure 3.26) having one less hydroxyl group. The
product ions from 1173.3 for compound C were 1059.1 (-114) Æ 945.1 (-114) Æ 831.2
(-114) Æ 701.2 (-130)Æ 544.3 (-157) Æ 351.1 (MS3; -157 and -H2O). The final
product at m/z 351.1 suggests that the aglycone is the same as that for CosD.

This however may not necessarily be true, since the aglycone may have the same mass,
but may differ in the position of hydroxyl groups. In some cases (e.g. fractions C, E, F
and H) molecules that had the same dissociation sequence and the same product ions
were well-separated by HPLC indicating that even if the sugar has the same molecular
mass they might be somehow different (different position or stereochemistry of
functional groups on the sugar, different conformation). Moreover, the colour of the
solutions (red for CosD, yellow for fraction B and orange for fraction C) and the UV-vis
absorption spectra obtained for these compounds (Figure 3.24) supported that even if
the fragmentation suggested that some of the compound had a similar aglycone
(chromophore of the molecule) the position of the functional groups must be different to
account for their different absorption properties. The fragmentation results obtained
here were in agreement with the preliminary observations made during the UV-vis
experiments. Compounds from fractions E, F and K had similar absorption maxima to
CosD that suggested a similar aglycone to that of CosD, and all the remaining fractions
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had different aglycone systems lacking one -OH

group as shown by the mass

spectrometry experiments (1189 for CosD compared with 1173).

CAD experiments were also carried out on the fragment ion corresponding to the
aglycone with the goal of determining whether the aglycone could be dissociated to
gather supplementary information on the position its hydroxyl groups. No further
fragmentation of the aglycone was observed beyond that described for CosD, making it
impossible to account for the positions of the hydroxyl groups on the aglycone of each
of the compounds. It is also important to note that it was not possible to distinguish if
the OH has been lost from sugar 2 or sugar 2′ using only mass spectrometry or if the
other sugars were similar to those present on CosD. There is a possibility that the sugar
residues present on the saccharide chains of compounds B to K were not identical to
those observed for CosD. The mass spectrometry experiments accounted for the masses
of the sugar units lost during the fragmentation process but did not give any information
on the sugar substitution (position and absolute configuration of the functional groups,
α- or β- glycosidic linkage). Although it is not possible to account at this stage for the
substitution patterns on the sugar and on the aglycone using mass spectrometry only, the
current MSn experiments have enabled some conclusions to be made about the sugars
and aglycones present on these natural products using only a small amount of material.
Full structural determination will require NMR experiments, but at present these are not
possible since these natural products were obtained in less than milligram quantities.

Table 3.9 summarises the results obtained for the CAD (MS2 and MS3) of all the
anthracyclines present in the HPLC fractions (A to K). The table indicates the masses of
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all product ions observed in MS2 experiments and their relative intensities in brackets,
and the mass of the aglycone after loss of water and ethylene in some cases. It also
shows the proposed number and position (sugar or aglycone) of hydroxyl groups that
were "lost" compared to the structure of CosD. For all the fractions analysed this way,
each of the major product ions (corresponding to the loss of one or more sugars) was
selected for further CAD experiments (up to MS5) confirming the sequence of sugars
observed in the MS2 and MS3 experiments. Fragmentation pathways as detailed as that
obtained for CosD could not be obtained for all of the anthracycline compounds and the
information was not sufficient to determine the position of the missing OH or the
configuration and the position of the functional groups present on the molecules.
Figure 3.30 shows a summary of the anthracyclines found in the different HPLC
fractions.

Figure 3.30. Summary of the anthracyclines found in the different HPLC fractions
during the purification of the S020 crude extract. The figure shows only the 32-45 min
region of the HPLC chromatogram. The colours code for compounds of the same mass
(Table 3.7) and showing the same CAD pattern (Table 3.9).
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Table 3.9. Main fragment ions observed in the MS2 and MS3 spectra of the compounds from fraction A to K with their relative abundances
(RA %), and attribution of the position(s) of the ‘lost’ -OH group(s) on the molecules.
Compound
Collision activated energy
2
applied (MS )
[M+H]

+

[M–114+H]

+

[M–2×114+H]

+

[M–114–130+H]
[M–3×114+H]

+

+

[M–2×114–130+H]
[M–4×114+H]

+

+

[M–3×114–130+H]

+

[M–2×114–2×130+H]
[M–4×114–157+H]

+

+ a

[M–3×114–130–157+H]

+ a

[M–2×114–2×130–157+H]

+ a

Collision activated energy
3
applied (MS )
Aglycone – H2O

b

Aglycone – 2 H2O

b

Aglycone – 2 H2O – CH2=CH2

b

A

B

C

D

E

F

G

H

I

J

K

35 V

36 V

38 V

39 V

37 V

36 V

36 V

37 V

36 V

37 V

38 V

1189.4 (90)

1173.2 (59)

1173.1 (2)

1157.3 (39)

1173.3 (26)

1173.3 (36)

1157.2 (9)

1173.3 (38)

1157.2 (11)

1141.3 (62)

1157.1 (13)

1075.2 (5)

1059.3 (5)

1059.1 (5)

1043.1 (6)

1059.2 (3)

1059.2 (5)

1043.3 (6)

1059.5 (2)

1043.2 (17)

1027.3 (3)

1043.5 (2)

-

945.3 (2)

945.1 (48)

929.1 (61)

945.2 (78)

945.1 (98)

929.2 (100)

945.2 (100)

929.1 (7)

913.2 (94)

929.2 (86)

945.3 (100)

929.3 (100)

929.1 (19)

913.1 (22)

929.2 (26)

929.1 (11)

913.2 (9)

929.2 (14)

-

-

-

-

-

831.2 (5)

815.2 (10)

831.3 (3)

831.3 (4)

815.3 (4)

831.3 (3)

815.3 (6)

799.2 (6)

815.4 (4)

831.3 (7)

815.4 (8)

815.2 (4)

799.2 (7)

815.3 (3)

815.3 (4)

799.2 (3)

815.3 (3)

-

-

-

-

-

-

-

-

-

-

-

701.3 (100)

685.3 (100)

701.2 (100)

-

-

701.2 (100)

685.2 (100)

701.3 (100)

701.3 (100)

685.3 (93)

701.3 (83)

685.4 (4)

-

-

701.3 (83)

685.3 (80)

685.3 (8)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

544.3 (8)

528.2 (12)

544.2 (13)

-

-

544.2 (11)

528.2 (14)

544.3 (19)

544.3 (10)

528.3 (10)

544.3 (13)

-

-

-

544.3 (17)

528.3 (11)

-

-

-

-

-

-

-

-

-

22 V

24 V

22 V

24 V

22 V

23 V

23 V

24 V

24 V

23 V

21 V

369.0 (64)

-

369.2 (7)

-

369.1 (80)

369.1 (16)

-

369.0 (100)

369.0 (6)

-

369.1(45)

351.0 (100)

334.9 (100)

351.1 (100)

335.0 (100)

351.1(100)

351.1 (100)

335.0 (100)

351.6 (38)

351.1 (100)

335.0 (100)

323.2 (33)

-

323.1 (15)

307.2 (12)

Position of the ‘missing’ oxygen
on sugar 2 or 2’

d

on the aglycone
a

323.2 (10)

323.2 (22)

-

323.1

c

323.2 (19)

307.4

c

351.1 (33)
323.2 (9)

Number of ‘missing’ oxygen
-

-

1

1

1

1

1

1

2

2

2

-

1

-

1

-

-

1

-

-

1

-

m/z selected to obtain the aglycone fragment by MS3
b
obtained by MS3 of the fragment selected in a

c

seen by MS4
d
see Figure 3.29

Since the masses of the anthracyclines purified in this work corresponded to molecules
that contained two intact trisaccharide chains, this supports that the array of
anthracyclines separated by HPLC were produced by the bacteria, rather than as a result
of sample degradation. Further experiments were carried out in order to determine if
complementary information about these compounds could be found. Two different
techniques, ion mobility mass spectrometry and acidic hydrolysis analysed by mass
spectrometry, were used to confirm the sugar sequence obtained by collision-activated
dissociation and to determine the stability of CosD in solution.

3.3.2.5.

Confirmation of the Sugar Sequence of CosD and Related
Anthracyclines by Ion Mobility Tandem Mass Spectrometry

Ion mobility mass spectrometry was used as a complementary technique to the
collision-activated dissociation method (section 3.3.2.4) to distinguish different
anthracyclines in fractions A to K collected from the HPLC purification. Fragmentation
experiments were carried out using the Synapt™ HDMS™ mass spectrometer which is
a quadrupole/travelling wave IMS/oa-Tof instrument. The advantages of this instrument
principally come from its Triwave™ technology, which allows ion mobility separation
with relatively high sensitivity but also different types of fragmentation.137,141
Time-aligned parallel (TAP) fragmentation (Figure 3.4) was carried out on each
anthracycline compound in order to confirm the sugar sequence. All solutions were
analysed using method Meth.IMSanthr (section 2.2.4.8). The trap and transfer collision
energies were optimised for each sample to obtain the best fragmentation possible.
Table 3.10 summarises the precursor ion selected as well as the collision energies used
for each compound.
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Table 3.10. Precursor ion selected for the TAP fragmentation experiments and collision
energies applied for each compound (for instrumental parameters see section 2.2.4.8).

Fraction
name

m/z selected
(Da)

Collision energy
applied (V)
Trap

Transfer

A

1189.6

39

37

B

1173.6

41

38

C

1173.6

38

34

D

1157.6

41

39

E

1173.6

41

41

F

1173.6

38

35

G

1157.6

38

36

H

1173.6

38

37

I

1157.6

35

38

J

1141.6

35

37

K

1157.6

35

40

Figure 3.31 shows TAP fragmentation results obtained for CosD (Figure 3.31 (A), (C)
and (E)) and for fraction D (Figure 3.31 (B), (D) and (F)). The precursor ions selected
([M + H]1+) for CosD and fraction D were 1189.6 and 1173.6, respectively. These ions
were subjected to CAD in the collision cell and the resulting fragments (product ions)
were separated in the travelling wave ion mobility cell. These products are aligned on
the diagonal (red line), separated on the basis of their drift times (ms, x axis) and their
m/z (y axis). These first generation product ions of CosD (A) were obtained by CAD of
the singly charged precursor ion [CosD + H]+ at m/z 1189.6 in the trap region under a
collision energy of 39 V (Table 3.10). Each product ion was singly charged, therefore,
the larger the ion, the greater was its cross section and the longer the time taken to cross
the drift cell. The chromatogram in Figure 3.31 (C) was obtained by extracting from the
driftscope the drift times of first generation product ions (red line). Each of the peaks on
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Figure 3.31. Driftscope of TAP fragmentation results for CosD (A) and Fraction D (B)
with the drift times of their first generation fragments ion ((C) and (D), respectively)
and their mass spectra ((E) and (F), respectively). The lines on (A) and (B) indicate the
fragments of first generation (red) and the TAP fragments (blue).
the chromatogram is the mobility of an ion. Ions were spatially separated with drift
times of 1.80, 2.62, 3.41, 4.01 and 4.50 ms for m/z 701.4, 831.5, 945.5, 1075.4 and
1189.9, respectively.

Once separated in the drift cell, packets of ions of identical mobility were fragmented
further in the transfer region and gave an array of time-aligned fragments (vertical blue
lines). The second generation product ions have the same mobility as their precursor
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ions because they were formed after the drift time separation; however, they have
different masses and are separated in the oa-Tof detector. Under the experimental
conditions the first generation product ions did not dissociate to give all the smaller
fragments ions that were obtained in the MSn experiments using the linear quadrupole
ion trap instrument; each ion only gave several fragments. For example, the ion at m/z
1189.9 fragmented to give product ions at m/z 945.5 and 701.4 with a drift time of
4.5 ms (see Figure 3.31 (A), TAP 1189.9) and the ion at m/z 945.5 dissociated to give
ions at m/z 831.5, 701.4 and 544.3 with a drift time of 3.41 ms (see Figure 3.31 (A),
TAP 945.5). In contrast, these ions gave fragment ions at m/z 1075.2, 945.3, 831.3,
701.3 and 544.3 (see Table 3.9). The combination of the different TAP product ions
observed on the driftscope gave the mass spectra shown in Figure 3.31 (E). The product
ions were characteristic of the sugar sequence that was present on the anthracycline.

The product ions from CosD (Figure 3.31 (E)) were at m/z: 1189.6 (high intensity,
[M + H]+, parent ion); 1075.4 (low intensity, -114, consistent with the loss of one of the
outermost sugars, 1 or 1′ from Figure 3.26, Rho); 945.5 (medium intensity, -130,
consistent with the loss of a middle sugar, 2 or 2′, deFuc); 831.5 (low intensity, -114,
consistent with the loss of the outermost sugar on the second trisaccharide chain, 1′ or 1,
Rho); 701.4 (high intensity, -130, consistent with the loss of the middle sugar from the
second chain, 2′ or 2, deFuc); 544.3 (low to moderate intensity, -157, consistent with
loss of one of the innermost amino sugars, 3 or 3′, RhN) and 351.1 (low intensity, -157 2 H2O, consistent with the loss of the second innermost amino sugar and a spontaneous
loss of water to form a double bond followed by a loss of a second molecule of water,
see product ions Figure 3.27). All the ions observed in these experiments had similar
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masses to that obtained during the MSn experiments (see Table 3.9), and as observed in
the collision-activated experiments, ions at m/z 1189.6, 945.5 and 701.4 were the most
abundant (see Figure 3.27), corresponding to the fragmentation of the weakest
glycosidic bonds between sugar 2 and 3 and sugar 2′ and 3′ (see Figure 3.26).

Similar observations were made for fraction D (Figure 3.27 (B)). First generation
product ions were spatially separated (red diagonal) with drift times of 1.67, 2.51, 3.15
and 3.93 ms for m/z 685.3, 815.4, 1043.6 and 1157.6, respectively (Figure 3.27 (D)).
Fragmentation of the first generation product ions gave several TAP sequences, for
example: at a drift time of 3.93 ms the ion at m/z 1157.6 fragmented to give product
ions at m/z 1043.6, 929.5, 913.5, 815.4 and 685.3 (see Figure 3.31 (B), TAP 1157.6); at
3.15 ms the ion at m/z 1043.6 fragmented to give ions at m/z 929.5, 913.5, 815.4, 685.3
and 528.2 (see Figure 3.31 (B), TAP 1043.6); and at 1.67 ms the ion at m/z 685.3
fragmented to give ions at m/z 528.2 and 335.1 (see Figure 3.31 (A), TAP 685.3). The
combined TAP fragmentation sequences allowed the determination of the sugar
sequence present on compound D. The fragment ions observed for fraction D were as
follows: m/z 1157.6 ([M + H]+) Æ 1043.6 (-114) Æ 929.3 (-114), 913.5 (-130) Æ 815.4
(-114) Æ 685.3 (-130) Æ 528.2 (-157) Æ 335.1 (-157 - 2 H2O). As observed for CosD,
the product ions observed for compound D and the relative intensities of the product
ions suggest that the glycosidic bond between sugars 2 and 3 (or 2′ and 3′) was the most
labile.

Some ions observed in the collision-activated dissociation experiments using the linear
quadrupole ion trap mass spectrometer (LTQ) were not observed in the TAP
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experiments using the Synapt™ HDMS™. In the case of CosD, the ions at m/z 369.0
and 323.2 were not observed and ions at m/z 335.0 and 307.2 were not observed for
fraction D. The former ions were not observed probably because the collision energies
applied were not high enough to sufficiently fragment the precursor ions or the
intensities of these ions were too low to be detected and appear in the mass spectra.
Similar experiments were carried out on the remaining anthracycline compounds.
Table 3.11 summarises the m/z of [M + H]+ precursor ion selected for dissociation in
addition to the product ions observed.

Table 3.11. Main product ions observed during the TAP fragmentation experiments.
Fraction
name

M/z
selected (Da)

Fragment ions observeda (Da)

A

1189.6

1189.6, 1075.6, 945.5, 831. 5, 701.4, 544.3, (369.0),
351.1, (323.2)

B

1173.6

1173.6, 1059.5, (945.3), 929.5, 815.4, 685.3, 528.2, 335.1

C

1173.6

1173.6, 1059.5, 945.5, 929.5, 831.4, 815.4, 701.3,
685.4, 544.2, (369.2), 351.1, (323.1)

D

1157.6

1157.6, 1043.6, 929.5, 913.5, 815.4, 799.4, 685.3,
528.2, 335.1, (307.2)

E

1173.6

1173.6, 1059.4, 945.5, 929.5, 831.4, 815.4, 701.3,
544.2, (369.1), 351.1, 323.1

F

1173.6

1173.6, 1059.6, 945.5, 929.5, (831.3), (815.3), 701.4,
544.3, (369.1), (351.1), (323.2)

G

1157.6

1157.6, 1043.6, 929.5, 913.5, 815.4, 799.4, 685.4,
528.2, (335.0)

H

1173.6

1173.7, 1059.6, 945.5, 929.5, 831.4, (815.3), 701.4,
544.2, (369.0), 351.1, (323.1)

I

1157.6

1157.6, 1043.6, 929.5, 815.4, 701.4, 685.4, 544.2,
(369.0), 351.1, (323.2)

J

1141.6

1141.7, 1027.6, 913.5, 799.4, 685.4, 528.3,
(335.0), (307.4)

K

1157.6

1157.7, 1043.6, 929.5, 815.4, 701.4, 544.3, (369.1),
351.2, (323.2)

a

Numbers in brackets represent the fragment ions that were not observed during the
TAP fragmentations but were observed in the MSn experiments (see Table 3.9). All
other ions were observed in both types of experiments.
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Table 3.11 shows that with the exception of a few fragment ions (shown in brackets),
both methods (TAP and MSn) gave similar results for the anthracycline compounds. In
the TAP experiments, the fragments corresponding to the loss of one to five sugar units
were observed (with the exception of compound B where m/z 945.3 was not seen),
confirming the sugar sequences established during the collision-activated dissociation
experiments using the LTQ. The ion (m/z 945.3) that was not observed for fraction B
was probably produced at low abundance; however, the remaining ions were identical to
those from the LTQ MSn work confirming the sequence. In all cases the same results
were obtained using the two different fragmentation methods; the only differences were
in low m/z fragments (< m/z 369) probably as a result of insufficient energies. Only a
few of these small fragments were not observed at all (compounds F and I); however,
the sugar sequences could be confirmed without these fragments.

Previous experimental results showed that some of the anthracyclines obtained from the
crude extract, compounds A to K, had identical masses (Table 3.7) and also “lost"
oxygen from the same position (Table 3.9). Since structural isomers of the
anthracyclines were separable by HPLC, experiments were carried out on isobaric
compounds to determine whether these were also separable by ion mobility mass
spectrometry (IMMS).

3.3.2.6.

Ion Mobility Mass Spectrometry

Previous results showed that the compounds collected from the purification of the
S. olindensis crude extract could be separated into 4 groups based on their masses
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(section 3.3.2.3). A group of compounds, fractions B, C, E, F and H had molecular
masses of 1172.6 Da, a second group, fractions D, G, I and K had molecular masses of
1156.6 Da, and fraction A (CosD) and fraction J had molecular masses of 1188.6 Da
and 1140.6 Da, respectively. Among the isobaric compounds some had identical
fragmentation patterns as observed in CAD experiments (up to MS5, section 3.3.2.4).
Compounds C, E, F and H ([M + H]+ at m/z 1173.6) had the OH group missing from the
aglycone whereas compound B had an OH group missing on sugar 2 (or 2′) (see
Table 3.9). Compounds D and G ([M + H]+ at m/z 1157.6) had one OH group missing
from the aglycone and one from sugar 2 (or 2′), whereas compounds I and K had two
OH groups missing from the sugars 2 and 2′.

Ion mobility allows separations of molecules as a function of their masses, shape and
charges. Ion mobility mass spectrometry was used to separate isobaric anthracyclines,
obtained by mixing aliquots from fractions containing anthracyclines with the same
mass as judged by the exact mass measurements (Table 3.7), to determine whether these
molecules had a different cross section/shape in the gas phase and could be spatially
separated in the travelling wave ion mobility cell. All combinations of isobaric
compounds were tested to determine whether separation was observable under the
conditions. This is important to test given the novelty of ion mobility separations using
a travelling wave ion mobility cell (TWIMS).139

Variations of wave height and velocity, IMS flow rate, capillary and cone voltage,
temperature and Triwave™ settings were carried out to achieve the best separation
possible. Varying the capillary, sampling cone and extraction cone voltages as well as
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the desolvation gas flow and temperature had an effect only on the ion abundances; the
best sensitivity was obtained experimentally by optimising each parameter. The DC
voltages applied to the entrance, bias and exit of the trap, IMS and transfer regions also
only had an influence on the ion abundances. The parameters that substantially
influenced the separation were the IMS gas flow and the wave velocity and height. An
increase (decrease) of the IMS gas flow decreased (increased) the mobility of all ions
making them travel faster (slower) through the mobility cell. The increase of the wave
velocity decreased the overall mobility of ions and narrowed the arrival time
distributions. An increase of the wave height, to the optimum value, increased the
separation and also decreased the ion mobilities as well as the arrival time distributions.
The wave height and velocity had independent effects but it was the combination of
these values that achieved best separation (data not shown). Once the separation
parameters were optimised (method Meth.IMSanthr, section 2.2.4.4), the anthracyclines
from the different HPLC fractions were analysed separately under the same conditions.
The drift times of these compounds are reported in Table 3.12.

Some of the fractions of the same mass had different drift times. For example,
compounds B and H both have molecular ions at m/z 1173.6, but their drift times are
3.98 and 4.95 ms, respectively. Figures 3.32 (A) and (D) show the drift plots that were
obtained when fractions B and C and fraction B and H were mixed together,
respectively.
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Table 3.12. Drift times obtained using TWIMS for the anthracyclines contained in the
different fractions separated by HPLC.

a

Fraction
name

Experimental
mass (Da)

Drift timea
(ms)

A

1189.5

4.56

B

1173.6

3.98

C

1173.5

3.98

D

1157.5

3.98

E

1173.9

4.43

F

1173.6

3.92

G

1157.6

3.86

H

1173.6

4.95

I

1157.6

4.30

J

1141.6

4.30

K

1157.6

5.20

TM

Triwave settings: trap and transfer collision energies: 6.0 V and 4.0 V, respectively;
IMS gas flow 25 mL/min; trap DC entrance, bias and exit voltages: 5.0 V, 27.0 V and
5.0 V, respectively; IMS DC entrance and exit voltages: 5.0 V and 2.0 V; transfer DC
entrance and exit voltages: both at 2.0 V; IMS wave velocity and height: 350 m/s and 14
V, respectively.
Figure 3.32 (B) and (C) show the corresponding chromatogram and mass spectra,
respectively, obtained for the mixture of fractions B and C. The mass spectra confirm
that the two compounds have the same masses, with [M + H]+ observed at m/z 1173.6.
The driftplot and the chromatogram did not show any separation, with only one peak at
a drift time of 4.05 ms observed for these two compounds even though their sugar
sequences were different. Compound C had the OH group missing from the aglycone
whereas compound B had the OH group missing from sugar 2 (or 2′).

Figure 3.32 (D) shows the drift plot obtained after analysis (Meth.IMSanthr) of the
solution mixture of isobaric compounds B and H of molecular mass 1172.6 Da.
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Figure 3.32. TWIMS of mixtures of fractions B and C ((A)-(C)) and fractions B and H
((D)-(F)). (G) Summarises the separation results for the mixtures of isobaric ions. The
blue arrows indicating a successful separation and the red arrows indicating no
separation. For example, it was possible to separate the anthracyclines present in
fractions H and B but not D and G. (A) Driftscope plot of a mixture of fractions B and
C; (B) Drift time of fractions B and C; (C) ESI mass spectrum of mixture of fractions B
and C; (D) Driftscope plot of a mixture of fractions B and H; (E) Drift time of fractions
B and H; (F) ESI mass spectrum of mixture of fractions B and H; (G) Summary of the
separation results.
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Figure 3.32 (E) and (F) show the corresponding chromatogram and mass spectra
obtained for the mixture, respectively. Compounds C and H had the same fragmentation
pattern as observed by MSn with the OH group missing from the aglycone whereas
compound B had the OH group missing from sugar 2 (or 2′). Unlike the results obtained
for the mixture of compounds B and C, the mixture containing compounds B and H was
resolved by TWIMS. A clean separation was observed on the driftscope and the
corresponding chromatogram with two peaks at drift times of 3.98 (Figure 3.32 (E) (1))
and 4.95 ms (Figure 3.32 (E) (2)). The corresponding mass spectra Figure 3.32 (F) (1)
and (2) were extracted from each of these peaks, respectively. By comparing the drift
times of each of these peaks to the drift time measured under the same conditions for the
separate anthracycline compounds it was possible to identify peaks (1) and (2) as
compounds B and H, respectively. The mass spectra (1) and (2) confirmed that the two
compounds had the same molecular mass and elemental composition, with their
[M + H]+ ion observed at m/z 1173.67 and 1173.65, respectively.

Figure 3.32 (G) shows all the combinations of anthracycline compounds tested and the
results of their separations. A blue arrow links two compounds when they were
successfully separated by IMMS and red arrows link the compounds for which the
separation was unsuccessful. For example, anthracyclines in fractions C and H were
separable by HPLC (Figure 3.30) and had different drift times (3.98 and 4.45 ms,
respectively, Figure 3.32 (G)), but had similar CAD mass spectra (Table 3.9). This is
consistent with these two compounds bearing the same sequence of sugars with the
same mass, with differences arising possibly from different conformations of the sugars
or location of the functional groups. In contrast, the compounds in fractions B and C
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were proposed to have different aglycones and a middle sugar differing by one hydroxyl
group as judged by CAD mass spectra. These compounds were separable by HPLC, but
not by ion mobility under the conditions of the current experiments.

Different molecules have been studied over time using a range of ion mobility
techniques. For example, small to large organic molecules have been separated by highfield asymmetric waveform ion mobility spectrometry (FAIMS)183 or more recently
isobaric metabolites from E. coli were separated by ambient pressure ion mobility mass
spectrometry.184 In recent studies, travelling wave ion mobility spectrometry (TWIMS)
has been used to separate isomeric alkyl anilines134 or peptides and proteins.137 To our
knowledge no previous ion mobility mass spectrometry separation studies have been
carried out on anthracyclines or closely related compounds using either TWIMS or
other ion mobility techniques.

3.4.

Summary and Future Directions

Crude anthracycline extracts containing cosmomycin D were obtained by methanol
extraction of culture supernatants from Streptomyces olindensis ICB20 in which
mutations had been introduced in order to stimulate the overproduction of CosD by the
bacteria. No method reported a satisfactory protocol to purify CosD, forcing us to
develop a new purification method. None of the attempts to purify the crude material by
chromatography alone yielded pure CosD. The pre-purification method introduced to
eliminate the major impurities by playing on the solubility of CosD was successful;
however, the compound was not pure enough to be used in any experiments and was
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purified further by HPLC (C4) and stability experiments carried out on CosD confirmed
that the storage of the pure compound in 100 mM NH4OAc, pH 7.5, was adequate. Over
time, the crude extract obtained from cultures of the Streptomyces organism changed in
their composition suggesting that spontaneous mutation had resulted in a decrease in the
amount of CosD produced and in the increased production of CosD-related compounds.
Each of these unknown compounds was collected and their structures and properties
investigated using several different techniques.

UV-visible spectrophotometry was used to determine their approximate concentration
as well as their absorption maxima in the visible region. The compounds were separated
in three different groups based on their visible absorbance maxima: fractions A, E, F
and K, had an absorbance maximum around 497 nm; fractions B, D, G and J, had a
maximum around 430 nm; and the remaining fractions C, H and I, had an absorbance
maximum around 460 nm. From these results Fraction E, F and K were expected to
have a similar aglycone to that of CosD (Compound A).

The exact mass of each compound, A to K, was obtained by high resolution mass
spectrometry which allowed determination of their elemental compositions. Several
compounds were found to have identical masses. Fractions B, C, E, F and H had
molecular masses of 1172.6 Da; fractions D, G, I and K had molecular masses of
1156.6 Da, and fraction A (CosD) and fraction J had molecular masses of 1188.6 Da
and 1140.6 Da, respectively. Owing to their molar masses and visible absorption
maxima these compounds were postulated to be related to CosD, all possessing two
trisaccharide chains and one to three fewer oxygen atoms compared to CosD. The
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position of the “missing” hydroxyl group as well as the sugar sequences were
determined and confirmed by two different mass spectrometric techniques.

CAD allowed determination of the sugar sequences on each compound by comparing
the fragmentation pattern to that observed for CosD which was confirmed by the TAP
fragmentation experiments. Among the isobaric compounds, some had identical
fragmentation patterns. Compounds C, E, F and H ([M + H]+ at m/z 1173.6) had the OH
group missing from the aglycone whereas compound B had the OH group missing from
sugar 2 (or 2′) and compounds D and G ([M + H]+ at m/z 1157.6) had one OH group
missing from the aglycone and one from the sugar 2 (or 2′), whereas compounds I and
K had two OH groups missing from the sugars 2 and 2′. Compound J ([M + H]+ at
m/z 1141.6) had one OH group missing from the aglycone and two from sugar 2 and 2′.
No fragmentation of the aglycone was observed making it impossible to determine the
exact position of the missing OH.

Preliminary information on the collisional cross-sections of the anthracyclines was
obtained by IMMS of isobaric compounds. Travelling wave ion mobility mass
spectrometry is a relatively new ion mobility method and researchers are currently
assessing its utility in separation and in fragmentation experiments. Only some of the
isobaric compounds bearing same sugar sequences were able to be separated under the
optimised experimental conditions. Knowing that these compounds could not be
identical owing to their different chromatographic behaviour, it will be of interest to
finally determine the structures of these compounds to understand the limits of
structural details required for separation using TWIMS.
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Mass spectrometric characterisation of these compounds was a useful tool to gain
preliminary information on the structure, composition and relative shapes of unknown
compounds only accessible in small quantities; however, this was not sufficient to
determine fully their complete structure. Crystallography or NMR of these compounds,
when obtained in sufficient quantities, will be needed to obtain unambiguous structure
determination. Once determined, it will be interesting to correlate the structures of these
anthracyclines with their drift times and also to carry out a complete characterisation of
these compounds in order to determine if they are novel anthracyclines. The diversity of
compounds produced by the Streptomyces organism could be an advantage, leading to
the production of novel compounds. Biological testing of these compounds and
comparison of their activities to CosD and Dn could lead to the discovery of potential
new anti-cancer drugs with fewer side effects and the possibility to counter the drug
resistance for certain types of cancer. These studies will be the subject of further
investigation in our laboratory and those of our collaborators.

131

CHAPTER 4
Mass Spectrometry of DNA-CosD Complexes

4.1.

Introduction

Mass spectrometry is a sensitive technique that can be used to study a wide range of
compounds, from small organic molecules39,123,177,185 to biomolecules such as proteins
and DNA.125,126,130 This fast and sensitive tool is also excellent for analysing complexes
involving biological macromolecules.102,104,107,186,187 Using mass spectrometry it is
possible to determine stoichiometries and binding affinities of non-covalent
complexes.102,105,107,187,188 In addition, tandem mass spectrometry has been employed in
numerous cases to evaluate the relative binding affinities and stabilities of novel
compounds

to assess their binding potential compared to clinically used

drugs.41,105,178,189

Among the wide range of DNA interactions reported in the literature, anthracyclineDNA interactions are widely studied owing to their chemotherapeutic potential.7,43,190,191
Most of these compounds such as the two well known chemotherapeutic agents
daunomycin and doxorubicin possess only one sugar unit linked to the aglycone.11-13
Only a few other compounds possessing a more complex glycosylation pattern, such as
di- and trisaccharide chains, have been studied in detail. These include the DNA
interactions of ditrisarubicin B, aclacinomycin A and cosmomycins A, B and C which
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were studied by fluorescence, desorption chemical ionization, field desorption tandem
mass spectrometry (for analysis of structure) and enzymatic and chemical
footprinting.14,39,41,165,192

Some properties of CosD, which contains two trisaccharide chains, have been reported
previously.7,10,37 In that early work, CosD was shown to induce differentiation in
cultured Friend F5-5 leukemia (mouse) cells under conditions where doxorubicin,
daunomycin and aclacinomycin A had no measureable effects.7 Although cosmomycin
D was isolated many years ago,10 no further investigations, other than the recent work
published by our group,7 report details on its DNA-binding properties and only limited
investigations have been carried out on its potential chemotherapeutic properties.7,10,37,41

The recent investigations conducted by our group on the DNA-binding properties of
CosD with a 16 mer double-stranded DNA using ESI-MS showed that 3-4 CosD
molecules bound to the DNA compared with 4-5 for Dn.7 Moreover, one agarose gel
experiment (a single anthracycline concentration) showed that compared to Dn and Dx,
fewer CosD molecules were needed to affect the mobility of DNA through agarose gel.7
These interesting differences between CosD and the anthracyclines Dn and Dx warrant
further investigation as anthracyclines that have different structural features are likely to
exhibit different interactions with cellular biomolecules. These differences may lead to
beneficial effects on biological activity that may confer these compounds anti-cancer
activities that are different to those of anthracyclines currently used in the clinic.
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DNA is an important target for drug action. Depending on its sequence, the DNA can
adopt many secondary structures. From the most common form (duplex B-DNA) to
more complex secondary structures (quadruplex or triplex, see below), each of these
forms has their biological relevance and plays a role in diverse biological
processes.193-195 Nucleic acids that are rich in guanines are capable of forming structures
called G-quadruplexes.196 These structures contain a square arrangement of guanines (a
tetrad) stabilized by Hoogsteen hydrogen bonding and by the presence of monovalent
cations (e.g. K+, NH4+) in the centre of the tetrad (Figure 4.1).194,195,197-200 Different
guanine-rich sequences can adopt a quadruplex structure and depending on the number
of repeating G-rich motifs in the oligonucleotide and the orientation of the strand
constituting the quadruplex, different topologies can be obtained.201-204 Some of these
topologies are represented in Figure 4.1 (B).

Figure 4.1. Quadruplex DNA. (A) Structure of a tetrad. The guanine bases are shown in
blue and the Hoogsteen hydrogen bonding in red; (B) Representation of quadruplex
structures with different strand arrangements: (a) 4-strand intermolecular quadruplex;
(b) 2-strand intermolecular quadruplex; and (c) 1-strand intramolecular quadruplex.
Monovalent ions contributing to the stabilization of the quadruplexes structures are
shown in orange and are localised in between the G-tetrads. Image adapted from
reference 201.

134

These guanine-rich sections are naturally occurring in several biologically significant
regions of the human genome such as the telomere region (situated at the end of the
chromosomes), at gene promoter regions, at the immunoglobulin switch region and at
other regions associated with certain human diseases.195,204,205 Telomere sequences
become shorter with each round of replication as DNA polymerases are inefficient in
replication at the ends of linear DNA.206,207 When the length of the telomere reaches a
critical size, the DNA is no longer able to be replicated and the cell dies. Telomeres are
thought to be important as they protect genes from being truncated and participate in the
regulation of the cell cycle.206,207 Telomerase is an enzyme which is able to maintain the
length of telomere by adding repeats of the DNA at the 3′ of the telomere region.206,207
Telomerase is inactive in normal somatic cells but is expressed in 80-85% of cancerous
cells. The activation of the enzyme in cancerous cells allows maintenance and
elongation of the telomere region and contributes to the ability of tumours to
proliferate.206,207

The formation of quadruplexes in telomeres has been shown to inhibit the activity of the
enzyme telomerase.208 Consequently, compounds that stabilise telomere DNA
sequences in their quadruplex form have been proposed as potential anti-tumour agents.
Some studies have reported the interaction of small molecules with quadruplex DNA;
among these compounds only a few showed some stabilising effect.198,209-212 Since
G-quadruplexes have been proposed as promising anti-cancer targets, the search for
novel small molecules capable of interacting with, and stabilizing G-quadruplexes
remains of great interest.
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4.2.

Scope of the Chapter

In this chapter, the focus is two-fold. The interactions of CosD with DNA is assessed as
a guide to its potential as an anti-tumour drug. In addition, the utility of ESI-MS in this
assessment is highlighted. In the first experiments, different DNA sequences of different
secondary structures were titrated with CosD to establish its binding affinity. Titration
experiments were carried out to determine the number of drug molecules required to
saturate the binding sites of a 16 mer dsDNA sequence and to compare the
stoichiometries observed under our experimental conditions to that of similar
experiments reported in the literature and in the previous preliminary experiments
conducted by our group. Additional experiments were carried out using forked (partially
double-stranded) DNA and quadruplex DNA. Similar experiments were conducted with
Dn and Dx in order to compare the DNA binding ability of CosD to that of these two
clinically used anthracyclines. Tandem mass spectrometry experiments were carried out
on complexes of different stoichiometries to evaluate the relative stability of
dsDNA-CosD complexes to those obtained with Dn and Dx under the same
experimental conditions. In a final section, mass spectrometry was used to evaluate the
protection offered by CosD bound to dsDNA during in vitro enzymatic digestion.
Characterisation of dsDNA-CosD complexes using complementary techniques is
described in Chapter 5.

4.3.

Results and Discussion

In all the experiments described herein, the concentrations of the solution buffer as well
as the concentration of DNA were carefully chosen to avoid non-specific interactions
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between the DNA and the drugs added to the solutions. This was done by using
micromolar concentrations of DNA and complexes in a relatively concentrated solution
of ammonium acetate to be compatible with the mass spectrometric experiments. The
sequence, Rt1 DNA (section 2.2.2.1, Table 2.3), was used for most of the experiments.
This is a non-self-complementary sequence; therefore avoiding any ambiguity in the
identification of the different ions present in the mass spectra.

4.3.1. ESI-MS of DNA-CosD Complexes
In this section, several titration experiments were carried out using different DNA
sequences to evaluate the binding affinity of CosD. The three structures selected for
these studies were: (i) 16 mer double-stranded DNA, (ii) quadruplex DNA, and
(iii) partially double-stranded DNA, called here forked DNA. All sequences are detailed
in Table 2.3.

4.3.1.1.

Binding to dsDNA Rt1

There are now many examples from our laboratory and others where non-covalent
drug-DNA complexes have been detected and analysed by ESI-MS.102,105,107,213 These
experiments are routine in these laboratories and preliminary screening of drug-binding
to previously prepared 16 mer DNA sequences can be carried out in approximately two
hours. In the current "screening" experiments, the double-stranded DNA, Rt1, was
mixed with various concentrations of Dn, Dx or CosD (dsDNA:anthracycline of 1:1,
1:3, 1:5, 1:7, 1:9, 1:11 and 1:13 for Dn and Dx, 1:1, 1:2, 1:3, 1:4 and 1:5 for CosD), and
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the mixtures were analysed by ESI-MS under the same experimental conditions (section
2.2.3 and 2.2.4.6). As the concentration of drug was increased, the number of drug
molecules bound to the DNA increased until a saturation point was reached. That is,
upon addition more drug solution, no more drug molecules were bound to the DNA.
This suggests that all the binding sites on the DNA were occupied. This behaviour has
previously been observed in our laboratory and others.107,189,214

Figure 4.2 shows the negative ESI mass spectra of Rt1 alone (A) and with each
anthracycline (Dn (B), Dx (C) and CosD (D)) in the mixture where all the binding sites
of DNA were saturated. The DNA-drug ratio needed to saturate the DNA was
dependent on the drug. Rt1 was saturated with Dn when the DNA-drug ratio was 1:11
(Figure 4.2 (B)), and with Dx and CosD when the DNA-drug ratios were 1:13 and 1:4,
respectively (Figure 4.2 (C) and (D), respectively).

It should be noted that electrospray produces multiply charged ions carrying different
numbers of charges. For free dsDNA (Figure 4.2 (A)) and for all the anthracycline
complexes with dsDNA (Dn (B), Dx (C) and CosD (D)) complexes carrying 7-, 6- and
5- charges were observed. The most abundant ions were those carrying six negative
charges. In the spectrum of Rt1 alone (Figure 4.2 (A)), the [Rt1-6H]6- ion was at
m/z 1626.8, in good agreement with the calculated value of 1626.2 (mass, 9763.5 Da).
Ions corresponding to [Rt1-5H]5- and [Rt1-7H]7- (m/z 1951.8 and 1393.8, respectively)
and single-stranded DNA (m/z 1201.0 and 1237.7), were also present but in low
abundance.
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Figure 4.2. Negative ion ESI mass spectra of saturating mixtures of anthracyclines with
Rt1 DNA. (A) Rt1 alone; (B) Rt1:Dn, 1:11; (C) Rt1:Dx, 1:13; (D) Rt1:CosD, 1:4. The
symbols on the mass spectra indicate the ions corresponding to: ss- or dsDNA alone
({); Rt1 + 2 anthracyclines (); Rt1 + 3 anthracyclines (U); Rt1 + 4 anthracyclines
(z); Rt1 + 5 anthracyclines (S); Rt1 + 6 anthracyclines (); Rt1 + 7 anthracyclines
(). (E) Binding profile of each anthracycline to Rt1. The intensities of ions from each
complex in a spectrum were summed and expressed as a percentage of the sum of the
intensities of all ions in the spectrum. Rt1:Dn ratio 1:11(); Rt1:Dx ratio 1:13 ();
Rt1:CosD ratio 1:4 (▬).
In Figure 4.2 (E), the relative abundances of the complexes containing different
numbers of drugs bound in the saturating mixtures were compared by summing the
intensities of ions from each complex and expressing this as a percentage of the sum of
the intensities of all other ions in the spectra. This comparison is referred to as a
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“binding profile” in this thesis. For Dn- and Dx-DNA mixtures, the most abundant
complex contained four molecules bound (e.g. Rt1 + 4Dn) with other ions observed
corresponding to complexes containing from 2 to 7 and from 2 to 6 drugs bound for Dn
and Dx, respectively (Figure 4.2 (B) and (C), respectively). For CosD, in saturating
conditions, the most abundant complex contained 3 CosD molecules (Rt1 + 3CosD) and
other ions corresponding to complexes containing from 2 to 4 CosD molecules were
present. The calculated m/z values for ions from complexes with Rt1 are shown in
Appendix 4.

The results obtained in these experiments were in agreement with previous ESI-MS
results analysing binding of anthracyclines to 16 mer dsDNA107,214 and our preliminary
ESI-MS analysis of CosD.7 The smaller number of CosD molecules bound to DNA
compared with Dn and Dx, is consistent with a larger “footprint” of CosD on the 16 mer
dsDNA Rt1. Intercalators containing planar aromatic ring systems are thought to be able
to intercalate between every second base pair of DNA, as described by the “neighbour
exclusion principle”.215 The addition of substituents or glycosylation can limit the
proximity of the intercalators bound to DNA as a result of steric hindrance. While the
rings of anthracyclines intercalate between DNA base pairs, the amino sugars bind to
the minor groove of DNA.216 There are no X-ray or NMR structures available for a
DNA-CosD complex or for any anthracyclines containing two trisaccharide chains;
however, a structure of aclacinomycin bound to 6 mer dsDNA shows that its single
trisaccharide chain also lies in the minor groove of the DNA.217 It seems likely that the
trisaccharide chains of CosD will behave in a similar way to the monosaccharide chain
of aclacinomycin and also bind in the DNA minor groove. ESI-MS experiments cannot
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directly comment on the structure of the DNA complexes detected. Consequently, it is
possible that some of the less abundant complexes may involve anthracyclines bound
non-specifically, perhaps as a result of electrostatic interactions between the positively
charged anthracycline drugs and the phosphodiester backbone of DNA. This possibility
was minimised in these experiments by using a high salt concentration (100 mM
ammonium acetate) and low concentration of DNA and anthracyclines.216

4.3.1.2.

Binding to Forked DNA

To investigate that the drug binding to DNA was “specific”, several DNA sequences
were designed. The term “specific” implies that the binding occurred via intercalation of
the chromophore in between the DNA base pairs and not via electrostatic interaction
between the positively charged drug and the negatively charged DNA backbone. The
hypothesis directing design of the sequences was that if double-stranded DNA is
required for binding, and non-specific electrostatic-only interactions are minimal under
the experimental condition used, then the maximum number of anthracycline molecules
that bind to the DNA is expected to be unchanged when single-stranded tails are added
to an initial double-stranded DNA. To investigate this binding specificity, a 10 mer
double-stranded DNA sequence was selected, F0AT (Figure 4.3), and was then
modified by addition of single-stranded tails constituted of poly dA or poly dT
sequences of either 10 or 20 nucleotides in length. The DNA sequences employed in
this study are represented in Figure 4.3. The DNA structures possessing two singlestranded tails added to the double-stranded section of the DNA are called forked DNAs
as they resemble the structure of the partially unwound DNA double helix during DNA

141

replication, also known as the replication fork. It is important to note that only poly dT
and poly dA sequences were selected to create forked DNA as strands containing
consecutive Gs are known to form quadruplex structures in solution.193,218

Figure 4.3. Double-stranded and partially double-stranded DNA. All sequences possess
an identical 10 mer double-stranded sequence (identical to F0AT) with single- or
double-stranded extensions constituted of poly dA and/or poly dT sequences. DNA
expected to be dsDNA is shown in black; ssDNA extensions are shown in red.

The various forked and dsDNAs used in this study were mixed with various
concentrations of Dn, Dx or CosD. The dsDNA:anthracycline mixtures prepared were
in the ratios 1:1, 1:3, 1:5, 1:7, 1:9, 1:11 and 1:13 for Dn and Dx, and 1:0.5, 1:1, 1:1.5,
1:2 and 1:2.5 for CosD. Each of these mixtures was analysed by ESI-MS under the
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same experimental conditions (section 2.2.3 and 2.2.4.6). Binding profiles were
obtained for each DNA-drug couple for the different ratios tested as described above.
Several of the binding profiles obtained from the titration experiments are shown in
Figure 4.4 and to enable comparison among the three drugs, the binding profiles
obtained for Dn, Dx and CosD with the same DNA sequence are represented on the
same graph (e.g. F0AT Figure 4.4 (A)). Only the binding profiles corresponding to the
DNA:drug ratios where the DNA was saturated (1:13 for Dn (green) and Dx (blue) and
1:2.5 for CosD (red)) are shown in the figure.

In this study, all the binding profiles obtained were examined; however, Figure 4.4
shows only the binding profiles obtained for some of the DNA sequences as they were
the most representative of the results obtained during these experiments. The most
abundant complex in the 1:13 mixtures of the 10 mer dsDNA F0AT with Dn was
[F0AT + 3Dn], for Dx was [F0AT + 1Dx] and [F0AT + 2CosD] for the 1:2.5 mixture
containing CosD (Figure 4.4 and Table 4.1). Since the F0AT sequence is six base pairs
shorter than the Rt1 DNA used previously (section 4.3.1.1), it was expected that fewer
anthracyclines would bind to the DNA sequence under saturating conditions. The results
obtained here for Dn (3 bound as the major complex for F0AT compared with 4 for
Rt1), Dx (1 for F0AT compared with 4 for Rt1) and CosD (2 for F0AT compared with 3
for Rt1) are consistent with this. Unlike the results obtained for Rt1, Dn and Dx did not
bind to F0AT with the same stoichiometry under saturating conditions. This observation
may be the result of a sequence preference of Dx that is not exhibited by Dn. Although
the structures of Dn and Dx are very similar, with the latter bearing an additional -OH
group, X-ray structures of Dn and Dx complexes with dsDNA have previously revealed
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Figure 4.4. Binding profiles of the anthracyclines Dn, Dx and CosD for the 10 mer
dsDNA, F0AT and poly dA and dT extensions (see Figure 4.3 for sequences). (A)
F0AT; (B) F10A1; (C). F20A1; (D) F10T1; (E) F20T1; (F) F10A1A2; (G) F20A1A2;
(H) F10T1A2; (I) F20T1A2. Data are shown for the 1:13, 1:13 and 1:2.5 saturating
mixtures of the DNA with Dn (green), Dx (blue) and CosD (red), respectively.
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structural differences that were proposed to account for the different clinical activities of
these two drugs.45 Differences in the binding profiles using the 16 mer sequence Rt1
were not observed.

Table 4.1. Summary of the most abundant complexes observed for all the different
DNA-drug mixtures in saturating conditions (ratios 1:13 for Dn and Dx and 1:2.5 for
CosD). The numbers in the column indicate the number of drugs bound to the DNA in
the most abundant complex in solution.
Drug

Dn

Dx

CosD

F0AT

3

1

2

F10A1

3

2

2

F10A2

3

2

2

F10T1

3

2

4

F20A1

3

2

2

F20A2

3

2

2

F20T1

3

2

4

F10A1A2

4

2

2

F20A1A2

4

2

2

F10T1A2

4

1

3

F20T1A2

4

2

5

DNA

Addition of single-stranded poly dA or dT tails of 10 or 20 bases to F0AT (e.g. F10A1
and F20T1) did not affect the number of drug molecules bound to the DNA for Dn
(3 drugs bound) and Dx (2 drugs bound) (Table 4.1). The same was observed for CosD
when poly dA tails were added (F10A1 and F10A2); however, when poly dT tails were
added, it appears that other interactions between CosD and the DNA favored the
binding of two additional drugs compared to the same sequences bearing dA tails
(e.g. F10T1 and F20T1). In the case of the forked DNAs (F10A1A2 and F20A1A2) the
addition of two dA tails of 10 or 20 bases long did not affect the number of drugs bound
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onto the DNA for any of the drugs as 4, 2 and 2 drugs bound were observed in each case
for Dn, Dx and CosD, respectively. To determine if more drugs would bind if the
double-stranded section was elongated, the single-stranded dA tails and dT tails were
matched up to form (Watson-Crick base paired) F10T1A2 and F20T1A2. The same
number of drugs that bound to the forked DNA sequences was observed for Dn and Dx,
however, one and three more bound CosD molecules were observed for F10T1A2 and
F20T1A2, respectively. The inability of the longer dsDNA to bind a greater number of
anthracyclines in the case of Dn and Dx is surprising at first glance. A possible
explanation for this is that Dn and Dx exhibit a sequence preference where binding to
double-stranded tracts of d(A)•(T) is relatively weak. Previous studies show that
intercalation of anthracyclines such as Dn and Dx, is preferred at CpG sites.45,57
Alternatively, this observation might be a reflection of the lower stability of A.T base
pairs and/or their complexes with the anthracyclines. Previously, we have observed a
higher abundance of single-stranded DNA in ESI mass spectra of DNA with AT-rich
termini (Beck, unpublished). Since a greater number of CosD molecules bind to
F10T1A2 and F20T1A2 than to the other related sequences, this suggests that CosD is
able to bind relatively tightly to AT-rich dsDNA and it is likely that its binding
stabilises this region of DNA against “unzipping” and subsequent dissociation of the
complex.

An additional factor was that non-specific binding of CosD was observed for the DNA
sequences containing dT tails (e.g. up to 8 CosD molecules were bound to F20T1 while
only 4 molecules were bound to F20A1). These observations were confirmed, when
under the same conditions, single-stranded DNA containing dA and dT of 10 and
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20 bases were titrated with Dn, Dx and CosD. These titrations revealed that the most
abundant complex corresponded to 1 drug bound for Dn and Dx (DNA:drug ratio 1:13)
while up to 3 bound CosD molecules were observed bound to single-stranded DNA
(DNA:drug ratio 1:6), especially in the case of single-stranded DNA bearing poly dT
sections (results not shown).

The results obtained here support the hypothesis that drug binding to DNA under the
conditions used for the titration experiments resulted from specific interactions with
dsDNA. The anthracyclines are most likely bound to the double-stranded region by
intercalation of the drug in between base pairs since increasing the length of singlestranded tails did not affect the number of drug molecules bound. Additionally, a
binding site preference was also highlighted since Dn and Dx behaved differently when
bound to the 10 mer dsDNA F0AT, compared to the binding observed to 16 mer
dsDNA (Rt1). Moreover, the results were consistent with previous studies showing that
anthracycline intercalation is preferred at CdG sites.45,57 This preferred binding was
shown when elongation of the double-stranded region by addition of a poly d(A)•(T)
tails did not greatly increase the number of drugs bound to the DNA except in the case
of CosD where 2 more drug molecules were bound.

4.3.1.3.

Binding to Quadruplex DNA

Similar screening experiments were conducted with quadruplex DNA to assess the
binding affinity of CosD. For these experiments, a synthetic parallel four-stranded
quadruplex structure formed from an 8 mer single-stranded DNA sequence containing
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five consecutive guanine bases, G5, was selected. This tetrameric quadruplex sequence
has previously been investigated by ESI-MS in our laboratory.219 The three dimensional
representation of the structure of G5 is most likely similar to that of the quadruplex
structure shown in Figure 4.1 (B) (a). For the titration experiments, several G5:CosD
mixtures were prepared in the ratios 1:1, 1:2, 1:3, 1:4, 1:5 and 1:6 (section 2.2.3) then
analysed using the Meth.qDNA method (Table 2.4, section 2.2.4.7). Some of the mass
spectra obtained as well as their corresponding drug binding profiles are presented in
Figure 4.5.

Figure 4.5. Titration of the quadruplex DNA G5 with CosD. (A) Mass spectrum of G5
alone; (B), (C) and (D) mass spectra of G5:CosD in ratios 1:1, 1:3 and 1:6, respectively;
(E) binding profile of CosD to G5 in different mixtures (see coloured legend). The
intensities of ions from each complex in a spectrum were summed and expressed as a
percentage of the sum of the intensities of all ions in the spectrum. For (A)-(D): | G5;
z G5+1CosD; S G5+2CosD.
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Figure 4.5 shows only some of the mixtures analysed. The mass spectrum (A)
corresponds to the solution containing the quadruplex DNA G5 alone and the mass
spectra (B), (C) and (D) correspond to the mixtures containing G5 and CosD in ratios of
1:1, 1:3 and 1:6, respectively. From these results, several observations can be made.
Firstly, several ions were observed for G5 DNA alone (Figure 4.5 (A)) and for the
spectra of the solutions containing the different DNA-drug mixtures. In this series of
experiments, the ions observed were the 6-, 5- and 4- ions, with the most abundant ions
corresponding to those carrying five negative charges. Although the charge state
distribution is spread over three different charge states as for the previous experiments,
the charge state distribution observed is highly dependent on the experimental
conditions.133 For example, increasing the cone voltage or the Rf lens voltage shifted the
charge state distribution toward the high m/z values. The adduct ions observed for the
quadruplex DNA are quite different from those observed for dsDNA. For B-form
dsDNA, a peak corresponding to the DNA is observed, sometimes followed by some
low intensity peaks at higher m/z corresponding to sodium or potassium adducts (e.g.
Figure 4.2 (A)). In the case of quadruplex DNA, ions to higher m/z correspond to the
quadruplex DNA with different numbers of ammonium ion adducts (e.g. Figure 4.5
(A)). Such adducts with different cations (e.g. sodium, lithium and ammonium) have
been observed previously in numerous reports.194,210,218,220

As shown in previous studies, the cations are localised in the core of the quadruplex
DNA and contribute to the stabilization of the quadruplex structure.133,219,221 The
number of cations bound within the quadruplex DNA depends on the number of
consecutive tetrads contained in the quadruplex, as each ammonium ion is bound
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between two consecutive tetrads. The number of ammonium ion adducted to the DNA is
equal to the number of consecutive tetrads minus one (see Figure 4.1 (B)).198,220,222,223
This relationship has been observed previously in our laboratory224 and in the case of
G5 under the experimental conditions used here, the most abundant ions in the mass
spectra corresponded to four ammonium ions bound to G5. In the spectrum of the
solution containing G5 alone (Figure 4.5 (A)), the ions corresponding to
[G5 + 4NH4+ - 9H]5- and [G4 + 4NH4+ – 8H]4- observed at m/z 2010.0 and 2512.6 were
in good agreement with the calculated values of 2009.2 and 2511.7 (mass of 9986.8 for
G5 and 18.0 Da for the NH4+ ion). Under these conditions the ion from quadruplex G5
alone was no longer observed, however, for each of the different charge states ions of
low to moderate intensities corresponding to G5 with two to seven ammonium ions
bound were observed. It is important to note that this relationship is only maintained
under soft experimental conditions where the quadruplex structure is conserved in the
gas phase, and that using different experimental conditions (e.g. increasing the cone
voltage or increasing the Rf lens voltage) led to the stripping of the ammonium ions and
the dissociation of the quadruplex structure. These conditions have previously been
investigated in our laboratory.225

The binding profiles shown in Figure 4.5 (D) were obtained from the mass spectra of
each of the solution mixtures analysed and obtained as previously described for the
dsDNA. Increasing the amount of CosD in the solution led to an increase in the
abundance of G5-CosD complexes in solution. In contrast to the results for the dsDNA,
even in the mixture containing a six-fold excess of CosD, only up to two molecules of
CosD were bound to the DNA and the ions corresponding to the free G5 remained the
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most abundant ions in the spectra. In conclusion, these observations suggest that CosD
does not possess a high affinity for tetrameric quadruplex DNA.

Furthermore, the presence of CosD bound to the DNA does not appear to influence the
amount of cation (ammonium) bound to the quadruplex G5. A similar binding pattern to
the one observed for the free DNA was observed for the G5-CosD complexes. This
suggests that CosD does not bind by intercalation in between the quadruplex tetrads
since no ammonium ion was displaced. No crystal structures of the binding of CosD to
quadruplex DNA are available to prove this suggestion; however, an X-ray crystal
structure of Dn bound to a similar quadruplex structure has been determined. In the
work carried out by Clark et al., the crystal structure of Dn with (TGGGGT)4 showed
that Dn does not bind to quadruplex DNA by intercalation but prefers to stack on the
terminal tetrad.203 It was also shown in this work that the terminal area of the
quadruplex (the last G tetrad) is large enough to accommodate simultaneously up to
three Dn molecules and that the daunosamine sugars form hydrogen bonds with the
minor grove of the quadruplex.203 Since the structure of CosD resembles that of Dn it is
possible that CosD also binds to quadruplex DNA G5 by end stacking. At present we
are attempting to crystallize G5-CosD complexes, however, low levels of binding make
this experiment challenging.

4.3.2. ESI-MS/MS of DNA-CosD Complexes
In contrast to other methods (e.g. circular dichroism spectroscopy), the precise
stoichiometries of complexes in a solution can be determined by mass spectrometry
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even where there are complexes with different stoichiometries present in solution.
A cautionary note is of course that the complexes do not dissociate to an appreciable
extent on transferral from the solution to the gas phase. The stoichiometries observed
for the anthracyclines are in agreement with other work and suggest that ESI-MS
conditions are sufficiently gentle to maintain the complexes.7,104-108,110

In addition, since the electrospray ionisation process generates ions with different
numbers of charges this allows the comparison of the dissociation pathways for
complexes carrying the same number of drugs bound but a different number of charges.
This provides an opportunity to test the stabilities of each of the complexes formed
between the dsDNA Rt1 and Dn, Dx or CosD to determine the effect of the charge on
their stability.

In order to prepare complexes for ESI-MS/MS experiments containing one, two and
three drug molecules bound to Rt1 as the most abundant in the mixture as judged by
ESI-MS, the solutions prepared for this study were selected by considering the drug
binding profiles obtained earlier (section 4.3.1.1) and are shown in Table 4.2. Since the
ions carrying six and five negative charges were the most abundant ions in the mass
spectra under the experimental conditions used, these two charges states were chosen
for analysis and their dissociation pathways compared for each of the complexes. All
experiments were carried out under the same experimental conditions (method
Meth.dsDNA, section 2.2.4.7, Table 2.4) and the maximum collision energy applied
during the CAD experiments was 24 V because it corresponded to the maximum
potential at which the quality of the mass spectra could be maintained.
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Table 4.2. Mixtures prepared for each drug to obtain the different complexes as the
most abundant in solution (based on binding profiles from section 4.3.1.1).

Drug
Most
abundant complex

Rt1:Drug mixtures
Dn

Dx

CosD

[Rt1 + 1drug]

1:1

1:3

1:2

[Rt1 + 2drugs]

1:3

1:5

1:3

[Rt1 + 3drugs]

1:5

1:9

1:4

All the complexes chosen for this study were subjected to the same conditions for CAD
fragmentation. The dissociation pathway for each of the complexes containing one, two
or three drug molecules bound to Rt1 were very similar so representative spectra
(Figure 4.6 and Figure 4.7) were selected to illustrate the results obtained for each of the
charge states. All the results obtained, however, were considered to enable comparison
among the different fragmentation pathways obtained for each drug at each charge state.

Figure 4.6 shows the negative ion ESI-MS/MS spectra of the ions Rt1 (A), Rt1 + 2 Dn
(B), Rt1 + 2 Dx (C) and Rt1 + 2 CosD (D) carrying five negative charges. Each
spectrum was obtained using a collision energy of 10 V. The dissociation pathway of
the precursor ion [Rt1 - 5H]5- at m/z 1951.8 (mass 9763.5 Da) (Figure 4.6 (A)) was as
follows: an increase in the collision energy applied to the precursor ion firstly caused
the loss of a guanine base (abbreviated by G), to give [Rt1 - 1G - 5H]5- at m/z 1921.7. A
further increase in the collision energy caused the loss of a second guanine base,
[Rt1 - 2G - 5H]5- at m/z 1891.3, which was followed at higher collision energies by the
dissociation of the duplex DNA to its single strands [Rt1A - 3H]3- and [Rt1B - 3H]3- at
m/z 1601.8 (mass 4808.2 Da) and 1651.1 (mass 4955.3 Da), respectively. The
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Figure 4.6. Negative ion tandem mass spectra (ESI-MS/MS) of the 5- charge states of:
(A) Rt1 (m/z 1951.9); (B) Rt1 + 2 Dn (m/z 2163.1); (C) Rt1 + 2 Dx (m/z 2169.7); (D)
Rt1 + 2 CosD (m/z 2428.0). z Rt1; { Rt1 – 1G; S Rt1 + 1 anthracycline; U Rt1 + 1
anthracycline – 1G;  Rt1 + 2 anthracyclines;  Rt1 + 2 anthracyclines – 1 G. The
precursor ion in each spectrum is indicated by an arrow. The collision energy applied
was 10 V.
peaks corresponding to the ssDNA are not shown on the spectra due to the m/z window
selected for the figure.

In the cases of the complexes formed with Dn and Dx, a similar dissociation pattern was
observed. For the ions [Rt1 + x Dn]5- and [Rt1 + x Dx]5-, where x = 1 (S), 2 ()
(Figure 4.6) or 3 drugs, the major dissociation pathway was the loss of a neutral drug
molecule to obtain the complexes [Rt1 + (x-1) Dn]5- and [Rt1 + (x-1) Dx]5-. In each
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spectrum, there were also ions of low abundance corresponding to the different
complexes formed with DNA where one guanine base had been lost (Figure 4.6 (B) and
(C)). Unlike for Rt1 alone, even at high collision energies, separation of the doublestranded Rt1 into single strands after loss of all the drugs bound was not observed. In
the case of CosD, the dissociation pathway was different to that observed for Dn and
Dx. At a collision energy of 10 V (Figure 4.6 (D)), and at all other collision energies
tested (up to 24 V), no CosD molecules were dissociated from Rt1 no matter how many
CosD molecules were initially bound in the complex. Under these conditions, Rt1 was
not separated into single strands, but ions of low abundance corresponding to the loss a
single guanine base were evident (Figure 4.6 (D)). Similar guanine loss to the one
observed here from the free and complexed Rt1 has been observed previously.129,213,226
The low-threshold nature of the base fragmentation process creates a competition
between non-covalent dissociation and covalent fragmentation when the collision
energy applied to a system is high.129 Owing to its labile nature the guanine base is the
often the first base to be lost under such conditions.226

The difference in dissociation pathway of the complexes obtained for the different drugs
can be explained in part since, the more stable the complex, the greater the collision
energy that needs to be applied to dissociate the complex. From the results obtained for
the different 5- charged complexes a few comments can be made. Progressive increase
in the collision energy produced an increase in the amount of drug lost for Dn and Dx
until all drug molecules were lost from the complex. Additionally, from the results
observed at equivalent collision energies (10 V) (Figure 4.6), the complex formed with
Dx was somewhat more stable than that with Dn as evidenced by the greater abundance
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of the product ions in the ESI-MS/MS spectrum for Rt1 + 1Dn (Figure 4.6 (B))
compared with Rt1 + 1Dx (Figure 4.6 (C)). The dissociation behavior and the relative
stabilities of Dn- and Dx-Rt1 complexes observed here was in agreement with results
previously reported in the literature for Dn- and Dx-DNA complexes with other studies
using different DNA sequences (12- and 14 mer sequences also bearing terminal
guanine residues).189,213 This difference in stability has been explained in terms of an
increase in activation enthalpy for DNA complexes with Dx compared with Dn as a
consequence of the extra H-bond that may be present in complexes with Dx.58,189 Under
the same experimental conditions, no CosD molecule was dissociated from the complex
even at high collision energies. Since increasing the energy did not yield any
dissociation from the complex, this suggests that the complexes formed with CosD are
more stable than those with Dn and Dx. It is likely that the sugars of CosD bind in the
minor groove, as it has been shown for other anthracyclines bearing several sugars, and
that the increased number of non-covalent interactions (hydrogen bonds formed
between the DNA minor groove and the sugars of CosD) result in a complex that has
greater stability and a larger footprint on DNA.

Figure 4.7 shows the negative ion ESI-MS/MS spectra of the ions from Rt1 (A),
Rt1 + 2 Dn (B), Rt1 + 2 Dx (C) and Rt1 + 2 CosD (D) carrying six negative charges.
These spectra were obtained by applying a collision energy of 6 V. As for the 5- ions,
spectra were chosen as they were the most representative of the results. The
fragmentation of 6- ion from the DNA alone, [Rt1-6H]6-, at m/z 1626.4 (mass 9763.5
Da) was similar to what was observed for the precursor ion [Rt1-5H]5- (Figure 4.6 and
4.7 (A)). Increases in the collision energy led to the loss of one guanine base and the

156

Figure 4.7. Negative ion tandem mass spectra (ESI-MS/MS) of the 6- charge states of:
(A) Rt1 (m/z 1951.9); (B) Rt1 + 2 Dn (m/z 2163.1); (C) Rt1 + 2 Dx (m/z 2169.7); (D)
Rt1 + 2 CosD (m/z 2428.0). z Rt1;  ssRt1; º ssR1 – 1G; S Rt1 + 1 anthracycline; U
Rt1 + 1 anthracycline – 1G;  Rt1 + 2 anthracyclines;  Rt1 + 2 anthracyclines – 1 G.
The precursor ion in each spectrum is indicated by an arrow. The collision energy
applied was 6 V.

dissociation of Rt1 into single strands to obtain [Rt1A - 3H]3- at m/z 1602.1,
[Rt1B - 3H]3- at m/z 1651.2 and [Rt1A - 1G - 3H]3- at m/z 1551.5. Compared to the
5- charge state, a lower collision energy was required to dissociate the [Rt1 - 6H]6- ion
showing that [Rt1 - 5H]5- was more stable than [Rt1 - 6H]6-. This difference in stability
is likely due to the additional charge present on the 6- ion resulting in increased
Coulombic repulsion resulting in a decrease in the energy required to dissociate the
DNA strands.129
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The dissociation pathway observed here for Dn and Dx was similar to that observed for
the 5- ions. All the complexes containing either one, two or three Dn- or Dx molecules,
successively lost a neutral drug molecule until all drugs in the complex were
dissociated. A loss of guanine bases was also observed, however, not for all the
complexes. This loss of guanine was only observed for the complexes possessing one
molecule of Dn and one and two molecules of Dx. This meant that the first drug
molecule to dissociate from the complexes was bound less tightly as less energy was
required for the dissociation of these drugs than for the dissociation of the glycosidic
bond to guanine. Once the collision energy was increased enough to dissociate all the
drugs bound in the complex, a further increase of the collision energy led to the
dissociation of the DNA double helix into single strands. This dissociation was not
observed in the case of the 5- complexes as the Coulombic repulsion was lower than in
the present case allowing maintenance of the DNA double helix even at high collision
energies.

The dissociation pathway of the Rt1-CosD complexes carrying six negative charges was
different from that with five negative charges and was different to the results observed
for Dn and Dx complexes. In contrast to the complexes carrying five negative charges,
an increase of the collision energy allowed the dissociation of one CosD from each
complex (one, two or three CosD bound to Rt1). In contrast to the results for Dn and
Dx, the CosD molecules lost from the complex were negatively charged, leaving the
remaining complex with one less negative charge. For example, one CosD molecule
was dissociated from [Rt1 + 2CosD - 6H]6- to give [Rt1 + 1CosD - 5H]5- carrying only
five negative charges (Figure 4.7 (D)). The resulting tightly bound complex resisted
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further loss of CosD molecules as the collision energy was increased to 24 V; it was not
possible to apply higher collision energies and maintain the quality of the mass spectra.
This difference in dissociation confirmed once more that complexes formed with CosD
are more stable than the complexes formed with Dn and Dx since at equivalent collision
energy, one to all the Dn and Dx molecules were dissociated from the complex while
only one CosD molecule was dissociated. Although no more loss of CosD was
observed, in common with the results observed for Dn and Dx, some low intensity
peaks corresponding to the loss of guanine were observed to give for example
[Rt1 + 2CosD - 1G - 6H]6- and [Rt1 + 1CosD - 1G - 5H]5- from both the precursor ion
[Rt1 + 2CosD - 6H]6- and the resulting fragment ion [Rt1 + 1CosD - 5H]5- (Figure 4.7
(D)). Similar behavior has been observed for the dissociation of actinomycin D from 12
mer dsDNA using a Q-Tof mass spectrometer similar to the one used in the current
experiments. This intercalator contains two bulky cyclic peptides that lie in the minor
groove.189

The results obtained here provided a rapid comparison of the binding affinities of the
three drugs tested using only a small amount of sample. Under these conditions, all the
complexes formed with CosD were more stable than the complexes formed with Dx
which were more stable that the complexes formed with Dn. Moreover, when each drug
was considered separately, all the complexes bearing five negative charges were more
stable than their equivalents carrying six negative charges. These relative stability
results for Dn, Dx and CosD were also supported by previous competitive binding
experiments that were carried out in our laboratory. In these experiments it was shown
that CosD was less easily displaced than Dn and Dx from their respective Rt1-drug
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complexes, confirming that the binding of CosD to Rt1 was tighter than the binding of
Dn and Dx.7

4.3.3. Enzymatic Digestion Analysed by ESI-MS
A large number of studies have been reported on enzymatic footprinting to determine
oligonucleotide sequence,227 drug binding site specificity162,165,166 or the chemical
footprint of compounds on DNA sequences.14 Many of these studies involving
anthracycline compounds showed that the number of base pairs protected in both
chemical and enzymatic protection assays was increased with the increased number of
sugars. Mono-, di- and trisaccharide anthracyclines protected 3, 4 and 6-8 base pairs
respectively.14,228 To our knowledge no study (other than the article published from this
work),229 has been carried out to investigate in vitro digestion of DNA-cosmomycin D
complexes. In the current work, a simple, rapid method was used to screen the footprint
of CosD and compare it to the footprint of Dn and Dx on the 16 mer Rt1 DNA. ESI-MS
was used to follow the in vitro digestion progress of Rt1-Dn, -Dx and -CosD complexes
for different time periods (1 min, 10 min, 20 min and 30 min) and was compared to the
digestion under the same conditions for the unprotected Rt1 DNA.

These digestion experiments were carried out using two enzymes: phosphodiesterase I
(PdI, an exonuclease) and Dnase (an endonuclease). The Rt1-anthracycline mixtures
selected for these experiments were chosen to give as the major complexes in solution
[Rt1 + 2 anthracyclines] and [Rt1 + 3 anthracyclines]. As judged by binding profiles
obtained earlier in section 4.3.1.1, the anthracycline mixtures prepared were the
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Rt1:drug ratios of 1:6, 1:6 and 1:2.5 for Dn, Dx and CosD, respectively. The products
from all the digestions were analysed by ESI-MS after dilution into 5 mM ammonium
acetate, 50% in acetonitrile using the method described in section 2.2.4.10. In this
solution, dsDNA is expected to separate to single strands. All experiments were carried
out on several occasions and the results were reproducible. Some of the mass spectra
obtained after digestion as well as the digestion profiles for each drug are shown in
Figure 4.8.

Figures 4.8 (A)-(D) show the mass spectra that were obtained after the digestion of Rt1
(A) or its complexes with Dn (B), Dx (C) or CosD (D) after treatment with PdI for
30 minutes. When Rt1 was treated with PdI, most of the ions observed in the mass
spectrum were from nucleotides arising from enzymatic digestion of the DNA ({), only
a little intact DNA (z) was left (Figure 4.8 (A)). Some of the major nucleotide products
observed after 30 min digestion with PdI were from the single strands of Rt1 and were
observed for example at m/z 1077.1, 1436.4 and 1823.1 and corresponded to Rt1B
[G1:G14]4-, Rt1B [G1:G14]3- and [dsRt1 - GA]5- (shown in the 3′→5′ direction),
respectively.

When the anthracycline-DNA complexes were treated with PdI for 30 min (Figure 4.8
(B)-(D)), there were more ions (and of greater intensity) from intact DNA (free or
bound ssDNA and free or bound dsDNA), than in the case where Rt1 alone was
digested (Figure 4.8 (A)), showing that anthracycline binding protected the DNA from
exonuclease cleavage. The amounts of intact DNA were similar for Dn (B) and Dx (C),
while the spectrum for the CosD-Rt1 mixture (D) showed a substantially greater number
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Figure 4.8. Analysis of nuclease digestion experiments using ESI-MS. (A)-(D). ESI
mass spectra of phosphodiesterase I digestions (30 min) after dilution into 5 mM
ammonium acetate, 50% in acetonitrile. (A) Rt1 alone; (B) Rt1 + Dn; (C) Rt1 + Dx;
(D) Rt1 + CosD. { Digested DNA fragments; z Intact free DNA (ss- or ds-);  Intact
ssDNA + anthracycline(s); S Intact dsDNA + anthracycline(s). Comparison of amount
of intact DNA remaining in nuclease digestion mixtures is shown in (E) for
phosphodiesterase I and (F) for Dnase. The bottom (hashed) section of the bars
represent intact free ss- or dsDNA, the middle pale grey section of the bars represents
the relative amount of intact ssDNA + anthracycline(s), and the small top section
(darker grey) represents intact dsDNA + anthracycline(s).
(and summed intensity) of ions. These data are represented graphically in Figure 4.8 (E)
where the intensities of ions from intact DNA were summed at each time point and
expressed as a percentage of the intensities of all ions in a spectrum of Rt1 DNA treated
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in the same way, but without enzymatic digestion by PdI. The results obtained for
doxorubicin are not shown in the graphs because they were very similar to those
observed for daunomycin. This similarity in the results of Dn and Dx is consistent with
the earlier ESI-MS data (Figure 4.2) that showed that the binding profiles of Dx and Dn
for Rt1 were similar, implying that the footprint on the DNA was similar. The combined
data for similar digestion experiments carried out with Dnase are shown in
Figure 4.8 (F).

Inspection of the graphs obtained in Figure 4.8 for PdI (E) and Dnase (F), show that
similar trends were observed for both enzymes. For the free DNA and all the
complexes, the longer the digestion time applied, the lower was the remaining amount
of intact DNA (ss- or dsDNA, free or bound). When the protection effects of the
different drugs were compared, the amount of intact DNA remaining was greater when
CosD was bound to Rt1 than when Dn or Dx were bound. Additionally, when the nature
of the intact DNA was identified, it was also observed that more CosD remained bound
to ss- or dsDNA than in the case of Dn and Dx. The greater amount of intact DNA
observed after digestion showed that CosD protected the DNA to a greater extent than
Dn or Dx.

The only deviation from this was observed when the mixtures had been treated with PdI
for 1 minute; the extent of digestion of Rt1-CosD was approximately the same as that
for free Rt1, and lower than for Rt1-Dn. Since PdI is a 3′ exonuclease, this may reflect
the location of binding of Dn and CosD on Rt1. That is, CosD molecules might not be
bound as close to the 3′ end of the DNA as Dn allowing PdI greater access to
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unprotected DNA. As digestion proceeded, however, the more extensive binding of
CosD compared to Dn (or Dx) impeded the phosphodiesterase. The results obtained
here were in agreement with results previously obtained for another trisaccharide
anthracycline. In this report,14 the plasmid DNA footprint study conducted by Sheldon
et al. using analysis by gel electrophoresis with ditrisarubicin, an anthracycline with two
trisaccharides chains in which the terminal sugars are fused, also showed that a greater
number of bases were protected from Dnase cleavage than with the less extensively
glycosylated Dn.

4.4.

Summary and Future Directions

In this chapter, the first extensive study of the DNA-binding properties of CosD an
anthracycline that has two trisaccharide chains linked to its ring system was reported.
Several methods involving ESI-MS were used to compare the binding of CosD and
other anthracyclines to dsDNA. Since CosD was a purified natural product available
only in milligram quantities, the sensitivity and the speed of analysis of the ESI-MS
technique enabled these comparisons to be carried out very efficiently, using less than a
milligram of CosD in all experiments once the methodology was developed.

Binding profiles obtained by ESI-MS were used to analyse the stoichiometries of the
anthracycline-Rt1 DNA complexes and showed that the DNA was saturated with CosD
at lower concentrations and that a smaller number of molecules were able to bind than
for Dn and Dx. These binding studies also revealed that CosD had a much greater
affinity for double-stranded DNA than for quadruplex DNA. Tandem mass
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spectrometry experiments showed that all CosD complexes were more stable to
dissociation than their Dn and Dx counterparts. Nuclease footprinting experiments
analysed by ESI-MS showed that CosD protected the DNA to a greater extent than Dn
and Dx. All these results support that CosD binds more tightly to DNA and exerts a
larger footprint than Dn or Dx.

Future work will include the titration of CosD with different DNA sequences and
structures. For example, titration results with the forked DNA showed increased binding
when one strand of dsDNA was extended with a single-stranded stretch of Ts. Different
secondary structures of DNA will also be tested. In the current work, only a tetrameric
G-quadruplex was tested for binding to CosD. Quadruplex DNA formed from the
folding of a single G-rich strand presents a very different topology for binding.

To confirm the observations made from the MS experiments reported here, additional
experiments carried out using techniques complementary to mass spectrometry are
detailed in the following chapter.
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CHAPTER 5
Characterisation of DNA-CosD Complexes
by Other Techniques

5.1.

Introduction

Mass spectrometry has developed as an excellent technique for screening non-covalent
binding interactions. Other techniques used for characterisation of non-covalent
complexes such as drug-DNA complexes include electrophoresis, thermal denaturation,
X-ray crystallography and circular dichroism. Although in some cases these techniques
require more substantial amounts of sample, they supply important information
complementary to that obtained by mass spectrometry. This includes information about
the impact of the drug binding on DNA lengthening and unwinding and the structure of
the complex including the location of hydrogen bonds. In order to obtain a more
complete understanding of the interaction of CosD with DNA, a complementary study
to that conducted by mass spectrometry (Chapter 4) was carried out using the following
techniques: gel electrophoresis, RNA transcription inhibition assays and circular
dichroism spectroscopy.

Gel electrophoresis is the most commonly used technique for the analysis and
identification of proteins, oligonucleotides, DNA and RNA143 and is also used in the
characterisation

of

many

DNA-drug

complexes. In particular, agarose gel
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electrophoresis has been used to investigate the topological changes occurring in
plasmid DNAs upon drug binding.230-232 The term “plasmid” was introduced in 1952 by
Lederberg. Plasmids are extra-chromosomal DNA molecules.233 They vary in size from
1 to 1000 kilobase pairs (kbp)234,235 and are usually found in bacteria (e.g. E. coli)236 but
can also be found in eukaryotic organisms (e.g. the 2-micrometre-ring in
Saccharomyces cerevisiae).237 pUC9 is a 1800 kDa double-stranded plasmid DNA of
2655 base pairs long. Plasmid DNAs of the same size migrate through agarose gels at
different speeds for a given set of conditions as a function of their topological forms.238
Open circular plasmids (relaxed, all supercoils have been removed) migrate more
slowly than linearised (the circular DNA has been opened by hydrolysis of
phosphodiester bonds) which migrates more slowly than supercoiled (the most compact
form).238

Figure 5.1. Schematic of the electrophoretic migration (left) for the different
topological forms of a same size plasmid DNA (right). The three migration bands
corresponding to the open circular (oc), linear (ln) and supercoiled (sc) forms are
identified on the gel by arrows. The migration direction, the electrode polarities and the
migration origin point are also specified. Schematic drawn from the descriptions made
in reference 238.
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The binding of small molecules to DNA has an effect on its overall conformation and
size and so influences its electrophoretic migration. This is illustrated in Figure 5.2.
Increasing the concentration of DNA-intercalating drugs in the presence of plasmid
DNA progressively unwinds the supercoiled DNA to accept the intercalating drug
resulting in a decrease in the rate of migration (Figure 5.2, lanes 1 to 4). At a specific
drug concentration, all supercoils are removed and the plasmid DNA reaches its open
circular (or relaxed) form (Figure 5.2, lane 4).

Figure 5.2. Effect of intercalating drug ethidium bromide on plasmid migration. The
drug concentration increases from lanes 1 to 10. From lanes 1 to 4, the increasing drug
concentration progressively uncoils the supercoiled plasmid DNA (sc) causing
retardation of the migration. At the concentration used in lane 4, the plasmid is in its
open circular form (oc). From lanes 5 to 10 additional amounts of drug cause the open
circular plasmid DNA to positively supercoil which is accompanied by an increase in
the band migration.
The concentration of drug at which the DNA is in its relaxed form allows the
calculation of the unwinding angle for the drug239 using the following equation:
Ø = 18 σ / rb(c)
Where Ø is the drug unwinding angle, σ the superhelical density and rb(c) is the drug to
nucleotide ratio for which all negative supercoils have been removed.240 Addition of the
drug to greater concentrations causes the DNA to progressively positively supercoil
(Figure 5.2, lanes 5 to 10). By comparing the effects of several drugs on the migration
of plasmid DNA, it is possible to compare their relative binding affinities. Several
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studies report the calculation of the unwinding angle for intercalating molecules
such as daunomycin, calichearubicin B and ethidium bromide. Their unwinding
angles were determined to be - 12.1º + 1.2º, - 5.3º + 0.5º and - 28.7º + 2.9º,
respectively.231,232,239,241,242

In the cell, the transfer of genetic information from DNA to proteins is carried out in
two stages: transcription and translation.243,244 In the transcription step, RNA
polymerase catalyses the synthesis of a specific mRNA molecule from a DNA template.
During the translation step, proteins are synthesised at the ribosomes where the genetic
information contained in the mRNA is used to code for the protein sequence.243,245
The overall transcription and translation processes are similar in prokaryotes and
eukaryotes systems; however, there are major differences as shown in Figure 5.3.

Figure 5.3. Schematic of the transcription and translation possesses in a prokaryotic (A)
and eukaryotic cell (B). Taken from reference 246.
In prokaryotes, there is only one type of RNA polymerase which specifically recognises
and binds to the promoter.247 In eukaryotes, three types of RNA polymerases participate
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in the transcription process.247 In both cases, additional agents called transcription
factors intervene in the binding of the RNA polymerase and also play a role in the
initiation of the transcription process.245,248 In prokaryotes transcription and translation
are coupled; the synthesised mRNA molecule can be immediately translated at the
ribosome because there is no nucleus to separate the two processes. In eukaryotes, in
contrast, owing to the presence of the nucleus, translation and transcription are
separated. The transcription step occurs in the nucleus while translation occurs in the
cytoplasm.

In prokaryotes, the production of RNA during transcription from a DNA template is
constituted of three major steps which are shown in a simplified schematic in
Figure 5.4. In a first step, the initiation step, the RNA polymerase, the enzyme
responsible for transcription, assisted by transcription factor(s) binds and initiates
transcription at a specific site on the DNA template called the promotor region. After
binding, the RNA polymerase locally unwinds the DNA and starts the synthesis of the
RNA strand. In a second step, the elongation step, the RNA polymerase increases the
length of the RNA chain by adding nucleotides to the 3′ end of the growing RNA
molecule matching the DNA template. As the enzyme progresses toward the terminator
region, the DNA double helix reforms. Transcription terminates shortly after the
polymerase reaches the terminator region, which contains a specific sequence in the
DNA template that signals the end of the transcription. The completed RNA strand
corresponding to the transcription unit is then released and the RNA polymerase
detaches itself from the DNA template unchanged and available to repeat the synthesis
process.245,249

170

Figure 5.4. Simplified schematic of the RNA production process in prokaryotic cells.
Figure inspired by the mechanistic description in reference 245.
Inhibition of the transcription process results in the incomplete synthesis of RNA and
proteins, and can ultimately cause cell death.250 As a result, inhibition of the
transcription step plays an important role as it may be exploited to target cancer cells
and viruses.250 Many anti-tumour drugs already exploit this mechanism by preventing
the synthesis of RNA. These drugs include anthracycline antibiotics such as
daunomycin251,252 and doxorubicin.251 Additional studies report the ability of several
other compounds such as marcellomycin,249 WP631 a bis-intercalating anthracycline
compound,252 metal complexes including cisplatin,253 ruthenium250 and dirhodium254
complexes and N-alkylated tetraazacyclododecane255 compounds to inhibit RNA
transcription.

Recognition of DNA by proteins and small molecules is an important element at the
centre of many biological processes such as DNA replication. Circular dichroism (CD)
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spectroscopy is a useful technique that allows a direct study of the conformational
changes occurring in solution as well as the interaction between molecules, and is
applicable to organic and biological molecules of all sizes. Some of the advantages of
CD are that it requires a low concentration of sample and a CD spectrum can be
obtained in only a few minutes.169,256

Double-stranded DNA molecules can adopt at least three different conformations
known as the A-, B- and Z-forms. Each of these forms possesses a different helicity
placing the DNA bases in a different orientation as shown of Figure 5.5.170 The CD
signals exhibited by DNA are due to the presence of numerous chiral carbon atoms on
its backbone. The base orientations in each DNA form are at the origin of the CD
signals recorded in the 200-300 nm region. The CD signals obtained in this region are
characteristic and sensitive to both the DNA sequence and conformation.170 Any
changes in the base orientation cause changes in the CD spectrum while differences in
the DNA sequence only influence the band intensity and wavelength of the maxima and
minima.257

Owing to the unique CD signature of each DNA conformation, CD has been used to
identify DNA secondary structures in solution; however, care should be taken when
interpreting CD spectra as in some cases the CD bands have not reflected the DNA
structure in solution.257-259 The three DNA conformations can be identified in most
cases by characteristic CD bands. B-DNA is a right-handed helical molecule that gives
the following characteristic CD bands: a positive band centred at 275 nm, a negative
band at 240 nm with a zero around 258 nm, a local maximum around 220 nm, and a
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Figure 5.5. Different possible conformations adopted by double-stranded DNA. B-form
(left), A-form (centre) and Z-form (right) DNA viewed perpendicular to the helix axis
(top) and down the helix axis (bottom). Figure taken from reference 171.

large positive band at 180-190 nm. The CD spectrum obtained for A-DNA possesses the
following bands: a positive band centred at 260 nm more intense than the B-DNA
equivalent, an intense negative band at 210 nm, a very intense positive band at 190 nm,
and a fairly flat region around 250-230 nm. In the case of Z-DNA, a left-handed helix
which only forms for certain sequences, the following CD bands are observed:
a negative band at 290 nm, a positive band at 260 nm, and a large negative signal at
180 - 185 nm.171
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Other than identifying the DNA structure present in solution, CD has also been
employed to determine the alpha helical content of a protein,260 DNA base composition
in terms of the guanine-cytosine content,261 the study of small chiral organic
molecules,256 changes in conformation upon binding of minor groove binding drugs and
determination of binding affinities.262 Further, the interactions of DNA, RNA or
proteins170,263 with small chiral molecules like anthracyclines169,264,265 have been
investigated by CD. The non-covalent binding of drugs to double-stranded B-DNA has
been well documented,169,264,266 and in each case the formation of such complexes
results in the perturbation of the DNA CD signals. Many of the DNA-binding molecules
that can bind to DNA do not possess any CD activity but they can produce a change in
the CD spectra upon binding to DNA. In this case these molecules acquire an induced
CD (ICD) that is characteristic of their interaction with the DNA and these changes are
a function of the geometry and the strength of the binding.171

5.2.

Scope of the Chapter

In this chapter, a detailed study of different DNA-drug complexes was carried out in
order to obtain a better understanding of the different effects of the drugs on the shape
and topological form of DNA. In a first set of experiments, DNA-drug complexes were
analysed by gel electrophoresis. The influence of the drugs (daunomycin, doxorubicin,
cosmomycin D and ethidium bromide) upon binding to plasmid DNA was determined
by the magnitude of the changes in DNA migration through agarose gels. Similar
experiments were also carried out using a much shorter linear DNA molecule (16 base
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pairs). A single earlier experiment was carried out in our laboratory on a similar short
DNA sequence; however, the experimental conditions used did not enable sufficient
resolution to distinguish between the migration of drug-free and drug-bound DNA. As a
result, a method was developed prior to carrying out the experiments to determine the
best running conditions for these types of DNA-drug complexes.

RNA transcription assays were conducted to evaluate the potential of each drug for
inhibition of the RNA transcription process. In vitro RNA production was carried out in
the presence of drugs at different concentrations and the RNA transcripts were analysed
by gel electrophoresis. The resulting band intensities were measured for each solution
and were plotted as a function of the drug concentration. From the graphs obtained, the
concentrations necessary to inhibit 50% of the RNA synthesis were estimated for each
drug. In the final series of experiments, DNA-drug complexes were analysed by circular
dichroism in order to establish the effects of the drug upon the DNA conformation.

5.3.

Results and Discussion

Three different techniques, agarose gel electrophoresis, RNA transcription assays and
circular dichroism spectroscopy were used in order to probe the changes caused to DNA
upon binding of three anthracycline compounds (daunomycin, doxorubicin and
cosmomycin D) and to compare these changes in some cases to that caused by ethidium
bromide under similar conditions.
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5.3.1. DNA Titration Experiments by Gel Electrophoresis
Previous work has shown that the migration of anthracycline-plasmid DNA complexes
through agarose gels was retarded compared to the migration of the plasmid DNA
alone.7,232,238 Preliminary experiments using one anthracycline concentration have been
carried out on CosD in our laboratory to assess the interaction of CosD with pUC18
plasmid DNA and to compare this with Dn and Dx using gel mobility shift assays.7 To
be able to compare the effects of Dn, Dx and CosD on the unwinding of the plasmid
DNA, a more detailed study was required using a range of drug concentrations. In this
chapter, experiments are described in which CosD was titrated with pUC9 plasmid
DNA to evaluate the effect of increasing concentrations of CosD on unwinding
supercoiled plasmid DNA. Separate preliminary work has also been carried out in our
laboratory on short DNA sequences (16 and 32 mer dsDNA)267 in order to investigate
the effect of Dn Dx and CosD on the mobility of these short DNA sequences. In these
experiments, the use of small pieces of linear DNA did not allow observation of the
effects of the drugs on the DNA migration through an agarose gel as the experimental
conditions used did not provide sufficient resolution to distinguish between the
migration of drug-free and drug-bound DNA.

Nevertheless, the preliminary results carried out in our laboratory (on plasmid and 16 bp
DNA sequences) have highlighted some interesting differences between CosD and other
anthracyclines which warrant further investigation, especially since they may lead to
beneficial effects on biological activity that might be exploited in the development of
new drugs.
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5.3.1.1.

Binding to Plasmid DNA

Intercalators stack between base pairs of dsDNA, causing it to lengthen, unwinding the
negative supercoil, and decreasing the mobility through agarose gels.241 The migration
of complexes of Dx, Dn and CosD with the plasmid pUC9 through agarose gels was
investigated to compare the degree of unwinding induced by intercalation. Plasmid
DNA was treated with a range of concentrations of the different anthracyclines and the
mixtures were electrophoresed on gels and stained using ethidium bromide. Figure 5.6
shows the gels for Dn (A), Dx (B), CosD (C) and EtBr (D). In each of the gels, lanes 1
and 15 contained only pUC9. The two major bands are from negatively supercoiled
closed circular DNA (sc) and open circles (oc). Lanes 2 and 16 contained pUC9
linearised by treatment with the restriction enzyme, HindIII. Lanes 4 to 13 contained
pUC9 with increasing anthracycline concentrations. The drug-to-nucleotide ratios, rb,
for Dn (Figure 5.6 (A)), CosD (Figure 5.6 (C)) and EtBr (Figure 5.6 (D)), were the same
in corresponding lanes. In the case of Dx, (Figure 5.6 (B)), a greater range of
concentrations was used since higher rb values were required to cause effects similar in
magnitude to those observed for Dn. With respect to the drug-to-nucleotide ratio, lane 4
for Dx (rb, 0.0130) is comparable with lanes 6 for Dn and CosD (rb, 0.0136) and lane 7
for Dx (rb, 0.0522) is comparable with lanes 13 for Dn and CosD (rb, 0.0515).

Comparison of the mobilities of plasmid DNA complexes with Dn (Figure 5.6 (A)), Dx
(Figure 5.6 (B)), CosD (Figure 5.6 (C)) or EtBr (Figure 5.6 (D)) reveals different
properties. As the concentration of Dn increased, the mobility of supercoiled (sc) DNA
decreased, consistent with results observed for other intercalators.268 When rb reached
0.0461 (lane 12), most of the DNA was in the relaxed form (oc). Some smearing was
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Figure 5.6. Agarose gel electrophoresis of drug-pUC9 complexes. (A) Dn-pUC9, (B)
Dx-pUC9, (C) CosD-pUC9, (D) EtBr-pUC9. In each gel, lanes 1 and 15 contain
plasmid only; lanes 2 and 16 contain pUC9 linearised by treatment with HindIII. No
samples were loaded in lanes 3 and 14. The drug-to nucleotide ratios, rb, for gels A, C
and D, lanes 4 to 13, were 0.0027, 0.0081, 0.0136, 0.0190, 0.0244, 0.0298, 0.0353,
0.0407, 0.0461 and 0.0515, respectively For gel B, the ratios for lanes 4 to 13 were
0.0130, 0.0261, 0.0391, 0.0522, 0.0652, 0.0782, 0.0913, 0.1043, 0.1173 and 0.1304,
respectively. The bands corresponding to supercoiled closed circular DNA (sc) and
open circles (oc) are marked by arrows and the difference in the migration maxima of
the drug-pUC9 complexes and pUC9 oc alone are indicated in yellow (in lane 14,
detailed later in this section).
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evident, particularly in lanes 12 and 13, suggesting that some of the Dn dissociated from
the DNA during electrophoresis. Similar behavior was observed for Dx, although higher
concentrations of the drug were required to observe a similar shift in mobility. The
greatest mobility shift was observed for CosD. Furthermore, the smearing that was
observed for Dn and Dx was not present. In contrast, resolvable bands were present,
representing stable CosD-plasmid complexes containing different numbers of bound
CosD and having different superhelical densities. These gel electrophoresis experiments
showed that CosD formed more stable complexes with plasmid DNA under these
conditions compared to Dn and Dx which dissociated to some extent during the
experiments. Under the experimental conditions, a saturation point was reached for Dn
and

CosD

where

no

further changes were discernible under the experimental

conditions as the anthracycline concentration was increased (lane 12, rb 0.0461 for Dn
and lane 10, rb 0.0353 for CosD). This corresponds to a molecule of Dn for every
~22 nucleotides and a molecule of CosD for every 28 nucleotides of pUC9 DNA.

At high concentrations of the anthracyclines, the overall intensity of the bands in a
given lane was diminished compared with the overall intensity at lower concentrations,
possibly because the binding of the anthracycline hindered binding of ethidium bromide
that was used for fluorescent detection of the DNA. This was supported by experiments
where complexes of Dn, Dx or CosD were prepared with 16 mer dsDNA (Rt1, see
section 5.3.2.2). Under some experimental conditions, as the concentration of an
intercalator is increased, closed circular DNA unwinds to the point that it comigrates
with open circular DNA. At higher concentrations again, the DNA becomes positively
supercoiled and the mobility increases.230 This behavior was observed for EtBr
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(Figure 5.6 (D)), which is a DNA intercalator (no groove binding interactions), but was
not observed under our experimental conditions for Dn, Dx and CosD. In this case the
plasmid DNA reached its open circular form for a concentration of drug-to-nucleotide
ratios rb = 0.0190 (lane 7), and when the drug concentration was increased further, the
plasmid DNA became positively supercoiled increasing its mobility through the gel (see
Figure 5.6 (D)).

A decreased in the mobility of the open circular DNA (oc) was also observed as the
concentration of anthracycline was increased. These differences in migration are
represented for each gel in lane 14 (Figure 5.6) by the yellow dotted lines and arrows. In
each case the lower dotted line represents the migration of the oc when no drug was
present in solution; the upper dotted line represents the reduced migration of the oc in
the presence of a high DNA:drug ratio. The arrows indicate the difference between the
two migrations. This difference in mobility of the open circular form at higher
anthracycline concentration was greatest for CosD. This is consistent with the positive
charges on CosD (two tertiary amines) neutralizing negative charges on DNA
decreasing the rate of migration through the gel as has been observed for other
positively charged DNA-binding compounds.268 The two effects, DNA-unwinding and
the effect of positive charge complicate calculation of an unwinding angle as a result of
intercalation of CosD or Dn.

5.3.1.2.

With Double-Stranded DNA Rt1

In this section, the change in the DNA conformation upon drug binding was
investigated. The drugs used were the same as for the plasmid DNA experiments (Dn,
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Dx, CosD and EtBr, see previous section), but the DNA used was a 16 mer doublestranded DNA, Rt1, identical to the sequence used in the mass spectrometry
experiments (see Chapter 4). Since early experiments in our laboratory using 16 and 32
mer dsDNA sequences in agarose gel mobility shift experiments were inconclusive, an
improved method was developed here.

Method Development
As a starting point, the conditions used above for the drug-plasmid DNA complexes
were used as a guide in the development of the new method. The plasmid DNA pUC9
(1800 kDa, 2655 base pairs, circular DNA) used for the previous experiments was much
larger than the Rt1 (10 kDa, 16 base pairs, linear DNA), consequently the agarose
concentration, the voltage and the buffer were some of parameters that had to be
adapted in order to analyse the Rt1-drug complexes by gel electrophoresis.

The new method was optimised stepwise from the initial parameters used for the
plasmid experiments. Firstly the gel concentration was increased. Using a much smaller
DNA sequence meant that the matrix had to be much more viscous in order to slow the
migration of the short Rt1 linear DNA that would otherwise migrate too fast through the
1% agarose gel used in the plasmid experiments. Owing to limitations such as the
solubility of the agarose in the buffer, obtaining a uniform gel consistency (avoiding air
bubbles that would affect the migration) and robustness of the gel once set (the gel
becomes brittle when the concentration of agarose is increased making it difficult to
manipulate) the maximum concentration that could be used was a 4% gel. In order to
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test the effect of voltage and the length of the experiments, EtBr-Rt1 mixtures were
loaded onto 4% gels.

Figure 5.7. Effect of time and voltage applied on the migration of Rt1:EtBr 1:6
complexes. (A) 30 V, (B) 50 V, (C) 70 V, (D) plot of the migration speed of Rt1:EtBr
1:6 complex under 30, 50 and 70 V. All gels were electrophoresed under the same
conditions (section 2.2.5.2) and each well contained the Rt1:EtBr 1:6 complex solution
where the DNA concentration was 10 µM (except on gel (C) where no solutions were
loaded in wells 13 to 16). In wells 1 to 12 the Rt1:EtBr mixtures were electrophoresed
for 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75 and 3 hours, respectively (A-C),
and in wells 13 to 16 the mixtures were run for 3.25, 3.5, 3.75 and 4 hours, respectively
((A) and (B)). The migration distances (Md) equations are shown in (D) and are
expressed in millimetres as a function of the running time (t).
The mixture chosen for the method development was the 1:6 Rt1-EtBr mixture for two
reasons: (i) EtBr already bound to DNA would allow a direct detection of the migration
band by UV fluorescence without any further treatment of the gel, and (ii) the ratio
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selected was shown by ESI-MS to saturate Rt1, thus maximizing the ability to detect the
DNA position in the gel. Figure 5.7 shows gels electrophoresed at 30 (A), 50 (B) and
70 V (C). Samples of EtBr-Rt1 were loaded at various times with the sample loaded in
lane 16 loaded first and the sample loaded in lane 1 loaded last. Figure 5.7 (D) shows
the migration distances at each voltage plotted as a function of running time.

The higher the voltage, the faster the DNA moves. The voltage applicable was limited
by overheating of the gel causing it to melt and decrease resolution. At 30 V
(Figure 5.7 (A)), the drug-DNA complexes migrated half way through the gel whereas
at 70 V (Figure 5.7 (C)), migration was fast but there was loss of resolution with the
band appearing more faint and more diffuse. From these results, it was determined that
the best conditions for analysis of complexes of drugs with the 16 mer dsDNA was
50 V for 3 hours, as this was a good compromise between migration distance and band
definition (Figure 5.7 (B), lane 12).

Rt1-Drug Titrations
In order to study the effect of each drug on the migration of Rt1 upon complexation,
several Rt1:drug ratios were studied and the resulting migration bands of the complexes
were analysed. For Dn, Dx and EtBr the DNA:drug ratios studied were 1:1 (rb 0.0313),
1:3 (rb 0.0938), 1:5 (rb 0.1563), 1:7 (rb 0.2188), 1:9 (rb 0.2813), 1:11 (rb 0.3438) and
1:13 (rb 0.4063) and were 1:1 (rb 0.0313), 1:2 (rb 0.0625), 1:3 (rb 0.0938), 1:4 (rb 0.1250),
1:5 (rb 0.1563) and 1:6 (rb 0.1875) for CosD. All solutions were electrophoresed under
the same conditions (gels not shown).
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In each case, the effects of each drug on the DNA migration were quite similar. As the
amount of each of these drugs was increased relative to the DNA, the migration of Rt1
through the gel decreased until a maximum was reached. The difference in the band
migration for this length of DNA (Rt1, 16 mer) was negligible for Dn, Dx and EtBr;
however, the migration of Rt1 was clearly affected by CosD. The Rt1-drug mixture in
which the DNA was saturated was determined from the gels and was 1:5 (rb 0.2188),
1:7 (rb 0.2188), 1:7 (rb 0.2188) and 1:4 (rb 0.2188) for Dn, Dx, EtBr and CosD,
respectively.

As observed previously for the drug-plasmid complexes, at higher concentrations of the
anthracyclines, the intensity of the bands was diminished compared with the intensity at
lower concentrations. This is most likely because the binding of the anthracycline
hindered binding of ethidium bromide which was used for fluorescent detection of the
DNA. Furthermore, bands were clearly evident in lanes containing Dn-, Dx- or
EtBr-DNA mixtures in contrast to bands in lanes containing CosD-DNA mixtures that
were only weakly stained. The inability to strongly stain the 16 mer dsDNA complexed
with CosD suggests that the ethidium bromide could not displace the CosD from the
DNA, which is consistent with the proposal that CosD binds more tightly to DNA than
Dn or Dx and is in agreement with the results from mass spectrometry (section 4.3.2).

In order to compare the impact of the migration changes caused by each drug upon
binding, the Rt1-drug mixtures in which the DNA was saturated with each drug were
electrophoresed on the same gel and the results are shown in Figure 5.8.
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Figure 5.8. Electrophoresis of the Rt1 DNA saturated with different intercalators, Dn,
Dx, EtBr and CosD. Lanes 1 and 14 contained Rt1A (single strand A of Rt1), lanes 2
and 15 contained Rt1B (single strand B of Rt1), lanes 3 and 16 contained Rt1 only and
no sample was loaded in lanes 4 and 13. The DNA-drug ratios were 1:5 (lanes 5 and 6,
rb 0.2188), 1:7 (lanes 7 and 8, rb 0.2188), 1:7 (lanes 9 and 10, rb 0.2188) and 1:4 (lanes
11 and 12, rb 0.2188), for Dn, Dx, EtBr and CosD, respectively.
For each of the drugs, two solutions containing the same Rt1-drug ratios were prepared
and run in two consecutive lanes in order to confirm the migration observed. The
different lanes contained single-stranded DNA (Rt1A (lanes 1 and 14), Rt1B (lanes 2
and 15)), Rt1 (lanes 3 and 16), Rt1-drug complexes (lanes 5 to 12) and no sample was
loaded in lanes 4 and 13. This gel summarises the effects of the intercalators showing
that under these conditions the change in the migration of 16 mer Rt1 DNA upon
binding by Dn, Dx, and EtBr was difficult to discern (compare lanes 3, 5-10 and 16). In
contrast, the binding of CosD caused a substantial change (compare lanes 11, 12 with
5-10). This suggests a substantial effect of the two trisaccharide chains on the
interaction of this likely intercalator with DNA.
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5.3.2. RNA Transcription Assays
These experiments were carried out to determine whether Dn, Dx, CosD and EtBr could
inhibit mRNA production in a commercial in vitro transcription assay. The
RiboMAXTM Large scale kit used contains the RNA polymerase necessary to produce
RNA from a DNA template. Transcription of the DNA template by the T7 RNA
polymerase results in the in vitro synthesis of two transcripts of different length. The
first transcript (RNA) is 1065 bases long while the second transcript is 2346 bases long.
The production of two transcripts of different length is due to the presence of a T7
transcription terminator sequence in the DNA template through which transcription is
only 70 to 80% efficient.

Figure 5.9. Gel electrophoresis separation of the RNA transcripts produced using the
RiboMax™ transcription assay kit. Lane 1 contains a sample in which the DNA
template was treated with the RNA polymerase and lane 2 contains DNA template that
had not been exposed to the RNA polymerase. The migration of the 1065 and the 2346
base long transcript as well as the migration of the DNA template are indicated on the
figure by arrows.
Figure 5.9 shows a control experiment in which no drugs were added to the
transcription assay mixtures. The two intense bands in lane 1 correspond to the two
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transcripts of different length showing that the RNA polymerase was able to bind the
DNA template and synthesise RNA. A third band of much lower mobility and intensity
was also observed, and corresponds to the DNA template. After verification of the
efficiency of the production of RNA, Dn, Dx and CosD at different concentrations were
added separately to solution mixtures to determine their potential in inhibiting the
production of RNA in the transcription assay. The gels obtained are shown in Figure
5.10 with Table 5.1 showing the respective drug concentrations used.

Table 5.1. Drug concentrations used during the RNA transcription inhibition assays
shown in Figure 5.10.
Well
number
4
5
6
7
8
9
10
11
12
13

Drug concentration (µM)
Dn
Dx
CosD
2.5
20
5
40
2
7.5
60
3
10
80
4
12.5
100
5
15
120
6
17.5
140
7
20
160
8
22.5
180
9
25
200
10

In these series of experiments (Figure 5.10, gels (A) to (D)) no RNA polymerase was
added in the samples loaded in lane 3 which lead to no production of RNA transcripts as
observed in Figure 5.9. Only the DNA template was present. In the case of C3, lane 16
for each gel, the solution composition was similar to the one of the control C2 (lane 3)
but where 1 µL of DNA-free water was replaced by the buffer used to make up the drug
solution. No drugs were present. From the band intensities observed on each of the gels,
the drug solution buffer had no inhibition effect on the production of RNA. Therefore,
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any decrease in band density observed in the experiments is the result of an effect of the
drug on RNA polymerisation.

Figure 5.10. RNA transcription assay gels. (A) Dn, (B) Dx and CosD (C). In each gel
lane 2 contains control C1; lane 3 contains control C2; lane 16 contains control C3 (see
Table 2.5, section 2.2.5.3). No sample was loaded in lanes 1, 4 and 15. The drug
concentrations for each gel, lanes 5 to 14 are shown in Table 5.1. The bands
corresponding to the 1065 bases long transcript (1), to the 2346 bases long transcript (2)
and the pGEM® DNA template (3), are marked by arrows.
Addition of increasing amounts of anthracyclines across lanes 5-14 had the same effect
for each of the anthracyclines tested (Figure 5.10). In each case, the progressive increase
of the drug concentration decreased the intensity of the band corresponding to the two
RNA transcripts on the gels, until no bands were observed. Using the Quantity One
software, it was possible to measure the band densities in each lane for each of the RNA
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transcripts. The concentrations and band density values are reported in Appendix 5. The
densities of the bands from the 1065 bases long transcript (indicated on the gels by (1))
for each solution were plotted against the concentration of drug used in each lane. In
each case a linear relationship was observed between the concentration of drug used and
the intensity of the band. As the intensity results for the two bands corresponding to the
two different transcripts were similar (results not shown) only the values for the 1065
bases long transcript were used to determine the drug concentration inhibiting RNA
synthesis in vitro to 50% of the control value (IC50, µM). The calculated IC50 values
were 9.3 + 0.6 µM for Dn, 37 + 6 µM for Dx and 3.1 + 0.3 µM for CosD. These values
represent the average of 3 experiments reported ± 1 standard deviation. From the results
obtained here the relative inhibition potential of each drug was established and ranked
from the most to the least potent compound in inhibiting RNA synthesis, giving:
CosD > Dn > Dx.

All the drugs tested here were DNA-binding drugs which intercalate (proposed for
CosD) in between DNA base pairs and modify the DNA conformation by causing
progressive partial unwinding of the double helix as shown in the previous experiments
(sections 5.3.1.1 and 5.3.1.2). Such unwinding was observed for CosD as migration of
the DNA template (Figure 5.10 (3)) was retarded when the drug concentration was
increased. No such change in mobility was observed for Dx and a minimal change was
observed for Dn. The results observed here were identical to the experiments previously
carried out on the shorter double-stranded DNA molecule RT1 (section 5.3.1.2.b)
confirming the greater effect of CosD in elongating the DNA compared to Dn and Dx.
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Previous studies on anthracyclines showed their presence in the cell nucleus which is
consistent with the site of the RNA production.249 It also has been suggested that
anthracyclines intervene in RNA synthesis by interfering in the separation of the DNA
template strand or the attachment of the polymerase to the DNA template.249 The results
observed here confirm previous observations. Anthracyclines at a concentration high
enough to saturate the DNA template interfere with the production of RNA by
preventing the initiation step249 and so in the production of RNA. Similar effects to the
one observed here for Dn, Dx and CosD were previously observed for several other
anthracyclines such as marcellomycin, daunomycin and the bis-intercalating molecule
WP631, where an increase in the concentration of the drug resulted in a smaller amount
of RNA being produced.249,251,252

It was previously observed by Fu et al. that complexes that bind more strongly to
double-stranded DNA might play a greater role in RNA transcription inhibition.250 The
RNA inhibition results obtained here were consistent with the gels (section 5.3.1) and
mass spectrometry (Chapter 4) experiments obtained previously showing that CosD
possessed the highest affinity for DNA compared to Dn and Dx and exerted a larger
footprint on DNA.

5.3.3. Circular Dichroism
The non-covalent binding of anthracyclines to DNA is well documented. Owing to the
flexible nature of DNA in solution, changes in the DNA secondary structure or
unwinding of the helical structure are often the result of DNA-drug complex formation
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which creates perturbations of the CD signals in the DNA spectrum.169,264,266,269,270
These changes in the CD spectrum of the DNA can be used to evaluate the relative
DNA-drug binding affinities as well as the mode of binding of the drug. In this section,
CD titration experiments were carried out to determine the effect of the three drugs Dn,
Dx and CosD, on the DNA conformation upon binding.

Before proceeding to the CD titration experiments, the optical activity of the individual
drugs, the buffer and the DNA alone were measured using identical conditions and
concentrations to that of the titration experiments to be detailed later in this section. For
Dn and Dx the drug concentrations tested were 20, 60, 100, 140, 180, 220 and 260 µM
and were 20, 40, 60, 80, 100 and 120 µM for CosD. All CD spectra were recorded
under the same conditions (see section 2.2.5.4) over the wavelength range 200 - 600 nm
and Figure 5.11 shows the results obtained.

Figure 5.11 (A) shows the CD spectra of Rt1 (black) and the buffer (blue). The DNA
possesses some CD activity in the 200 - 300 nm region and the following bands were
observed: a positive band centred at 277.6 nm, a negative band at 247.8 nm passing
through a zero at 263.2 nm, a local maximum at 220.4 nm and a large positive band at
200 nm. The CD bands observed for Rt1 were characteristic of B-form DNA.170
The buffer possesses almost no CD activity with only a small negative band observed
around 220 nm.

The CD spectra obtained for the anthracyclines (Figures 5.11 (B), (C) and (D)) showed
some CD activity over the 200 - 600 nm range as previously observed for several other
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anthracyclines.269,270 CD signals of anthracyclines have several origins: the presence of
chiral carbons on the aglycone (e.g. carbon C7 and C9), chiral carbons on the sugar
moiety, the functional groups present on the molecule, the conformation adopted by ring
A (the unsaturated ring on the chromophore), and the nature and orientation of the
glycosidic bonds.170,256 As a result of these variables, the CD spectra of anthracyclines
can vary greatly from one compound to the other;256 however, when the results obtained
for Dn, Dx and CosD were compared, the CD spectra were similar. Each anthracycline
possessed negative bands centred around 202.2 and 293.6 nm, a zero around 216.8 nm
and a positive band centred around 232.6 nm.

Figure 5.11. CD spectra of Rt1 (A), Dn (B), Dx (C) and CosD (D). The spectra in (B),
(C) and (D) have been acquired for several concentrations of drugs (see coloured legend
below figure). For the spectra shown in (A), the DNA concentration was 20 µM and the
buffer was an aqueous solution of 100 mM ammonium acetate at pH 7.5.
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The main differences in the respective spectra arose from the relative intensities of these
bands and the position of additional positive bands above 300 nm. At similar
concentrations, the bands observed for CosD had ellipticities that were nearly double
those observed for Dn and Dx. These increases were most likely due to the increased
number of chiral carbons present on CosD compared to Dn and Dx as CosD possesses
more sugars, as well as differences in the aglycone functional groups. Several articles
report CD studies of anthracyclines in the 280-700 nm region.169,256,264 The bands
present in this region were identified and correspond to different electronic222
transitions.256 The negative bands centred around 290 - 300 nm and the positive bands at
480 - 500 nm are associated with the π-π* transitions polarized along the short and long
axes of the molecule, respectively,256,264 while the positive bands around 320 and 350
nm were associated with the n-π* electronic transition corresponding to the C=O
functional groups at C12 and C5, respectively (see Figure 1.1).256 The differences in the
bands above 300 nm are a reflection of the difference in substitution of each of the
respective aglycones. The CD spectra obtained for Dn and Dx were identical to those
reported previously.169,256 An additional observation can be made from these results.
The anthracyclines showed CD signals in the same region as the DNA, and at higher
concentrations, the CD spectra obtained for the drug (e.g. 120 µM for CosD) showed
CD bands as intense as those observed for the DNA. As a result, the CD spectra
recorded for each of the drugs were used to calculate difference spectra (details to
follow) to evaluate the changes induced on the DNA CD spectrum solely due to the
drug binding.
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DNA-drug stock solutions were progressively added to obtain several Rt1:drug
mixtures. For Dn and Dx, the Rt1:drug mixtures were 1:1, 1:3, 1:5, 1:7, 1:9, 1:11 and
1:13 and were 1:1, 1:2, 1:3, 1:4, 1:5 and 1:6 for CosD with a DNA concentration of
20 μM for all solutions. These specific ratios were selected for the CD titration
experiments as they were used for the ESI-MS DNA titration experiments and showed
saturation of the Rt1 DNA for the high drug ratios (section 4.3.1.1). The CD spectrum
for each solution was recorded over the 200 - 600 nm range (Figure 5.12 (A), (B) and
(C)) and the difference CD spectra (Figure 5.12 (D), (E) and (F)) were obtained by
subtracting the corresponding CD spectra of the drug alone (recorded earlier) from the
CD spectra of the DNA-drug mixtures (e.g. 120 μM CosD was subtracted from the
spectrum for the DNA:CosD 1:6 mixture). As there was no evidence of new major CD
bands at wavelengths over 400 nm in the subtracted CD spectra, the CD spectra shown
in Figure 5.12 only display the results obtained over the 200 - 400 nm range which
corresponds to the region where changes in the CD spectra of DNA were observed.

Changes in the DNA spectra were observed with increasing anthracycline concentration
(Figure 5.12 (A)-(C)). As each drug exhibited CD activity in the DNA region
(Figure 5.11), analysis of the effect of the drug binding to DNA was rendered more
difficult. The subtracted spectra shown in Figure 5.12 for Dn (D), Dx (E) and CosD (F),
allow a direct observation of the CD induced in the DNA solely due to the binding.
Similar data manipulation has been previously conducted for nogalamycin and
analogs.265 Using the same principle, the differences in ellipticity observed in
Figure 5.12 for Dn (D), Dx (E), and CosD (F) were used to provide a relative order of
the DNA-binding affinities of the compounds to Rt1.
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Figure 5.12. Circular dichroism spectra of the double-stranded DNA Rt1 titrated with
Dn (A), Dx (B), and CosD (C). Difference CD spectra obtained for Dn (D), Dx (E) and
CosD (F). The difference spectra were obtained by subtracting the drug contribution
from the CD spectra recorded for the titration mixtures. The coloured legend at the
bottom of the figure indicates the DNA:drug mixture ratios.

Figures 5.12 (D)-(F) show the effect of increasing the amount of drug in solution on the
ellipticity of the DNA CD bands. Similarities and differences were observed in these
spectra. For all compounds, an increase of the amount of anthracyclines was
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accompanied by an increase in the ellipticity of the positive band at 277.6 nm. The
increase in the ellipticity, given the same concentration of anthracyclines was the
greatest for Dn, followed by for CosD and Dx. However, for Dn, saturation of the
change in ellipticity was observed in Rt1:drug mixtures of 1:5 and over. For Dx, the
ellipticity was firstly decreased for low ratios, then increased as increasing amounts of
Dx was present. For CosD, the ellipticity increase was not as strong as that observed for
Dn but did not saturate at higher ratios. Unlike the other two compounds, a shift of the
band maximum to longer wavelength was observed for CosD, from 277.6 nm for the
DNA alone to 281.8 nm for the 1:6 ratio. These observations are in agreement with
previous experiments which reported an increase in the intensity of the positive CD
band of double-stranded DNA upon drug binding. Whatever the anthracycline bound to
the DNA, progressive addition of drug caused an increase in the intensity of the positive
band around 277.2 nm which has previously been attributed to the unwinding of the
double-stranded DNA.269 As observed before in the gel electrophoresis experiments
(section 5.3.1), the binding of each of the drugs causes progressive unwinding of the
double helix.

Additional changes were observed around 238.2 and 247.8 nm. For all drugs, an
increase in the anthracycline concentration led to a decrease in ellipticity of the band at
247.8 nm and appearance of a new band at 238.2 nm. For Dn, saturation of each band
was also observed as anthracycline concentrations were increased above 1:9
accompanied by a shift of the band at 247.8 to 245.2 nm. For CosD, no saturation was
observed for either of the two bands, but the band at 247.8 nm was shifted to 249.4 nm
and the intensity of the band at 238.2 nm was much more pronounced than for Dn.

196

For Dx, the band at 247.8 nm did not have any apparent shift and the band at 238.2 nm
was only observed in low intensity for the highest concentration of Dx. In the same
region, a shoulder was observed around 259.8 nm for Dn and CosD but not observed for
Dx. An inflection point, called an isoelliptic point, was also observed in the CD spectra
for Dn and CosD at 293.6 and 300.8 nm, respectively, but not for Dx. The appearance
of isoelliptic points has been reported previously and reflects an equilibrium between
free DNA and a single type of drug-DNA complex.262,271 Absorbance measurements for
each sample were recorded during the CD analysis. As optimal CD measurements
require a sample absorbance of 0.2 to 1.5, all solutions exhibiting absorbances over 1.5
in the region below 220 nm, will not be commented upon here.

The last significant change observed in these CD spectra was the appearance in all
cases, of a new negative band around 300 - 315 nm for which the ellipticity increased
upon increasing the anthracycline concentration. The band was centred around
302.4 nm for Dn and Dx and around 311.4 nm for CosD. Saturation was observed for
Dn and CosD in the 1:11 and 1:5 mixtures, respectively, and no distinct trend was
observed for Dx. This band in the 300 - 320 nm region which is accounted for by
the π-π* and n-π* transitions is the most sensitive band indicating DNA-drug
intercalation, and the increased ellipticity in this region accounts for an increase in the
amount of drug intercalating into the DNA.264,270

The overall changes occurring upon the binding of the anthracyclines are consistent
with formation of DNA-drug complexes via intercalation as has been established in
other studies.16,49 The similarities and differences observed for the CD spectra originate
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from the similarities and differences in the compound structures. They possess related
aglycones but with different substituents and with different numbers and types of sugars
that are able to interact differently with the DNA minor groove. CosD caused a bigger
distortion of the CD spectrum of the DNA than Dn and Dx. The greater the influence of
the drug on the band ellipticity, the stronger the effect of the drug on the DNA
conformation and the more tightly the compound binds to the drug.265 From the results
obtained in these experiments, it was confirmed that CosD showed stronger binding to
DNA compared to Dn and Dx, the two currently used clinical drugs.

5.4.

Summary and Future Directions

Agarose gel titration experiments conducted on plasmid and short linear DNA (Rt1)
showed that each of the anthracyclines studied here uncoiled plasmid DNA by
unwinding of the DNA double helix upon intercalative binding. It was shown that CosD
had a greater effect than Dn and Dx on DNA elongation and unwinding of the double
helix, and that the DNA complexes formed with CosD were more stable than those of
Dn and Dx. The inhibition by the three anthracyclines of RNA transcription was also
investigated. For each drug, increased concentrations resulted in greater inhibition of
RNA production. The concentration needed to cause similar inhibition of the process
was much lower for CosD than for the two drugs Dn and Dx, in agreement with the
observation that CosD exerts a larger footprint on DNA than Dn and Dx. This larger
coverage of the DNA prevents recognition of the DNA template by the RNA
polymerase. The CD studies carried out showed that the changes induced on the DNA

198

conformation upon binding of the three anthracyclines were similar, with CosD showing
once more a greater ability to perturb the DNA conformation than Dn and Dx.

This is the first extensive study of the DNA-binding properties of CosD, an unusual
anthracycline with two trisaccharide chains. CosD caused greater modification of DNA
conformation upon binding. Inducing changes in the shape of DNA is thought to be the
origin of the mode of action of anthracyclines as it prevents the recognition of the DNA
by TPII, and interferes with RNA synthesis. All the different techniques used during
this study led to the same conclusion: CosD had a greater DNA-binding affinity for Rt1
than Dn and Dx making it an interesting compound with potential clinical application.

The journey between confirming significant and extensive binding of CosD to dsDNA
and its possible clinical use will be long. Furthermore, since Dn and Dx gained use in
the clinic, few of the many natural anthracyclines have been developed as drugs. It will
be important to investigate the extent to which CosD is able to enter cells. Early work
which showed it was able to induce differentiation in leukemia cells suggest this is the
case.38 Another possible application of CosD is suggested by this observation. CosD
might prove to be a useful reagent for investigating the differentiation process itself.
This observation should be followed up to determine whether it is reproducible. More
detailed studies will also involve determination of other effects on cellular activities (in
cell culture) such as replication, transcription and induction of apoptosis.
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CHAPTER 6
Attempted Synthesis of β-Rhodomycinone, the
Aglycone of Cosmomycin D

6.1.

Introduction

Aglycones of anthracyclines are composed of tetracyclic ring systems (see section
1.1.1). The presence of different substituents on the aglycones creates compounds with
different biological activities.8,18,62,63 For example, daunomycin, which differs from
doxorubicin by just one hydroxyl group on the side chain attached at position C9 (see
Figure 3.1), is used to treat acute lymphoblastic or myeloblastic leukemia while
doxorubicin is used to treat solid tumours, sarcomas and carcinomas.19,22 CosD, which
possesses a different aglycone to daunomycin and doxorubicin as well as additional
sugars,10-12 has been shown to have anti-leukemia activity and is able to induce Friend
leukemia cell differentiation. This activity is not observed for daunomycin or
doxorubicin.38 In contrast to daunomycin and doxorubicin, CosD does not possess a
ketone group at the C13 position (see Figure 3.1). This ketone is thought to be
responsible, at least in part, for the dose-limiting cardiotoxicity of daunomycin and
doxorubicin when they are used clinically as anti-tumour agents.272
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Owing to these structural and bioactivity differences, it is of interest to evaluate the
influence of the sugars (length, number and composition of saccharide chains) on the
binding affinity of anthracyclines to DNA. We are particularly interested in
investigating the different glycosylated forms of CosD. Originally it was intended that
these CosD analogues could be accessed through partial hydrolysis10 of the sugar
chains; however, after purification of CosD from Streptomyces olindensis ICBC20
cultures, the isolated quantity was too low (less than 1 mg) to make this strategy viable.
An alternative approach toward accessing larger quantities of either CosD or a synthetic
precursor was therefore required. One possible strategy is to synthesise the CosD
aglycone (β-rhodomycinone) and subsequently attach the desired saccharide chains. The
resulting compounds bearing the CosD aglycone but possessing different saccharide
chains could then be used in a comparison study evaluating the importance of the sugars
for DNA binding. These studies could potentially lead to the identification of new
anthracyclines with commercial and/or clinical applications.

Two alternative strategies towards synthesising β-rhodomycinone from simple
precursors are: (i) total synthesis from simple precursors using the routes described in
the literature,273-277 or (ii) semi-synthesis from an inexpensive precursor that is available
in large quantities. Total synthesis was deemed impractical due to the large number of
steps involved so it was decided to proceed with a semi-synthesis.

The ideal starting material for a semi-synthesis would be a compound that already
possesses a closely related aglycone, is available commercially in large quantities and is
relatively cheap. Daunomycin appeared as an ideal candidate since it bears an aglycone
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that is very similar to β-rhodomycinone and is commercially available in large
quantities at relatively low cost owing to its widespread use as an anti-tumour agent.19,21

Several studies in the literature report reactions that modify functional groups in the
daunomycinone and similar aglycones. These functional group modifications include
deoxygenation of the carbonyl function at C14278 and demethylation of the 4-methoxyl
group279 amongst others (see Figure 3.1). There are no studies that have reported the
complete semi-synthesis of β-rhodomycinone from daunomycin. Based on the literature
precedents, a semi-synthesis of β-rhodomycinone was devised.

6.2.

Scope of the Chapter

In this chapter, the semi-synthesis of the CosD aglycone, β-rhodomycinone, was
attempted from the readily available precursor daunomycin. In the attempted synthetic
route, the functional groups present in daunomycin were to be modified to afford the
desired β-rhodomycinone. Functional group conversions previously reported in the
literature for similar systems were to be adapted to the daunomycin system. The
unexpected discovery of a novel reaction through the course of these studies indicated
that our original route was not viable. In a revised synthetic route, the order of reactions
was changed and one protection step was added. The chemistry behind the functional
group modifications remained the same. A rapid DNA-binding study was conducted
with each of the compounds synthesised and the relative binding affinities for Rt1
dsDNA was evaluated and compared to that of Dn, Dx, CosD and EtBr.

202

6.3.

Results and Discussion

This section describes strategies towards the synthesis of the CosD aglycone, the
β-rhodomycinone. The detailed synthetic methods and details of the characterisation of
the compounds prepared on this synthetic path and their structures are described in
section 6.6.

6.3.1. Initial Synthetic Route Towards β-Rhodomycinone
Our initial route towards β-rhodomycinone 6 sought to make use of: (i) acid-catalyzed
hydrolysis of the daunosamine sugar from daunomycin.HCl 1;280 (ii) conversion of the
daunomycinone aglycone 2 to its 13-benzenesulfonylhydrazone 3 followed by reduction
to give the 13-deoxyanthracyclinone 4;278 (iii) demethylation of the 4-methoxyl group
of 4,279 and finally (iv) regio- and stereoselective benzylic hydroxylation at C10 with
trimethylamine-N-oxide281 to afford 6. This route is outlined in Scheme 6.1.

Deglycosylation of daunomycin 1 proceeded smoothly under the conditions reported by
Yoo et al.280 to afford 2 in 89% yield (lit. 98%). Walsh and Olson278 recently disclosed a
method for preparing 13-deoxyanthracyclines wherein anthracycline 13-keto groups
were converted to 13-arylsulfonylhydrazones, which were subsequently reduced under
acidic conditions with NaCNBH3 to the deoxygenated methylene compounds. The
13-arylsulfonylhydrazones of doxorubicin were obtained in good yields by reaction with
various p-substituted (i.e. p-CH3, p-Cl, p-F, p-NO2) benzenesulfonylhydrazines in
anhydrous methanol. When these reactions were adapted to daunomycinone 2, it was
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Scheme 6.1. Reagents: (a) 0.2 N HCl, 90-95 oC, 89%;280 (b) NH2NHSO2Ph, THF, 18 h,
25 oC, quant.; (c) NaCNBH3, PTSA, DMF, 15 min, 110 oC; (d) AlCl3, CH2Cl2, under
N2, 24 h, 25 oC;279 (e) trimethylamine-N-oxide, DMF, 40 h, 25 oC.281
found that conversion to the 13-benzenesulfonylhydrazone 3 was, for solubility reasons,
best carried out in anhydrous THF. Under these conditions, reaction of 2 with
benzenesulfonylhydrazine was quantitative (single spot by TLC; THF:petroleum spirit
1:1) after overnight stirring at rt (Scheme 6.1). 1H and 13C NMR spectra for 3 (CDCl3)
were complex and difficult to interpret. This was attributed to the compound being a
mixture of cis- and trans-benzenesulfonylhydrazones and perhaps different H-bonded
conformational isomers (see later explanation, Scheme 6.4).

The crude benzenesulfonylhydrazone 3 was initially subjected to the reductive
conditions reported by Walsh and Olsen278 (p-toluenesulfonic acid (PTSA) or
pyridinium p-toluenesulfonate (PPTS) with NaCNBH3 in methanol at 60 oC). It was
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found that these reactions consistently provided multiple products by TLC analysis as
well as unchanged 3, and showed no evidence by mass spectrometry (ESI-MS in +ve
and -ve ion modes) for the formation of the desired product 4 (expected MWt of 384.1).
ESI-MS (-ve ion) analysis of the crude reaction mixtures also displayed a prominent
peak at m/z 365.2, corresponding to an [M-H]- species 18 mass units lower than for 4.
Lack of success with the conditions of Walsh and Olsen led us to explore the reduction
using other combinations of hydride reagents (NaCNBH3, NaBH4, NaBH(OAc)3), acids
(CH3CO2H, PTSA, PPTS) and solvents (MeOH, CH3CO2H, THF) at various
temperatures. None of these reactions provided any trace of 4 and similarly showed
multiple products and unreacted 3 by TLC analysis as well as negative ion ESI-MS
spectra in which a peak at m/z 365.2 was apparent (as before).

Using Maryanoff’s conditions for the reduction of tosylhydrazones to methylenes (i.e.
NaCNBH3, PTSA, 1:1 DMF:sulfolane, 110 oC),282 it was noted that: (i) 3 was
completely consumed within 15 min and a single new spot of higher Rf than 3 was
visible by TLC; (ii) the reaction mixtures prominently displayed the previously
observed peak at m/z 365.2 in their negative ion ESI mass spectra. After purification by
silica gel chromatography and comprehensive 2D-NMR characterization (DQF-COSY,
HMQC, HMBC, and NOESY), it was clear that the product was not 4 but a novel
anthracyclinone 5. The absolute stereochemistry (7S,9R,13S) of the new compound was
unambiguously assigned based on the 7S,9S stereochemistry of the daunomycin
precursor and from NOEs present in the NOESY spectrum (Figure 6.1).
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Figure 6.1. NOEs observed in the NOESY spectrum of 5 (500 MHz, 600 ms mixing
time) confirming its absolute stereochemistry.
It was noted that the yields of 5 were consistently around 30%, which seemed low
considering the clean conversions that were observed by TLC. Further investigation
showed that the remaining mass corresponded to highly polar (presumably polymerized)
material that could only be eluted from a silica gel column using MeOH. Attempts to
optimize the yield of 5 by varying the reaction conditions met with limited success,
although it was determined that sulfolane could be omitted from the reaction without
affecting the yield.

The generally accepted mechanism, shown in Scheme 6.2, for the reduction of
tosylhydrazones to methylenes under acidic conditions invokes an initial hydride attack
on the sp2 carbon of a protonated tosylhydrazonium ion to generate the reduced
tosylhydrazine derivative. Elimination of p-toluenesulfinic acid from the tosylhydrazine
subsequently gives rise to a diazene intermediate which decomposes by losing N2 to
afford the corresponding methylene compound.283

206

Scheme 6.2. Generally accepted mechanism for the reduction of tosylhydrazones to
methylenes with NaCNBH3 under acidic conditions. Adapted from reference 283.
An analogous mechanism for the formation of 5 from 3 (see Scheme 6.3) can be
postulated wherein the developing negative charge at C13 resulting from loss of N2 in
the final step does not protonate to yield 4 but instead attacks C7. Under the acidic
reaction conditions, the C7-OH could protonate to create a good benzylic leaving group
which loses H2O following attack by C13 to yield 5.

Scheme 6.3. Proposed mechanism for the reduction of 3 with NaCNBH3 under acidic
conditions to obtain 5 (7S,9R,13S-5a and 7S,9R,13R-5b).
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This mechanism would explain the formation of two epimeric compounds 5a and 5b
which differ in stereochemistry at position 13. It does not, however, account for the fact
that only the 7S,9R,13S stereoisomer of 5 (ie 5a) was isolated from the reaction. The
7S,9R stereochemistry is predicted in 5 from the above mechanism based on the 7S,9S
stereochemistry of the daunomycin.HCl 1 precursor. However, unless hydride reduction
of the benzenesulfonylhydrazone 3 is stereospecific, with the hydride ion attacking the
protonated benzenesulfonylhydrazonium ion from just one face, some of the 7S,9R,13Repimer (5b) should also be formed.

The A-ring of daunomycinone 2 is known to prefer a conformation in which the two
hydroxyl groups at C7 and C9 adopt a pseudo-diaxial orientation stabilized by an
intramolecular pseudo-6-membered hydrogen bond (H-bond) ring (Scheme 6.4, 2).284
Similar

conformations

are

probable

for

the

cis-

and

trans-isomers

of

benzenesulfonylhydrazone 3 (Scheme 6.4, cis-3a and trans-3a); however, 3 presents
additional H-bond donor and acceptor groups in its benzenesulfonylhydrazone moiety
which could potentially compete with the C7-OH for H-bonding to C9-OH by forming
5- and 6-membered H-bond rings. These alternative H-bonded conformers could either
retain the pseudo-diaxial orientation of the C7 and C9 alcohols (Scheme 6.4, not shown)
or, alternatively, a ring-flip could occur to reposition the two alcohols in a pseudodiequatorial orientation (Scheme 6.4, cis-3b and trans-3b). As mentioned previously,
1

H and

13

C NMR spectra for 3 were extremely complex, supporting the notion that 3

probably exists (in CDCl3) as an equilibrium mixture of a number of these
isomers/conformers which interconvert slowly on the NMR timescale.
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Scheme 6.4. Proposed mechanism for the stereospecific formation of 7S,9R,13S-5.
Protonation of cis-3b and trans-3b under acidic conditions would result in formation of
the cis- and trans-benzenesulfonylhydrazonium ions cis-3c and trans-3c. Models
indicate that the Re faces of cis-3c and trans-3c are both significantly shielded from
approaching nucleophiles by the axial hydrogen at C7. If cis-3c and trans-3c represent
the predominant species present in the reaction, facially-selective hydride attack from
their respective Si faces could produce a stereoselective reduction leading exclusively to
the sulfonylhydrazine 3d, bearing R-stereochemistry at C13. Spontaneous elimination of
PhSO2- from 3d followed by N2 loss would then furnish 7S,9R,13S-5 by the mechanism
described above.

After thorough searching of the literature, it was evident that 5 represented the first ever
example of an unprecedented class of compounds which bear a bridgeheadhydroxylated bicyclo[3.1.1]heptanol with a fused aromatic ring.
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The bicyclo[3.1.1]heptane ring system is a common structural element found in
numerous monoterpene and sesquiterpene natural products. For instance, the pinane
skeleton 7, containing a bicyclo[3.1.1]heptane ring with a gem-dimethyl bridge, is a
common constituent of monoterpenes from the wood and leaf oils of many higher
plants, particularly Coniferae, as well as some algae and insects.285 Closely related
α-pinene 8 is the most widely distributed monoterpene and is a major component of
turpentine

oil.285

Bicyclo[3.1.1]heptanes

containing

a

fused

aromatic

ring

(e.g. benzopinane 9) are not naturally occurring but reports of their synthesis and
properties

abound.286-291

Bicyclo[3.1.1]heptane

derivatives

functionalized

with

bridgehead oxygen atoms (e.g. bicyclo[3.1.1]heptan-1-ol 10) are known constituents of
naturally occurring glycosides,292 as are their unsaturated derivatives containing double
bonds within the six-membered ring.292 To our knowledge, bicyclo[3.1.1]heptanes
bearing both a bridgehead-alcohol and a fused aromatic ring (e.g. 11) are a previously
unreported class of compounds, making compound 5 the first compound of this class.

Figure 6.2. Structures of known compounds (6-11) related to the newly synthesised 5.
The initial route described in Scheme 5.1 towards the synthesis of β-rhodomycinone
from daunomycin where the daunosamine sugar was removed up front led to the
unexpected stereospecific formation of the novel anthracyclinone 5. Although this was
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an interesting finding which was able to be published,293 it also meant that
β-rhodomycinone could not be accessed via this route. It was clear that a revised
synthetic strategy which avoids the formation of 5 was required.

6.3.2. Alternative Synthetic Route Towards β-Rhodomycinone
Formation of 5 appeared to be aided by the benzylic hydroxyl group at C7 which
allowed formation of H2O as a good leaving group. This problem was not encountered
by Walsh and Olsen278 when the reductions were carried out on anthracyclines
containing glycosidic linkages to sugars at C7. It was thus decided to proceed with a
revised synthesis where the sugar moiety was retained through this step. The revised
synthetic pathway thus involved: (i) retention of the daunomycin 1 sugar (daunosamine)
with its hydroxyl and primary amine functions protected;294 (ii) conversion of the
sugar-modified daunomycin derivative 12 to its 13-benzenesulfonylhydrazone 13
followed by reduction to give the 13-deoxyanthracyclinone 14;278 (iii) regio- and
stereoselective benzylic hydroxylation at C10 with trimethylamine-N-oxide of 14;279
(iv) demethylation of the 4-methoxyl group of 15,281 and finally (v) acid-catalyzed
hydrolysis of the modified daunosamine sugar from 16 to afford β-rhodomycinone 6.280

It was thought that retention of the sugar would prevent formation of the
bicyclo[1.1.3]heptane compound in the reduction step and would also improve the
solubility properties of all intermediates for easier handling. The revised route is
outlined in Scheme 6.5. Relevant literature precedents for all reactions are given.
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Scheme 6.5. Reagents: (a) trisphosgene, DIEA, CH2Cl2, 4 h, 0 ºC, 69%;294 (b)
NH2NHSO2Ph, THF, 18 h, 25 oC, quant.; (c) NaCNBH3, PTSA, MeOH, 18 h, 60 oC;
(d) trimethylamine-N-oxide, DMF, 40 h, 25 oC;281 (e) AlCl3, CH2Cl2, under N2, 24 h, 25
o 277
C; (f) 0.2 N HCl, 90-95 oC.280
Daunomycin is highly polar and highly water soluble. In order to decrease polarity and
facilitate purification on silica columns, the 3′-hydroxyl and 4′-amine groups present on
the daunosamine sugar were converted to the less polar oxazolidinone derivative
(Scheme 6.5, 12). This reaction was carried out following the experimental conditions
reported by Hein et al.294 for converting norephedrine to its oxazolidinone equivalent
(Table 6.1, condition 1). The use of these conditions with daunomycin did not yield the
desired compound 12 but instead resulted in deglycosylation. The lack of success with
the Hein et al. conditions led us to explore other combinations of bases (triethylamine
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(TEA) and diisopropylethylamine (DIEA)), equivalents of reagents and solvent
(dichloromethane (CH2Cl2) and tetrahydrofuran (THF)) at various temperatures and
reaction times. These conditions are summarised in Table.6.1.

Table 6.1. Experimental conditions investigated for the formation of daunomycin
bearing a sugar protected as an oxazolidinone 12.
Reagents

Eq.

Solvent

Temperature

Time (h)

Yield 12
(%)

1a

Triphosgene
TEA

1.1
3

Dry
CH2Cl2

0 oC
then 25 oC

2.5
then O/Nb

0c

2

Triphosgene
TEA

1.1
3

Dry
THF

0 oC
then 25 oC

2
then O/N

17

3

Triphosgene
DIEA

3
3

Dry
CH2Cl2

0 oC
then 25 oC

5
then O/N

0c

4

Triphosgene
DIEA

3
3

Dry
CH2Cl2

0 oC

4

69

5

Triphosgene
DIEA

3
3

Dry
CH2Cl2

-15 oC

5

45

Cond.

a

Conditions reported by Hein et al.294
b
O/N indicates overnight
c
Only deglycosylated daunomycin obtained.
Changing the solvent from CH2Cl2 to THF led to the formation of 12 but only in low
yield (Table 6.1, condition 2). Changing the base from TEA to DIEA led to a better
yield of 12 (Table 6.1, condition 4). Allowing the reaction to warm to room temperature
led to deglycosylation (Table 6.1, condition 3). In an attempt to increase the yield of the
reaction, lower temperatures were investigated. The optimum reaction conditions were
eventually identified as: trisphosgene, DIEA, CH2Cl2, for 4 h at 0 oC (Table 6.1,
condition 4). These conditions allowed the formation of 12 in 69% yield.

The next step was to reduce the 13-keto group of 12 in order to obtain the deoxygenated
anthracycline 14. As described previously, Walsh and Olson278 reported a method for
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preparing 13-deoxyanthracyclines wherein anthracycline 13-keto groups are converted
to 13-arylsulfonylhydrazones and subsequently reduced under acidic conditions with
NaCNBH3 to the requisite methylene compounds. It was found that conversion of 12 to
the 13-benzenesulfonylhydrazone 13 was best carried out in anhydrous THF, wherein
its reaction with benzenesulfonylhydrazine (1.05 equivalent) was quantitative (single
spot by TLC; CH2Cl2:acetone 4:1.5) after overnight stirring at room temperature
(Scheme 6.5). As observed previously for the benzenesulfonylhydrazone 3, the 1H and
13

C NMR spectra for 13 (CDCl3) were complex and difficult to interpret, presumably

because it exists as a mixture of cis- and trans-benzenesulfonylhydrazones and perhaps
different H-bonded conformational isomers (see Scheme 6.4).

The crude benzenesulfonylhydrazone 13 was subjected to the reductive conditions
reported by Walsh and Olsen278 (p-toluenesulfonic acid (PTSA) or pyridinium
p-toluenesulfonate (PPTS) with NaCNBH3 in methanol at 60

o

C, Table 6.2,

condition 1). After 40 min of reaction under these conditions, no starting
benzenesulfonylhydrazone 13 remained and three new compounds were observed by
TLC. Positive ESI-MS confirmed that the compound possessing an Rf = 0.570
(CH2Cl2:acetone 2:1) had a mass corresponding to 14 (ESI-MS: [M+H]+ = 540.19).
After purification by silica gel chromatography and preparative HPLC, comprehensive
2D-NMR characterization (DQF-COSY, HMQC, HMBC, and NOESY) was carried out
on the product. This clearly established that the compound identified by ESI-MS with a
mass of 540.19 Da ([M+H]+) and a TLC Rf = 0.570 (CH2Cl2:acetone 2:1) was the
13-deoxyanthracyclinone 14.
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The yield of 14 (about 21%) was lower than that reported by Walsh and Olsen for the
reduction of the doxorubicin benzenesulfonylhydrazone (86-98%).278 The low yield
obtained led to exploration of the reduction using other combinations of reagents. The
conditions investigated are summarised in Table 6.2.

Table 6.2. Reaction conditions
benzenesulfonylhydrazone 13 to 14.
Cond.

Reagents

investigated

for

the

reduction

of

Eq.

Solvent

Temperature

Time

Yield (%)

1a

NaCNBH3
PPTS

12
2

Dry MeOH

60 oC

40 min

21 %

2

NaCNBH3
PTSA

12
12

Dry MeOH

60 oC

1.5 h

< 10%

3

NaCNBH3
PTSA

12
12

Dry MeOH

60 oC

O/Nb

< 10%

4

NaCNBH3
PPTS

12
2

Dry MeOH

70 oC

1.5 h

< 10%

5

NaCNBH3
PPTS

12
2

Dry MeOHc

60 oC

45 min

18-19%

a

Conditions reported by Walsh and Olsen278
O/N indicates overnight
c
Reaction carried out at half concentration
b

The low yield of 14 using pyridinium-p-toluene-sulfonate (PPTS) led to trial of an
alternative

acid,

p-toluenesulfonic

acid

(PTSA),

for

the

reduction

of

the

benzenesulfonylhydrazone intermediate 13.282,295,296 This modification did not improve
the yield of 14. After 1.5 h under these conditions (Table 6.2, condition 2), only one
new compound (14 as identified by ESI-MS) was observed by TLC, however its yield
was low (<10%). Unreacted starting material 13 was the only other compound present.
The reaction time was extended to encourage the reaction but this did not improve the
yield of 14. Unreacted 13 remained as the major compound (80-90%) and two new
uncharacterised compounds of higher Rf were observed by TLC (Table 6.2, condition
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3). Increasing the reaction temperature (Table 6.2, condition 4) and using PPTS
increased the reaction rate but did not improve the yield of 14 (< 10%).

In all of the attempted reductions, the starting material 13 was dissolved in MeOH
before addition of the reagents. It is known that daunomycin dimerises in solutions
greater than 10 μM.297,298 In the reactions attempted here, 13 still possesses the
tetracyclic aglycone of daunomycin which is responsible for the dimerisation process.297
It is possible that in the high concentrations used in these reactions (9 mM), 13 might
also dimerise and this could limit the reaction from taking place by preventing the
reagents from accessing the hydrazone functional group. The reaction was therefore
attempted using the same reagents as for condition 4 (Table 6.2) but at half the
concentration. This modification unfortunately did not improve the yield of 14.

The highest yield of 14 observed was around 20% which is too low to proceed to the
next step in the synthesis. Further optimisation of the reaction conditions are needed to
increase the yield in order to continue along this route towards β-rhodomycinone 6.
Alternative conditions for the attempted reduction of 12 that could be tried include:
(i)

bis(triphenylphosphine)copper(I)

tetraborohydride

in

chloroform299

or

(ii) (p-tosylsulfonyl)hydrazine, NaCNBH3, ZnCl2 in MeOH at 60 ºC for 1.5 h.300

Owing to time constraints, these reactions have not been attempted here and the
synthesis of β-rhodomycinone from daunomycin was not completed.

216

6.4.

DNA-Binding Studies of the Synthesised Intermediate
Compounds in the Route Toward β-Rhodomycinone

Although we did not succeed in the synthesis of the final compound, β-rhodomycinone,
several intermediate compounds were obtained. In total, six compounds were
synthesized: 2, 3, 5, 12, 13, 14. The structural characterisation of the compounds are
presented in section 6.6. All possess a structure related to that of Dn, the starting
material, differing in one or two functional groups as described in the previous sections.
These differences are at specific positions on the molecule, so these compounds were
used to test the importance of the functional groups present on Dn in its binding to
double-stranded DNA.

The binding affinity comparisons between these newly synthesised compounds and Dn
were carried out with the double-stranded DNA, Rt1, and the mixtures were analysed by
ESI-MS in negative mode using the instrument conditions described in Table 2.4,
section 2.2.4.6. Compound 13 was easily obtained from 12, and although it was pure
enough to proceed to the synthesis of 14 without purification, it was not pure enough to
be used in the DNA titration experiments. The other compounds 2, 3, 5, 12, 14, were not
soluble in water. Stock solutions of each of the drugs were prepared in methanol to their
individual maximum solubility. The concentrations of the stock solutions used for each
drug are summarised in Table 6.3. Unlike the other compounds, the Dn stock solution
was in 100 mM ammonium acetate, pH 7.5. To obtain identical conditions to that of the
other compounds, volumes of 100 mM ammonium acetate, pH 7.5, equal to the added
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volume of each compound were replaced by methanol in the different DNA-Dn
mixtures.

Several titration solutions were prepared for each of the compounds with the following
v/v DNA:test compound ratios: 1:1, 1:3, 1:5, 1:7, 1:9, 1:11, 1:13. As all the stock
solutions had different concentrations, the corresponding DNA-test compound molar
ratios for each solution were calculated and are summarised in Table 6.3.

Table 6.3. Concentrations of stock solutions of test compounds and Rt1:compound
molar ratios used in the titration experiments.

a

Compound

Stock solution
(mM)

DNA:drug ratiosa

2

0.231

1:0.2, 1:0.7, 1:1.2, 1:1.6, 1:2.1, 1:2.5, 1:3

3

0.503

1:0.5, 1: 1.5, 1:2.5, 1:3.5, 1:4.5, 1:5.5, 1:6.5

5

1.080

1:1, 1:3.2, 1:5.4, 1:7.6, 1:9.7, 1:11.9, 1:14

12

1.200

1:1.2, 1:3.6, 1:6, 1:8.4, 1:10.8, 1:13.2, 1:15.6

14

0.641

1:0.6, 1:1.9, 1:3.2, 1:4.5, 1:5.8, 1:7.1, 1:8.3

Dn

1

1:1, 1:3, 1:5, 1:7, 1:9, 1:11, 1:13

The final concentration of dsDNA was 5 μM. The total reaction mixture
volume was 200 μL.

Prior to mixing the test compounds with DNA to obtain the different titration mixtures,
a test was conducted on Rt1 alone to determine whether the presence of methanol in
solution had an effect on the stability of the dsDNA. Solutions containing up to 13 µL
of methanol, which corresponded to the maximum volume of stock solution added to
the DNA, were analysed under the same conditions as that for DNA-test compound
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complexes. The ESI mass spectra obtained for Rt1 alone with and without any methanol
in solution (not shown) were very similar: the ratios of single- and double-stranded
DNA in solution remained identical; the ions observed and their relative intensities were
the same in both cases. The main difference observed was in the overall intensities of
the peaks as they were slightly higher in the sample containing the methanol, most
likely as it assisted the desolvation process.

The DNA:test compound mixtures were all homogeneous up to the 1:13 v/v ratio with
the exception of the solution prepared using compound 5 (Figure 6.3 (A)). For this
compound, only the 1:1 (1:1 v/v) and 1:3.2 (1:3 v/v) mixtures were homogeneous
(Figure 6.3 (B)). The Rt1:test compound mixtures prepared were analysed by mass
spectrometry. Figure 6.4 shows the spectra obtained for the mixtures with the highest
test compound concentration as they show the maximum number of molecules that were
able to bind to the DNA.

Figure 6.3. Rt1 titrating solutions. (A) DNA:test compound solutions in a v/v 1:13 ratio
and (B) DNA:5 titration mixtures.

219

Figure 6.4. Mass spectra of the Rt1:test compound solutions in 1:13 v/v ratio for Rt1
alone (A), Compounds 2 (B), 3 (C), 5 (D), 12 (E) and 14 (F) and Dn (G). The different
DNA charges states are 7- (), 6- (z) and 5- ({). The numbers inside the symbols
represent the number of molecules bound. The peaks marked with  correspond to
single-stranded Rt1.
Small amounts of complex with one molecule bound were observed for 2 and 3
(Figure 6.4 (B) and (C), respectively) and no binding was observed for 5 (Figure 6.4
(D)). Complexes with different numbers of molecules bound were observed for 12
(Figure 6.4 (E)). The most abundant complex corresponded to 1 molecule bound to the
DNA with the presence of some complex with 5 molecules bound. In the case of
compound 14 (Figure 6.4 (F)), some ions corresponding to the formation of complexes
were observed; however they did not corresponded to the binding of compound 14 to
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the DNA. It seemed that over time the compound degraded into a compound that had
the same mass as compound 12. For Dn, the main complex observed was 4 Dn
molecules bound with some complexes possessing up to a maximum of 9 molecules
bound.

From these differences in the binding abilities of the compounds tested, the following
observation can be made: the removal of the daunosamine sugar from Dn (e.g.
compound 2) has the greatest effect on the DNA binding affinity, the number of
molecules bound being reduced to only one but at very low abundance. The
modification of the OH and NH2 functional group on the sugar to the
3′,4′-oxazolidinone derivative 12 (Figure 6.4 (E)) reduces the binding affinity of the
compound or at least hinders the binding of multiple molecules relative to Dn
(Figure 6.4 (B)). The modification of the side chain at position C9 (e.g. compound 3,
Figure 6.4 (C)) does not seem to affect the binding affinity of the aglycone as judged by
ESI-MS, as there is no difference in binding between 2 and 3 which only differ by the
side chain at C9.

In conclusion, using the small samples of compounds tested here, it was confirmed that
the sugar is a crucial element in the binding to DNA as any functional modification
decreased substantially the binding affinity to DNA. In many previous studies changes
in the sugar greatly affected the biological activity of the anthracyclines.18,51,64 Such
changes also affected the solubility in water. This is an important consideration as the
compounds need to be readily administered and able to reach their targets.
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6.5.

Summary and Future Directions

In the initial synthetic route, β-rhodomycinone was targeted by modifying the functional
groups present on daunomycin after removing the daunosamine sugar moiety. The
advantage of this strategy was that it uses non-polar intermediates that are more easily
purified by column chromatography. The first step in the deoxygenation of
daunomycinone

proceeded

as

planned

with

quantitative

transformation

of

daunomycinone to its benzenesulfonylhydrazone derivative; however, the reduction of
the benzenesulfonylhydrazone to afford the deoxygenated product could not be
achieved. Different conditions were investigated and in all cases the major product was
a compound that did not correspond to 13-deoxy-daunomycinone. After complete NMR
characterisation, the product was identified as a novel compound which possessed a
bridgehead-hydroxylated bicyclo[3.1.1]heptanol with a fused aromatic ring. Conditions
could not be found that prevented formation of this compound leading to adoption of an
alternative synthetic strategy.

The revised synthetic route carried the daunosamine sugar moiety through the synthesis
in order to prevent the undesired cyclisation reaction. The sugar was protected at its
hydroxyl and primary amine functions to decrease the polarity of the compound and
facilitate purification of intermediates by column chromatography. The sugar was
protected in good yield and transformation to the benzenesulfonylhydrazone was facile.
Reduction of the benzenesulfonylhydrazone to obtain the 13-deoxy product was
successful; although the yield of the product was low. Experimentation to optimize the
yield of the reaction did not identify conditions that were better than those reported by
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Walsh and Olsen.278 Alternative reducing conditions were postulated but owing to time
constraints these were not attempted.

Although the synthesis of β-rhodomycinone from daunomycin was not completed here,
the intermediate compounds obtained were investigated in titration experiments which
confirmed the importance of the sugar moiety for DNA-binding affinity. Additionally,
the unsuccessful route towards β-rhodomycinone provided access to a novel
anthracyclinone that was the prototypical member of a new class of compounds, namely
the bridgehead-hydroxylated bicyclo[3.1.1]heptanols.

Implementation of the revised synthetic strategy in future work will hopefully provide
access to gram quantities of β-rhodomycinone. Upon accessing the aglycone it is
envisaged that various numbers and types of saccharides could be added to its C7 and
C10 hydroxyl groups through regioselective glycosylation reactions. Methods for
carrying out these reactions are described in the literature.301,302 The CosD analogues
synthesised in this manner could then be directly compared alongside CosD in
experiments aimed at determining the contributions of various saccharide chains to
DNA-binding.
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6.6.

Compound Characterisation

Daunomycinone (2)
Daunomycin hydrochloride 1 (1 g, 1.77 mmol,
O

O

OH

1.0 eq.) was dissolved in 50 mL of 0.2 M HCl
OH
o

solution and stirred at 90 C for 3.5 h. After
OMe O

OH OH

completion of the reaction, the mixture was

2

extracted with EtOAc (3 x 100 mL). The organic layers were combined, washed twice
with brine (100 mL), dried over anhydrous MgSO4, filtered and concentrated under
reduced pressure. The TLC pure (THF:Pet. spirit 1:1, Rf = 0.6) daunomycinone 2 was
obtained as a red powder in 89% yield and used without further purification. The
material was spectroscopically identical to that reported by Rho et al.280.

Daunomycinone-13-benzenesulfonylhydrazone (3)
Benzenesulfonylhydrazine (38 mg, 1.38 mmol,
O

1.1 eq.)

OH

N

H
N SO 2Ph

was added to a stirring solution of
OH

daunomycinone 2 (500 mg, 1.25 mmol, 1.0 eq.)
OMe O

in anhydrous THF (30 mL) under N2. The

OH OH
3

resulting solution was stirred at rt for 18 h before being concentrated under reduced
pressure to afford the TLC pure (CH2Cl2:acetone 5:1, Rf = 0.21) sulfonylhydrazone 3 as
a red solid (mp 183-185 ºC, HR-MS: [M+H]+ = 553.1274; C27H24N2O9S requires:
[M+H]+ = 553.1281) which was used without further purification. 1H and

13

C NMR

spectra of 3 were complex due to cis and trans isomers and multiple rotamers (see
section 3.1).
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(7S,9R,13S)-6,9,11-Trihydroxy-4-methoxy-13-methyl-7,8,9,10-tetrahydro-7,9methanonaphthacene-5,12-dione (5)
A solution of 3 (200 mg, 0.36 mmol, 1.0 eq.)

O

OH
OH

and PTSA (180 mg, 1.01 mmol, 2.8 eq.) in
anhydrous DMF (8 mL) was stirred at rt for
5 min under argon. Sodium cyanoborohydride

OMe O

OH
5

(91 mg, 1.44 mmol, 4.0 eq.) was then added and the stirring solution was immediately
placed into a pre-heated oil bath at 110 oC and stirred for a further 15 min. The reaction
was cooled to rt before adding H2O (10 mL) and EtOAc (80 mL) and stirring vigorously
for 2 h. The two-phase mixture was then added to a separating funnel and the EtOAc
layer removed and placed aside. Saturated NaCl solution (50 mL) was added to the
aqueous phase which was then further extracted with EtOAc (2 x 80 mL). The EtOAc
extracts were combined, washed with brine (100 mL), dried over anhydrous MgSO4 and
concentrated. The residue was purified by column chromatography (petroleum
spirit/ethyl acetate) to afford 5 (42 mg, 32%) as red needles; mp 234 – 236 oC, TLC
(CH2Cl2:acetone 5:1) Rf = 0.66. HR-MS: [M+H]+ = 367.1092; C21H18O6 requires:
[M+H]+ = 367.1103. IR νmax: 3381 (br., OH), 2952, 2925, 2850, 1610, 1583, 1283,
1242, 993. [α]25D= +35.8 (c = 0.03, dioxane). 1H NMR (500 MHz, CDCl3) δ: 0.72
(d, 3H, 14-H, J = 6.6 Hz), 1.75 (d, 1H, 8-Ha, J = 8.8 Hz), 2.19 (dt, 1H, 8-Hb,
J1 = 7.6 Hz, J2 = 0.9 Hz), 2.49 (q, 1H, 13-H, J = 6.6 Hz), 2.84-3.00 (AB syst, 2H,
J1 = 38.0 Hz, J2 = 17.97 Hz, J3 = 1.1 Hz), 3.73 (t, 1H, 7-H, J = 6.5 Hz), 4.08 (s, 3H,
C-15 Ar OCH3, J = 6.6 Hz), 7.37 (dd, 1H, 3-H, J1 = 8.3 Hz, J2 = 0.9 Hz), 7.76 (dd, 1H,
2-H, J1 = 8.5 Hz, J2 = 7.6 Hz), 8.03 (dd, 1H, 1-H, J1 = 7.6 Hz, J2 = 1.22 Hz), 13.20 (s,
1H, 11-OH), 13.59 (s, 1H, 6-OH).

13

C NMR (500 MHz, CDCl3): δ: 9.8 (C-14), 29.8
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(C-7), 33.5 (C-10), 42.0 (C-8), 45.0 (C-13), 56.9 (C-15), 73.9 (C-9), 110.6 (C-11a),
112.1 (C-5a), 118.3 (C-3), 119.8 (C-1), 121.4 (C-4a), 135.6 (C-2), 136.0-136.1 (2C,
C-10a C-12a), 144.6 (C-6a), 155.3-155.4 (2C, C-6 C-11), 161.2 (C-4), 186.7 (C-12),
187.7 (C-5).

Daunomycin-3′,4′-oxazolidinone (12)
O

A solution of daunomycin hydrochloride 1

OH

OH

(100 mg, 0.177 mmol, 1.0 eq.) and trisphosgene
(157.8 mg, 0.532 mmol, 3 eq.) in dry CH2Cl2
(20 mL) was stirred under argon and cooled to
o

0 C. DIEA (99 µL, 0.532 mmol, 3 eq.) was

O

O

O

OH O
O

12
O

NH
O

then added dropwise and the resulting solution
was stirred at 0 oC for a further 4 h. The reaction mixture was washed twice with cold
0.2 M HCl (20 mL) and twice with cold H2O (milliQ, 20 mL). The washed organic
layer was dried over MgSO4, filtered and concentrated under reduced pressure. The
residue was purified by column chromatography (CH2Cl2:acetonitrile) to yield 12
(68.4 mg, 69%) as a red powder; mp 192-194 oC, TLC (CH2Cl2:acetone 4:1.5)
Rf = 0.233. HR-MS: [M+H]+ = 554.1659; C28H27NO11 requires: [M+H]+ = 554.1662.
IR νmax: 3340 (br., OH), 2944, 2925, 2830, 1638, 1450, 1426, 1386, 1369, 1227, 997,
910. 1H NMR (500 MHz, CDCl3) δ: 1.37 (d, 1H, 6’-H, J = 6.5 Hz), 1.66 (ddd, 1H,
2’eq-H, J1 = 15.4 Hz, J2 = 7.8 Hz, J3 = 3.3 Hz), 2.03 (dd, 1H, 8a-H, J1 = 14.4 Hz,
J2 = 10.6 Hz), 2.26 (ddd, 1H, 2’ax-H, J1 = 15.5 Hz, J2 = 5.4 Hz, J3 = 2.7 Hz), 2.39 (s,
3H, 14-H), 2.46 (d, 1H, 8eq-H, J = 14.7 Hz), 2.77 (d, 1H, 10eq-H, J = 18.8 Hz), 3.06 (d,
1H, 10ax-H, J = 18.8 Hz), 3.99 (s, 3H, 15-H), 4.09 (qd, 1H, 5’-H, J1 = 6.5 Hz,
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J2 = 1.3 Hz), 4.27 (d, 1H, 3’-H, J = 9.6 Hz), 4.56 (dd, 1H, 4’-H, J1 = 9.6 Hz,
J2 = 1.4 Hz), 4.67 (s, 1H, 9-OH), 5.20 (s, 1H, 7-H), 5.55 (t, 1H, 1’-H, J = 6.6 Hz), 6.19
(s, 1H, N-H), 7.29 (d, 1H, 3-H, J = 7.2 Hz), 7.69 (t, 1H, 2-H, J = 8.1 Hz), 7.86 (d, 1H,
1-H, J = 7.6 Hz), 13.04 (s, 1H, 5-OH), 13.76 (s, 1H, 11-OH).

13

C NMR (500 MHz,

CDCl3): δ: 15.94 (C-6’), 24.99 (C-14), 29.53 (C-2’), 33.17 (C-10), 35.50 (C-8), 48.07
(C-3’), 56.81 (C-15), 64.71 (C-5’), 67.40 (C-7), 76.20 (C-4’), 76.95 (C-9), 99.23 (C-1’),
111.22 (C-11a), 111.32 (C-5a), 118.63 (C-3), 119.82 (C-1), 120.77 (C-4a), 134.05
(C-11), 134.75 (C-6), 135.41 (C-12a), 135.85 (C-2), 155.79 (C-6a), 156.45 (C-10a),
159.43 (C-7’), 161.06 (C-4), 186.49 (C-12), 186.74 (C-5), 212.31 (C-13).

Daunomycin-3′,4′-oxazolidinone-13-benzenesulfonylhydrazone (13)
Benzenesulfonylhydrazine (163 mg, 0.95 mmol,
1.05 eq.) was added to a stirring solution of 12

O

OH

(500mg, 0.90 mmol, 1.0 eq.) in anhydrous THF
(60 mL) under argon. The resulting solution was

S
O2

OH
O

O

OH O

stirred at rt for 18 h before being concentrated

O
13

under reduced pressure to afford in quantitative

N

H
N

O NH

quantities the TLC pure (CH2Cl2:acetone 4:1.5,

O

Rf = 0.167) sulfonylhydrazone 13 as a red solid (HR-MS: [M+H]+ = 708.1868;
C34H33N3O12S requires: [M+H]+ = 708.1863) which was used without further
purification and not stable over time. 1H and 13C NMR spectra of 13 were complex due
to cis and trans isomers and multiple rotamers (see section 3.1).
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13-deoxy-daunomycin-3′,4′-oxazolidinone (14)
A solution of 13 (50 mg, 0.07 mmol, 1.0 eq.)

O

OH

and NaCNBH3 (53.2 mg, 0.85 mmol, 12 eq.) in
OH
o

dry MeOH (8 mL) was stirred at 0 C for 5 min
O

O

OH O

under argon. PPTS (35.5 mg, 0.14 mmol, 2 eq.)
was then added and the stirring solution was
placed into a pre-heated oil bath at 60 oC and

O
14
O

NH
O

stirred for 40 min. The reaction was removed from the heat and saturated NaHCO3
(20 mL) was added and the solution stirred at rt for 5 min. Methanol was removed from
the reaction mixture under vacuum and the remaining aqueous mixture was extracted
with CH2Cl2 (2 x 20 mL). The organic layers were combined, dried over MgSO4 and
concentrated under reduced pressure. The crude residue was purified by column
chromatography on silica (CH2Cl2:acetonitrile) to afford 14 (32.0 mg, 21%) as a red
powder; mp 172-174

o

C, TLC (CH2Cl2:acetone 2:1) Rf = 0.570. HR-MS:

[M+H]+ = 540.1873; C28H29NO10 requires: [M+H]+ = 540.1870. IR νmax: 3351 (br.,
OH), 2953, 2927, 2862, 2820, 1598, 1440, 1386, 1253, 1036, 910. 1H NMR (500 MHz,
CDCl3) δ: 1.08 (t, 3H, 14-H, J = 6.8 Hz), 1.41 (d, 3H, 6’-H, J = 5.9 Hz), 1.62-1.72 (m,
1H, 13-Ha/b), 1.62-1.72 (m, 2H, 2’-H), 1.72-1.84 (m, 1H, 13-Ha/b), 1.72-1.84 (m, 1H,
8-Ha/b), 2.17 (d, 1H, 2’-Ha/b, J = 15.2 Hz), 2.48-2.54 (m, 1H, 8-Ha/b), 2.48-2.54 (m,
1H, 10-Ha/b), 3.21 (d, 2H, 10-Ha/b, J = 18.8 Hz), 4.06 (s, 3H, 15-H), 4.12 (s, 1H, N-H),
4.13 (s, 1H, 5’-H), 4.22 (d, 1H, 3’-H, J = 8.2 Hz), 4.53 (d, 1H, 4’-H, J = 9.1 Hz), 5.25
(s, 1H, 7-H), 5.45 (s, 1H, 9-OH), 5.57 (s, 1H, 1’-H), 7.36 (d, 1H, 3-H, J = 8.2 Hz), 7.76
(t, 1H, 2-H, J = 7.8 Hz), 8.00 (d, 1H, 1-H, J = 7.3 Hz), 13.31 (s, 1H, 6-OH), 13.93 (s,
1H, 11-OH). 13C NMR (500 MHz, CDCl3): δ: 7.7 (C-14), 15.9 (C-6’), 29.9 (C-2’), 35.7
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(C-13), 36.3 (C-10), 37.8 (C-8), 48.0 (C-3’), 56.9 (C-15), 64.5 (C-5’), 69.6 (C-9), 70.5
(C-7), 76.3 (C-4’), 99.1 (C-1’), 111.3 (C-5a), 111.4 (C-11a), 118.5 (C-3), 119.9 (C-1),
121.2 (C-4a), 135.2 (C-10a), 135.8 (C-12), 135.8 (C-2), 136.6 (C-6a), 156.4 (C-6),
157.0 (C-11), 159.1 (C-7’), 161.2 (C-4), 186.9 (C-12), 187.2 (C-5).
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APPENDIX 1
Summary table of the 39 possible comparisons in order to evaluate the impact of each
parameter (time, temperature and pH) on the degradation of CosD in solution.
Test
Time
Time
Time
Time
Time
Time
Time
Time
Time
Time
Time
Time
Time
Time
Time
Temperature
Temperature
Temperature
Temperature
Temperature
Temperature
Temperature
Temperature
Temperature
Temperature
Temperature
Temperature
Temperature
Temperature
Temperature
pH
pH
pH
pH
pH
pH
pH
pH
pH

Constant parameters
pH
Ta (°C)
3.5
5.5
7.5
9.5
10.5
3.5
5.5
7.5
9.5
10.5
3.5
5.5
7.5
9.5
10.5

4
4
4
4
4
25
25
25
25
25
40
40
40
40
40

pH

Time (h)

3.5
5.5
7.5
9.5
10.5
3.5
5.5
7.5
9.5
10.5
3.5
5.5
7.5
9.5
10.5

1
1
1
1
1
4
4
4
4
4
18
18
18
18
18

T (°C)

Time (h)

4
4
4
25
25
25
40
40
40

1
4
18
1
4
18
1
4
18

Solutions comparedb
to CosDc
S1 - S6 - S11
S2 - S7 - S12
S3 - S8 - S13
S4 - S9 - S14
S5 - S10 - S15
S16 - S21 - S26
S17 - S22 - S27
S18 - S23 - S28
S19 - S24 - S29
S20 - S25 - S30
S31 - S36 - S41
S32 - S37 - S42
S33 - S38 - S43
S34 - S39 - S44
S35 - S40 - S45
S1 - S16 - S31
S2 - S17 - S32
S3 - S18 - S33
S4 - S19 - S34
S5 - S20 - S35
S6 - S21 - S36
S7 - S22 S37
S8 - S23 - S38
S9 - S24 - S39
S10 - S25 - S40
S11 - S26 - S41
S12 - S27 S42
S13 - S28 - S43
S14 - S29 - S44
S15 - S30 - S45
S1 - S2 - S3 - S4 - S5
S6 - S7 - S8 - S9 - S10
S11 - S12 - S13 - S14 - S15
S16 - S17 - S18 - S19 - S20
S21 - S22 - S23 - S24 - S25
S26 - S27 - S28 - S29 - S30
S31 - S32 - S33 - S34 - S35
S36 - S37 - S38 - S39 - S40
S41 - S42 - S43 - S44 - S45

a

Temperature
See Table 3.1 for the solution names
c
Solution that was not treated, and analysed under the same conditions as the digested
solutions
b
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APPENDIX 2
Absorbance/l (with l = 0.1 cm) values for Dn obtained for the different absorption
maxima 290, 481, 497 and 532 nm, over the range of concentrations tested: 0 to 0.95
mM Dn in DMF (0 to 38 µL of the 10 mM Dn stock solution in DMF in a total volume
of 400 µL).
Volume of
10 mM stock
solution

Concentration
(mM)

0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
22
24
26
28
30
32
34
36
38

0
0.025
0.050
0.075
0.100
0.125
0.150
0.175
0.200
0.225
0.250
0.275
0.300
0.325
0.350
0.375
0.400
0.425
0.450
0.475
0.500
0.550
0.600
0.650
0.700
0.750
0.800
0.850
0.900
0.950

Absorbance/l (cm-1) at the
different wavelengths (nm)
261
-0.214
0.603
0.964
1.376
1.744
2.159
2.460
2.900
3.263
3.649
3.759
4.297
4.797
5.195
5.559
5.956
6.284
6.685
6.976
7.515
7.947
8.701
9.542
10.328
10.963
11.754
12.490
13.169
14.108
14.777

290
0.001
0.208
0.359
0.536
0.682
0.848
0.990
1.165
1.320
1.494
1.657
1.798
1.956
2.125
2.269
2.440
2.585
2.733
2.886
3.075
3.223
3.563
3.906
4.229
4.513
4.852
5.164
5.469
5.803
6.110

480
0.001
0.265
0.494
0.740
0.949
1.182
1.416
1.639
1.859
2.117
2.357
2.559
2.763
3.002
3.208
3.440
3.656
3.862
4.092
4.364
4.574
5.077
5.569
6.011
6.420
6.898
7.336
7.778
8.275
8.705

497
0.001
0.260
0.481
0.721
0.925
1.150
1.378
1.596
1.809
2.059
2.295
2.490
2.689
2.924
3.123
3.348
3.560
3.760
3.980
4.244
4.453
4.941
5.421
5.856
6.248
6.714
7.140
7.572
8.055
8.477

532
0.001
0.143
0.255
0.377
0.486
0.599
0.718
0.828
0.939
1.068
1.193
1.294
1.398
1.520
1.625
1.744
1.856
1.963
2.078
2.216
2.322
2.576
2.820
3.043
3.252
3.491
3.712
3.933
4.186
4.407
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APPENDIX 3
Absorbance/l (with l = 0.1 cm) values for Dn aglycone obtained for the different
absorption maxima 290, 481, 497 and 532 nm, over the range of concentrations tested: 0
to 0.95 mM Dn in DMF (0 to 38 µL of the 10 mM Dn aglycone stock solution in DMF
in a total volume of 400 µL.
Volume of
10 mM stock
solution

Concentration
(mM)

0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
22
24
26
28
30
32
34
36
38

0
0.025
0.050
0.075
0.100
0.125
0.150
0.175
0.200
0.225
0.250
0.275
0.300
0.325
0.350
0.375
0.400
0.425
0.450
0.475
0.500
0.550
0.600
0.650
0.700
0.750
0.800
0.850
0.900
0.950

Absorbance/l (cm-1) at the
different wavelengths (nm)
261
-0.214
0.579
1.050
1.469
1.783
2.184
2.570
3.079
3.469
3.888
4.326
4.727
5.093
5.488
5.905
6.279
6.697
7.069
7.517
7.893
8.291
9.194
9.919
10.709
11.593
12.324
13.224
14.014
14.950
15.239

290
0.001
0.214
0.396
0.571
0.730
0.895
1.067
1.251
1.427
1.583
1.776
1.951
2.111
2.277
2.450
2.604
2.773
2.946
3.132
3.292
3.468
3.889
4.209
4.539
4.910
5.243
5.601
5.922
6.321
6.583

480
0.001
0.282
0.526
0.772
1.008
1.237
1.470
1.725
1.964
2.196
2.452
2.693
2.908
3.145
3.377
3.597
3.827
4.083
4.338
4.564
4.819
5.415
5.845
6.295
6.801
7.263
7.764
8.208
8.793
9.126

497
0.001
0.283
0.524
0.767
1.002
1.227
1.458
1.710
1.946
2.175
2.428
2.666
2.878
3.113
3.341
3.560
3.785
4.039
4.288
4.517
4.764
5.354
5.780
6.226
6.721
7.178
7.672
8.115
8.691
9.022

532
0.001
0.162
0.292
0.421
0.552
0.668
0.792
0.929
1.055
1.178
1.312
1.443
1.558
1.686
1.812
1.930
2.050
2.186
2.322
2.440
2.573
2.885
3.112
3.352
3.616
3.862
4.124
4.363
4.674
4.856
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APPENDIX 4
Calculated m/z values for ions from complexes formed between the dsDNA Rt1 and Dn,
Dx or CosD. All values shown in bold correspond to the ions observed in the mass
spectra of the different titration mixtures.

Complex

[M - 4H]-4

[M - 5H]-5

[M - 6H]-6

[M - 7H]-7

Rt1

2439,9

1951,7

1626.2

1393.8

Rt1+ 1 Dn

2571.7

2057.2

1714.2

1469.1

Rt1+ 2 Dn

2703.6

2162.7

1802.1

1544.5

Rt1+ 3 Dn

2835.5

2268.2

1890.0

1619.9

Rt1+ 4 Dn

2967.4

2373.7

1977.9

1695.2

Rt1+ 5 Dn

3099.3

2479.2

2065.8

1770.6

Rt1+ 6 Dn

3231.2

2584.7

2153.8

1845.9

Rt1+ 7 Dn

3363.0

2690.2

2241.7

1921.3

Rt1+ 1 Dx

2575.7

2060.4

1716.8

1471.4

Rt1+ 2 Dx

2711.6

2169.1

1807.4

1549.1

Rt1+ 3 Dx

2847.5

2277.8

1898.0

1626.7

Rt1+ 4 Dx

2983.4

2386.5

1988.6

1704.4

Rt1+ 5 Dx

3119.3

2495.2

2079.2

1782.0

Rt1+ 6 Dx

3255.1

2603.9

2169.8

1859.6

Rt1+ 1 CosD

2737.0

2189.4

1824.3

1563.6

Rt1+ 2 CosD

3034.1

2427.1

2022.4

1733.4

Rt1+ 3 CosD

3331.3

2664.8

2220.5

1903.2

Rt1+ 4 CosD

3628.4

2902.5

2418.6

2073.0
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APPENDIX 5
Density values of electrophoretic bands obtained during the RNA transcription assays
(Chapter 5). These values were obtained from Figure 5.10 to determine each drug
concentration inhibiting RNA synthesis in vitro to 50% of the control value.

Dn concentration (μM)

Density

Control value
2.5
5
7.5
10
12.5

271335.9
327013.2
266888.6
208058.1
102595.0
41219.1

Dx concentration (μM)

Density

Control value
20
40
60
80
0

315211.4
229815.9
130718.2
42392.4
6845.5
315211.4

CosD concentration (µM)

Density

Control value
1
2
3
4

250996.4
267418.0
214179.4
104331.0
58894.6
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